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Regulation of transcription through protein complex assembly is critical for the 
maintenance of cellular homeostasis. Dysregulation of transcription is unexpectedly a 
cause or consequence of most human disease. Thus, there is significant therapeutic 
potential in discovering novel mechanisms to restore normal protein-protein interaction 
(PPI) networks in transcription. Targeting these transcriptional PPIs with small molecules 
has historically been challenging as the interactions occur over broad surface areas with 
relatively weak binding affinities. Within this dissertation, I describe two emergent 
strategies, namely natural products screening and protein-observed 19F-NMR, that 
allowed for the identification of small molecule inhibitors of the activator interaction 
domain (AcID) of Med25, a critical coactivator protein in transcription. 
Med25 AcID is a transcriptional coactivation domain that interacts with several 
transcriptional activators that have been implicated in cancer and disease, including the 
ETV/PEA3 family and the oxidative stress response factor ATF6α. An overarching goal 
of this dissertation was to identify small molecule inhibition of Med25 AcID that will allow 
for future study of the role of Med25 in cancer processes such as metastasis and 
tumorigenesis. 
This dissertation first describes the mechanistic details that define the interactions 
between Med25 AcID and its native protein partners to enable the identification of small 
molecules that selectively inhibit Med25 AcID. As demonstrated, the AcID motif interacts 
with each of its binding partners using discrete modes of molecular recognition. The 
significant differences between the interactions of Med25 AcID with the ERM and ATF6α 
activators (e.g. differences in binding locations and relative dependence on electrostatic 
xviii 
 
interactions) highlight the diversity of molecular mechanisms through which Med25 AcID 
functions. Small molecule inhibitors of Med25 AcID were then identified, guided by these 
mechanistic details. Natural products discovery and protein-observed 19F-NMR were 
leveraged to target Med25 AcID, which interacts with its protein partners over broad 
surface areas with relatively weak binding affinities. These two strategies have provided 
recent successes for other transcriptional PPIs. The 34913 lipopeptide, which exhibits 
effective inhibition of the Med25-ATF6α PPI in a cellular context, and nine preliminary hit 
fragments were successfully identified using those strategies. Collectively, this 
dissertation represents a tremendous advance in the identification of small molecules that 
target a challenging transcriptional coactivator, Med25 AcID, that will allow for subsequent 





Targeting protein-protein interactions involved in transcription  
 
A. Abstract 
Transcription, the central process that maintains normal homeostasis and cellular 
function, is tightly regulated through a series of protein-protein interactions (PPIs).1 
Unsurprisingly, dysregulation of transcription is often attributed to human disease, either 
by cause or effect.2 Thus, there is a need for small molecules that can restore normal 
transcriptional output; targeting transcriptional PPIs represent a viable avenue towards 
this goal. However, targeting transcriptional PPIs is challenging to such an extent that 
these PPIs were once considered undruggable as they are typically transient in nature, 
are relatively low affinity interactions, and occur over large surface areas.3,4 While the 
discovery of small molecule modulators remains challenging, recent advances in 
chemical screening libraries and methodologies have made them tractable for small 
molecule intervention.  
This introductory chapter will define the principles and regulatory mechanisms that 
underscore transcriptional PPIs and their roles in human disease. The features of 
transcriptional PPIs and the difficulties of targeting them with small molecules will be 
discussed. Finally, emergent strategies that leverage natural products discovery and 
fragment-based NMR screening to overcome the inherent challenges in modulating 
transcriptional PPIs will be discussed.  
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B. Protein-protein interactions in transcription 
Protein-protein interactions (PPIs) between transcriptional activators and 
transcriptional coactivators are a key component of the regulatory network of 
transcription.1,5 The activator proteins are minimally composed of a DNA-binding domain 
(DBD) responsible for interaction at specific DNA promoter elements and a transcriptional 
activation domain (TAD) responsible for making contacts with transcriptional coactivators 
(Figure 1.1).6–8 The minimal assembly of these three elements (DNA, activator, and 
coactivator) at a specific gene promoter allows for subsequent localization of the pre-
initiation complex and RNA Polymerase II.9 Following the recruitment of RNA Polymerase 
II, the gene will be transcribed into messenger RNA (mRNA) for future translation into 
protein.10 However, the multimeric assembly is much more complex than this simple 
model might suggest. Each of the transcriptional proteins make specific contacts with 
multiple binding partners and nearly half of all transcription factors have been 
computationally predicted to be intrinsically disordered, or lacking an ordered structure in 
solution.11–14 Additionally, it has been suggested that a single activator may need to recruit 
multiple protein complexes to a promoter region to remodel chromatin structure prior to 




Multidomain coactivator complexes 
 Within transcriptional PPI networks, certain coactivators function as hub proteins 
or protein complexes that can bind to multiple proteins at either the same interface or at 
multiple interfaces simultaneously.16,17 Data suggest that hub proteins are capable of 
binding multiple proteins at multiple interfaces. High levels of structural plasticity allows 
Figure 1.1. Model of transcriptional regulation. (A) A high-affinity interaction 
between masking proteins and DNA-bound transcriptional activation domains (TADs) 
suppresses TAD activity and subsequent transcription. (B) Transient interactions 
between TADs and coactivators, including hub coactivators, leads to recruitment of 
general transcription factors and RNA Polymerase II (RNAP II) and subsequent 
activation of transcription. 
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these proteins to exhibit multiple conformations to adapt towards differing partner proteins 
as needed.18,19 Additionally, coactivator hubs tend to contain few “hot spot” clusters at 
their binding interfaces and a high prevalence of α-helices at multifunctional interfaces.20 
To overcome these characteristics, coactivator hubs often bind activator partners 
following a post-translational modification of the activator or through allosteric 
communication between binding sites of the coactivator.21–23 Two critical and well-studied 
hubs that contain multiple binding interfaces include the Mediator complex and the master 
coactivator CBP/p300.24,25  
 Recruitment of the Mediator complex, which consists of thirty-one protein subunits 
in humans, to DNA promoter regions is required for activated transcription of the majority 
of genes that code for proteins.26–28 This hub coactivator complex functions as a bridge 
that links multiple components of the transcriptional machinery through specific protein-
protein interactions (Figure 1.2).25,29,30 The Mediator complex acts through contacts with 
transcriptional activators, general transcription factors, and RNA Polymerase II itself.31,32 
Several Mediator-activator PPIs are important in the regulation of cellular homeostasis 
and thus have significant relevance in disease, including hormone and nuclear receptors 
(e.g. estrogen and androgen receptors) and the well-studied oncogenes p53 and ESX.33–
37 Furthermore, the Mediator complex has been directly linked to several human diseases 




CBP/p300 represents a second example of a hub coactivator with multiple binding 
interfaces that can be occupied simultaneously (Figure 1.3).24 CBP/p300 functions as a 
bridge between transcriptional activators and general transcription factors involved in the 
assembly of the pre-initiation complex.43 Differing from the Mediator complex and its 
multiple protein subunits, CBP/p300 consists of multiple coactivator domains on a single 
polypeptide.44–46 However, like the Mediator complex, CBP/p300 makes several contacts 
Figure 1.2. The Mediator complex is a critical coactivator hub. A composite image  
of the structure of the Mediator complex (human) showing the approximate relative 
location of each subunit. The Head, Middle, Tail, and Kinase modules are indicated by 
color; Med1 and Med26 are not always present in the complex. Protein binding 
partners for specific subunits are indicated. Figure adapted from Malik et. al (2010). 
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with transcriptional activators, such as p53, MLL, c-Jun, and HIF-1α, that have been 
implicated in human diseases.47–51  
 
Transcriptional protein-protein interactions and disease 
 Due to the importance of transcription in cellular homeostasis, dysregulation of 
transcriptional PPIs is either a cause or effect of many human diseases.2 Dysregulation 
of these processes occurs through several mechanisms including abnormally elevated or 
reduced expression of transcriptional proteins, the formation of fusion oncoproteins by 
chromosomal translocations, and genetic mutations within transcriptional proteins that 
elevate or reduce their activity.52 The transcriptional activator c-Myc represents an 
excellent example of an overexpressed activator in cancer.53 Elevated expression levels 
of c-Myc lead to overexpression of oncoproteins involved in cell cycle and metabolic 
regulation.54 Another example of the disease impact of overexpressed activators can be 
shown by the influences that the ETV/PEA3 family of activators (ETV1/ER81, 
ETV4/PEA3, and ETV5/ERM) play in cancer metastasis and tumorigenesis.55–57 These 
activators are amplified in concert with the Ras and PI3 kinase pathways and demonstrate 
high correlation with tumor invasion through the action of matrix metalloproteases.58 With 
Figure 1.3. Structural organization of the hub coactivator CBP/p300. The domain 
organization of CBP/300 is shown. Protein binding partners for specific domains are 
indicated below the relevant domain. Figure adapted from Majmudar et. al (2012). 
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respect to c-Myc and the ETV/PEA activators, elevated transcriptional activity occurs 
through an increase in the frequency of their interactions with coactivators and other 
transcription factors. Thus, the study and inhibition of these, and related PPIs represent 
an avenue to target and study disease processes. 
 
Features of transcriptional protein-protein interactions 
 As described, transcriptional coactivators interact with multiple binding partners; 
the same is true for transcriptional activators through their TAD motifs. Most, if not all 
TADs are considered amphipathic, meaning that their primary structures consist of acidic 
and polar residues interspersed with hydrophobic amino acids, and are intrinsically 
disordered in solution.59,60,13 TADs tend to make specific contact with two classes of 
proteins, namely transcriptional coactivators and masking proteins (Figure 1.4).8,61 
Masking proteins typically form specific and high affinity interactions with activators 
(nanomolar dissociation constants) for the purposes of suppressing, or ‘masking’, the 
activation of downstream gene production.62 Well-studied examples of activator 
interactions with masking proteins include p53-MDM2 and Gal4-Gal80.63,64 Crystal 
structures of both complexes have highlighted the importance of ‘hot spot’ residues, 
hydrophobic interactions, and small interaction interfaces that characterize masking-TAD 
PPIs.65,66 These features differ dramatically from activator-coactivator PPIs which are low-
to-moderate affinity (micromolar dissociation constants) and occur over large interfaces 
(800-2500 Å2).67–69 These PPIs tend to involve a mechanism in which the activator and 
the coactivator undergo conformational changes upon binding.70 In this scenario, the 
intrinsically disordered TAD adopts an α-helical structure upon binding to a coactivation 
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domain, causing the coactivator to allow for an induced fit between the activator and 
coactivator pair. For example, the activators pKID and Gcn4 are both intrinsically 
disordered prior to interaction with CBP/p300 KIX and Med15, respectively.71,72 Finally, 
activator-coactivator PPIs often exist in multiple “fuzzy” conformations and/or 
orientations, which is thought to be a critical determinant for the transiency and lack of 




Figure 1.4. Diversity of transcriptional protein-protein interactions. PPIs can be 
classified according to the affinity and the surface area of the interaction. Examples 
found within transcription of all four classes of PPIs are shown. Figure adapted from 
Mapp et al. (2015).  
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C. Small molecule modulation of transcriptional protein-protein interactions 
Difficulties in targeting transcriptional protein-protein interactions 
 Modulation of PPIs with small molecules has been historically challenging with 
significantly fewer than 0.01 % of all binary PPIs in the human cell having been 
successfully targeted.75–77 In fact, many PPIs, particularly those involving transcriptional 
proteins, have been previously classified as undruggable.3,4,78 The specific difficulty 
towards targeting transcriptional PPIs arises from inherent features of 
activator-coactivator PPIs, as described above. Examples of molecules that target unique 
classes of PPIs are provided in Figure 1.5.79–82 Coactivator-activator interactions are 
transient with binding interactions that demonstrate weak affinity over large surface 
areas.68,69 Weak interactions occurring over large interfaces have traditionally been more 
challenging to target with small molecules, as fewer than four percent of known molecules 
that target PPI are represented by these characteristics.76,83 Targeting this class of PPI  
requires a structurally plastic and large molecule that can overcome the lack of ‘hotspot’ 
residues within the broad and poorly defined interface.84 Additionally, due to their transient 
nature, the structural basis of many transcriptional PPIs have been poorly studied.85 This 
fact has also significantly hampered the potential for small molecule discovery as the 
specific elements of individual PPIs (e.g. binding orientations, hydrophobic regions/clefts 
of binding interfaces) are unknown. As a result of these collective characteristics of 
transcriptional PPIs, traditional screening, medicinal chemistry efforts, and rational design 
methodologies have led to limited success towards the discovery of novel small molecule 
modulators.86 Nevertheless, as described below, methodologies are being developed that 
demonstrate potential for the discovery of small molecules to target transcriptional PPIs. 
10 
 
Natural products to target transcriptional protein-protein interactions 
Natural products discovery offer promise towards targeting transcriptional PPIs; 
several natural products have recently been developed as tool compounds to target PPIs 
A. 
B. 
Figure 1.5. Small molecule modulation of diverse classes of protein-protein 
interactions. (A) Modulators of PPIs were categorized based on diverse classes of 
PPIs. An majority of known PPI modulators target PPIs with high affinity and small 
surface areas. (B) Examples of small molecules that target unique PPIs that represent 
each of the four PPI classes are provided. Figure adapted from Cesa et al. (2015). 
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(Figure 1.6).87–91 To highlight the broad utility of natural products, approximately 80% of 
all drugs available on the U.S. market in 2012 were natural products or derived from 
natural products.92,93 Natural product compounds derive great utility from their inherent 
structural complexity, ability to maintain high degrees of rigidity and chirality, and vast 
diversity of molecular structures and scaffolds.87 In fact, nearly 40% of compounds 
represented in the Dictionary of Natural Products contain unique structural elements that 
are not otherwise represented in purely synthetic compounds.95 Furthermore, it is thought 
that only a small fraction, particularly from the marine environment, of the total chemical 
matter that nature has designed has been identified by the scientific community 
suggesting that majority of potential compounds are still to be discovered.96–98 The 
discovery of these novel molecules should be forthcoming due to recent advances in 
fermentation, sample collection techniques, structural elucidation technologies, and 





The discovery of lichen-derived natural products, sekikaic acid, and lobaric acid, 
that target CBP/p300 KIX represent an excellent example of the potential that natural 
products can provide for modulation of transcriptional PPIs. These molecules, which 
belong to a class of molecules known as depsides and depsidones, were identified using 
an iterative screening strategy against the CBP KIX-MLL PPI.87,101 While high-throughput 
screening of a traditional drug-like small molecule library (50,000+ compounds) had failed 
to identify inhibitors of this PPI, high-throughput screening of natural product extracts 
isolated from marine sediment-derived microbes, cyanobacteria, lichens, and sponges 
(16,320 total) provided sekikaic acid and lobaric acid, both of which are potent inhibitors 
Figure 1.6. Examples of natural product small molecules. The field of natural 
products represents a broad range of structurally diverse molecules that have been 






of CBP KIX-MLL (IC50 of 17 µM and 25 µM, respectively). Subsequent computational 
analysis of sekikaic acid revealed that its lowest energy suite of conformations 
demonstrate that the molecule adopts an orientation that mimics an amphipathic α-helix, 
suggesting that the depside class of natural products likely function as helical mimetics.  
 
Fragment screening to target transcriptional protein-protein interactions  
The screening of fragment-based libraries for the discovery of small molecule 
inhibitors of PPIs has become increasingly common since pioneering work in this area 
during the mid-1990s.102–105 Fragments are small molecules that typically obey a ‘Rule of 
Three’ (MW less than 300 Da, no more than three each of hydrogen bond donors and 
acceptors); though these are rules are not strictly followed.106–108 There are several 
benefits of screening fragments instead of traditional chemical libraries.109 Fragments can 
be screened at high concentrations due to their high solubility in aqueous solutions and 
their ability to maintain high ligand efficiency. Discovered fragments tend to rely more on 
hydrogen bond interactions with the protein-of-interest than traditional small molecules 
which rely more heavily on hydrophobic interactions.104 Additionally, specific to the 
screening of PPIs, fragments are capable of interacting with one of the typically three to 
five regions critical for interaction with binding partners within a broad interface and have 
been successful in targeting highly dynamic regions within proteins.68 Following initial 
fragment discovery against a target PPI, fragments can then combined with other hot 
fragments or optimized into more potent compounds using structure-activity 





Table 1.1. Examples of small molecules fragment modulators of protein-
protein interactions. Fragments that modulate PPIs are shown; To demonstrate the 
power of fragment screening, ‘ABT-263’ and ‘IL-2 inhibitor’ are shown alongside the 





Fragment screening using NMR methodologies 
While multiple methodologies (e.g. surface plasmon resonance and Tethering) 
have been successfully used for the screening of fragment libraries, protein-observed 
NMR methods have been the most commonly and effectively used, particularly against 
PPIs.110–117 First, NMR chemical shifts are extremely sensitive to their surrounding 
chemical environment, giving rise to an assay that is capable of efficient detection of 
weakly associating fragments (single-digit millimolar binding affinities). Secondly, NMR 
experiments allow for protein-ligand interactions to be determined in solution near 
physiological conditions and unrestricted by artificial matrices, offering a native, 
well-folded protein. NMR screening can provide a large amount of structural and 
biochemical characterization of protein-fragment interactions, even during the screening 
process itself. This structural and biochemical characterization can include determination 
of the binding location and binding affinity of the hit fragment towards the protein.118,119  
Most protein-observed NMR strategies for screening use two-dimensional 
heteronuclear single quantum correlation (HSQC) techniques that make use of 15N-1H 
correlations in amide bonds or 13C-1H bond correlations in methyl groups of amino acid 
side chains.120 While HSQC protein NMR is most common and can provide the highest 
degree of structural information during the screening process, it does have serious 
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limitations. HSQC NMR requires a homogenous protein sample, long instrumental time 
(upwards of two hours per experiment), expensive isotopic reagents to produce 
15N-labeled or 13C-labeled protein, and time-intensive analysis of the resultant 
two-dimensional NMR spectra. Additionally, with regards to 1H, 15N-HSQC, this method 
only detects chemical shift perturbations of amide N-H bonds, offering minimal, if any, 
insight into side chain interactions. 
Protein-observed 19F-NMR (PrOF NMR) represents an alternative NMR method 
for fragment screening. PrOF NMR requires the incorporation of 19F through the 
integration of fluorinated amino acids into a protein-of-interest or through chemical 
modification to covalently label a residue onto the protein-of-interest with a fluorinated 
molecule.121,122 Relative to HSQC methodologies, PrOF NMR is desirable for a its short 
experimental time (as short as five minutes per experiment), rapid analysis of one-
dimensional spectra, and the ability to observe side chain interactions of a select number 
of residues.122,123 Inherent advantages also offered by the 19F nucleus include its native 
isotopic abundance (100%), magnetic sensitivity (83% as sensitive as 1H), and its low 
background signal in protein NMR (19F does not occur naturally in proteins).124 This 
strategy has been recently applied for the successful discovery of fragment-based 
inhibitors of the CBP/p300 KIX domain and its PPI network and as the orthogonal 
screening strategy against the SPRY-domain-containing SOCS box protein 2 and 
AMA1.125–127 Additionally, this methodology has been successfully applied for the 
simultaneous screening of two proteins of similar structure (BrdT and BPTF), indicating 




D. Thesis Summary  
The subsequent chapters of this dissertation describe the protein-protein 
interaction network of the Mediator subunit Med25 and the discovery of small molecule 
inhibitors that target Med25-activator PPIs. Med25 functions through its activator 
interaction domain (AcID) to bridge transcriptional activators to the Mediator complex to 
enable activated transcription of their target gene products. Specifically, Med25 AcID 
interacts with transcriptional activators that include the herpes simplex viral activator 
VP16, the activator ERM/ETV5 (implicated in cancer progression and metastasis), and 
the hypoxic stress response activator ATF6α (involved in the unfolded protein 
response).128–130 However, many questions regarding the selectivity of activators for 
unique Med25 binding sites and individual modes of molecular recognition remained 
unanswered prior to beginning this project.  
This dissertation describes the discrete binding modes between Med25 AcID and 
its protein partners as well as the development of small molecule inhibitors of the AcID 
motif. These small molecules will be invariably useful towards the dissection of Med25 
AcID function in vitro and in the cellular context as mechanistic probes in the elucidation 
of the role of Med25 in the regulation of transcriptional programs. Chapter Two describes 
the interaction between Med25 AcID and two of its protein partners, CBP and ATF6α, 
using HSQC NMR. Additionally, this chapter describes a mutagenesis study that utilized 
protein mutagenesis coupled with fluorescence polarization assays to investigate Med25 
AcID interactions with each of its native partners. Chapter Three expands upon the 
findings of Chapter Two to enable the generation of binding models that describe Med25 
AcID and its interactions with discrete protein ligands using PrOF NMR of Med25 AcID. 
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Furthermore, this chapter leverages PrOF NMR to gain mechanistic understanding of 
Med25-small molecule interactions. Chapter Four describes the discovery of small 
molecule inhibitors of Med25 AcID. First, this chapter describes the identification of 
preliminary hit fragments using PrOF NMR of Med25 AcID to enable a rapid screening 
process. Finally, this chapter describes the identification and mechanism of action of a 
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Investigation of Med25 AcID and its protein-protein network 
 
A. Abstract 
The activator interaction domain (AcID) of Med25 is a transcriptional coactivation 
motif that interacts with several transcriptional activators that are critical for normal cellular 
processes and certain disease states, including the ETV/PEA3 family transcription 
factors, the herpes simplex viral protein VP16, the oxidative stress response factor 
ATF6α, and the master coactivator CBP.1–4 However, Med25 AcID biochemistry and its 
modes of molecular recognition for individual binding targets had been poorly understood 
prior to this study. This chapter explores the binding modes for unique Med25 AcID-
activator interactions to describe putative binding sites of the AcID domain. Additionally, 
this chapter describes the identification and biochemical characterization of the minimal 
interacting sequences of CBP and ATF6α for Med25 AcID. These findings demonstrate 
that Med25 AcID contains two binding sites that are 180° apart, termed the H1 and H2 
sites, and a putative third site flanked by H1 and H2. Data suggests that some activator 
ligands (VP16 H1 and VP16 H2, in particular) are capable of binding at multiple sites on 
Med25 AcID. Others, such as ERM and ATF6α bind selectively at one site. This chapter 
builds a critical foundation for understanding the Med25 AcID-activator interactions further 
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capable of efficiently Tethering to Med25 AcID and characterized its interactions with WT Med25 AcID. 




explored using protein-observed 19F NMR in Chapter 3 and leveraged for small molecule 
discovery in Chapter 4. 
 
B. Introduction 
The protein-protein interactions (PPIs) between transcriptional coactivators and 
transcriptional activation domains (TADs) represent the molecular underpinnings of 
transcription and are therefore tightly regulated.5,6 Dysregulation of transcriptional PPI 
networks is common in disease states, and altered transcriptional networks are often 
either a cause or a direct effect of the disease.7,8 These PPIs are frequently transient, 
occur over large surface areas (>1500 Ǻ) and demonstrate weak-to-moderate binding 
affinity.9–11 The transcriptional coactivator involved in a particular PPI is typically capable 
of interacting with a wide array of TADs.12 Likewise, transcriptional activators are also 
known to bind multiple proteins. This capability to bind multiple ligands often results from 
the ability of the coactivator to adopt multiple conformations dependent upon TAD 
binding.5,13 A better understanding of the subtle differences in binding mode and 
conformations of the coactivator would allow for further study of the impact of these PPIs 
on transcription and their implications for disease .   
 
Mediator subunit Med25 and AcID motif 
Med25, a subunit of the Mediator complex, is a transcriptional coactivator that has 
recently been implicated as a critical protein in the recruitment of the pre-initiation 
complex and subsequent gene transcription for a number of TADs.1 Med25 consists of 
three unique motifs – a von Willebrand factor type A (VWA) domain that anchors Med25 
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to the multiprotein Mediator complex, a nuclear receptor (NR) box that is reported to 
interact with retinoic acid receptor α and the estrogen receptor α, and an activator 
interaction domain (AcID) that interacts with several TADs implicated in disease.1–4,14,15 
Transcriptional activators reported to interact with Med25 AcID include VP16, a 
component of the herpes simplex virus responsible for lytic infections1,16; ERM, a member 
of the Ets family of transcription factors that has been implicated in cancer progression 
and metastasis2,17,18; and ATF6α, an endoplasmic reticulum stress response transcription 
factor that is involved in the unfolded protein response.3,19,20 Additionally, the master 
coactivator CBP has been reported to interact with Med25 AcID; the biochemical rationale 
for this PPI is still relatively unknown.4  
 
 The AcID motif is an unprecedented structural fold among transcriptional 
coactivators, because it consists of a central β-barrel with three surrounding α-helices.21–
23 Typical transcriptional coactivator motifs, such as KIX and TAZ domains, consist 
primarily of α-helices.24,25 This motif is also unique in that it is only found in Med25 and 
Prostate Tumor Overexpressed 1 (PTOV1).26 Interestingly, PTOV1, which contains two 
Figure 2.1. Domain architecture of Med25 and the structure of the AcID motif. At 
left, the domain architecture of Med25 (one AcID motif) and PTOV1 (two AcID motifs). 
At right, a cartoon image of Med25 AcID to demonstrate central β-barrel with three 
surrounding α-helices. (PDB 2XNF) 
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AcID motifs, is overexpressed in a variety of cancers while not expressed at detectable 
levels in healthy tissues.27–29 Additionally, it has been shown to compete with Med25 for 
interaction with CBP.26 
Med25 AcID-activator protein-protein interactions 
Previous NMR studies have reported on the interactions between Med25 AcID and 
the two canonical VP16 TADs, termed VP16 H1 and VP16 H2.21,23 These data 
demonstrated that Med25 AcID contained at least two presumed binding sites. Titration 
of VP16(413-451), the H1 TAD, into 15N-labeled Med25 AcID perturbed specific residues 
in the cleft of Med25 AcID formed by β1–β3–β5 and α2 (Figure 2.2.A).23 This cleft of 
Med25 AcID is hereby referred to as the H1 site. Similarly, titration of VP16(452-490), the 
H2 TAD, into 15N-labeled Med25 AcID perturbed specific residues in the cleft of Med25 
AcID formed by α1 and β6–β7–β4 (Figure 2.2.B).21 This region of Med25 AcID is hereby 
referred to as the H2 site. Additional reports of 1H,15N-HSQC NMR studies of Med25 AcID 
in complex with ERM/ETV5 and ETV4 TADs1 found that the TADs of both bound to the 
H1 site.17,3 A third putative site within Med25 AcID, formed at the junction of β4-β2 and 
α2, was also recently reported to interact with the DNA-binding domain (DBD) of ETV4, 
as demonstrated by 1H,15N-HSQC NMR (Figure 2.2.C). 
 However, even with these published reports, many questions regarding the 
selectivity of peptide ligands for unique binding sites and individual modes of molecular 
recognition remain. For example, the Med25-VP16 NMR publications disagree above the 
relative importance of the H1 versus H2 binding sites for interaction with VP16 TADs and 
subsequent VP16 transcriptional activation.21,23 This discrepancy requires a rigorous 
analysis of the binding determinants of each site and the selectivity of differing activator 
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ligands for one site over the others. Additionally, the minimal interacting regions of CBP 
and ATF6α have not been reported. Identification of those sequences would allow for the 
biochemical characterization of these proteins with the AcID motif of Med25. 
 









Figure 2.2. Med25 AcID contains multiple binding sites. (A)The H1 binding site 
(teal), as defined by Milbradt et al. (2011)23, is formed by β1–β3–β5 and α2. (B) The 
H2 binding site (red), as defined by Vojnic et al. (2011)21, is formed by α1 and β6–β7–
β4. (C) A proposed third binding site (green), as defined by Currie et. al. (2017)30, is 
formed by β4-β2 and α2. (PDB 2XNF) 








Role of electrostatic contacts in Med25 PPIs 
Electrostatic contacts have been shown to play a significant role in activator-
coactivator PPIs, consistent with the acidic nature of TAD sequences.31 Thus, it had been 
expected that Med25 AcID PPIs might also be dependent on electrostatic contacts to 
drive the binding of acidic TADs to the highly basic AcID motif. Experiments performed 
by Steve Sturlis (Mapp lab, University of Michigan) demonstrated that a 10 fold increase 
in the concentration of NaCl in fluorescence polarization (FP) experiments resulted in a 
>30 fold decrease in affinity of the VP16 peptides for Med25 AcID. This result is consistent 
with Med25 AcID being dependent upon electrostatic interactions. It was hypothesized 
that electrostatic interactions could be leveraged for the study of one Med25 binding site 
at a time, allowing for observation of activator interactions that might occur selectively 
within that binding site.  
 
C. Results and discussion 
Characterization of the Med25 AcID-CBP protein-protein interaction 
Previous work had demonstrated that GST-tagged CBP(1-460) interacted 
specifically with the AcID domain of Med25 in vitro.4 While coactivator-coactivator PPIs 
are common (e.g. CBP iBiD interacts with steroid receptor coactivator 132), the Med25-
CBP interaction is interesting because CBP was thought to be functioning as a TAD 
mimic. All other reported PPIs involving Med25 AcID represented more traditional 
activator-coactivator interactions. As such, more in-depth biochemical study of the CBP-
Med25 PPI was intriguing but required the discovery of a minimal sequence of CBP 




An analysis using the Basic Local Alignment Search Tool (BLAST) of CBP(1-460) 
against the transcriptional activation domain of VP16, found that CBP(20-44) shared 
homology (38% identity, 52% similar) with a portion of the VP16 activation sequence 
(Figure 2.3).33 Like the VP16 TAD, CBP(20-44) is very negatively charged (-7 charge) 
and contains a high percentage of aromatic and bulky hydrophobic residues. 
Following the identification of the short sequence within CBP that shared homology 
with a VP16 TAD, a small panel of CBP-derived peptides extending from residue 20 
through residue 76 of CBP were synthesized. This encompassed the entirety of the 
predicted TAD-like sequence from 20-44 as well as additional patches of hydrophobic 
residues and a predicted α-helical sequence C-terminal to that sequence. The CBP(20-
44) sequence in particular had many of the critical characteristics of a canonical TAD, 
including a high number of negatively charged and aromatic amino acids as well as a 
region predicted to adopt an α-helical structure.31,34 Six peptides in total were designed 
and synthesized – CBP(20-44), CBP(20-55), CBP(30-44), CBP(33-55), CBP(50-64), and 
CBP(59-76). Each peptide was appended with a N-terminal fluorescein and an 
accompanying β-alanine linker for use in FP assays to detect direct binding with Med25 
AcID.   
Figure 2.3. Sequence alignment of CBP(20-44) and VP16(454-486). A basic local 
alignment search of CBP(1-460) demonstrated that CBP(20-44) was homologous to 
the VP16 H2 transcriptional activation domain. CBP(20-44) shares numerous acidic 




 FP assays were consistent with a model in which residues 20-44 of CBP are the 
primary determinant for the interaction between Med25 AcID and the N-terminal region 
of CBP, as CBP(20-44) peptide bound Med25 AcID with a dissociation constant of 1.0 ± 
0.1 µM. Binding affinity for Med25 AcID was not increased by shortening or extending this 
sequence, as evidenced by CBP(30-44) (Kd = 5.9 ± 0.3 µM) and with CBP(20-55) (Kd = 
2.5 ± 0.3 µM) respectively. The most C-terminal peptides tested, CBP(50-64) and 
CBP(59-76), demonstrated very limited interaction with Med25 AcID with dissociation 
constants of 115 ± 11.1 µM and > 500 µM respectively. These results were unsurprising, 
 Figure 2.4. Minimal Med25 AcID-interacting sequences of CBP. (A) Sequence of 
CBP from 20-76. Predicted α-helical regions, from 32-38 and from 62-75, are bold and 
underlined. Synthesized peptides are shown, labeled and depicted as colored boxes, 
beneath their corresponding sequences. (B) Direct binding experiments between 
fluorescein-labeled CBP peptides and purified Med25 AcID. Binding curves are 
colored to match the sequences shown in (A). Data curves reported are average and 
standard deviations of triplicates of two independent experiments. 
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given the relative lack of negative charge present at the C-terminal region of the CBP(20-
76) sequence.    
 A variant of the CBP(20-44) peptide replacing the N-terminal fluorescein with a 
acetyl group was synthesized to demonstrate that the observed PPI did not result from a 
specific interaction between Med25 AcID and fluorescein itself. In FP experiments with a 
50% bound complex of Med25 AcID with fluorescein labeled CBP(20-44), acetylated 
CBP(20-44) was capable of disrupting this complex with a Ki of 9.4 ± 0.8 µM  (Figure 2.5). 
This level of inhibition, approximately 10x less than the binding affinity for Fl-CBP(20-44), 
suggests that the fluorescein at the N-terminus of CBP(20-44) peptide does contribute 
slightly to the direct binding FP experiment. However, this degree of increased binding 
affinity can be explained by the hydrophobicity of fluorescein. 
 
Following confirmation that CBP(20-44) bound to Med25 AcID in FP experiments, 
1H-15N-HSQC experiments were performed to determine the binding site(s) of Med25 
AcID responsible for this PPI. Acetylated CBP(20-44) peptide was titrated into 15N-labeled 
Med25 AcID at 0, 1, 2, and 5 equivalents of peptide relative to protein. This titration 
demonstrated dose-dependent chemical shift perturbations of backbone amide bonds of 
Figure 2.5. Acetylated CBP(20-44) inhibits Med25 AcID interaction with 
Fluorescein-CBP(20-44). At relative fraction bound of 1.0, Med25 AcID was 50% 
bound with Fl-CBP(20-44). The data curve reported provides representative averages 
and standard deviations of triplicates. 
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selected Med25 AcID residues (Figures 2.6, 2.7, 2.8). These dose-dependent chemical 
shifts demonstrated that Med25 AcID makes a specific PPI with CBP(20-44) and retention 
of most 1H-15N resonances suggests that the overall structural fold of the protein remains 
intact.  
 
Figure 2.6. 1H-15N-HSQC NMR spectra of Med25 AcID-CBP(20-44) complexes. 
An overlay of the HSQC spectra of 15N-labeled Med25 AcID with DMSO (black), one 
equivalent of CBP(20-44) (light blue), two equivalents of CBP(20-44) (dark blue), and 
five equivalents of CBP(20-44) (pink) is shown.  
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Peaks in all of the collected HSQC spectra were assigned to specific residues using both 
a previously published NMR assignment21 and a de novo assignment performed by Andy 
Henderson (Mapp lab, University of Michigan). Notable residues of Med25 AcID that are 
most significantly affected by the addition of CBP(20-44) include residues located within 
the H1 face along β2/β1/β5 and α3 (L406, Q409, E410, K413, M450, Q451, C497, V498, 
A504, C506, N535, and G536) in addition to the H2 face along β4/β7/β6 and α1 (G462, 
L464, R466, N467, R469, V471, Q472, M512, L513, S516, G524, and L525). There were 
also several shifted peaks that correspond to residues that sit along β1/β2, the C-terminal 
Figure 2.7. Chemical shift perturbations within Med25 AcID induced by 
saturating CBP(20-44) conditions. The magnitude of chemical shift perturbations, 
in Hz, are shown upon saturation of 15N Med25 AcID with five equivalents CBP(20-
44). Residues that shift 1-2 standard deviation (SD) above the mean (light blue), >2 
standard deviations above the mean (dark blue), and that broaden into noise (red) 
are considered to be significantly affected by CBP(20-44).  
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end of β4, α2, and on the loop between β2-β3 (L400, L406, Q430, N434, E437, N438, 
L439, K440, F473, H474 L483, K484, G485, and L486).  
 
These data do not demonstrate that CBP(20-44) specifically interacts at the H1 or 
H2 sites of Med25 AcID. This indicates that CBP(20-44) binds to Med25 AcID with a 
Figure 2.8. Chemical shift perturbations within Med25 AcID induced by 
saturating CBP(20-44) conditions. Mapped onto the structure of Med25 AcID are 
chemical shift perturbations upon binding to five equivalents CBP(20-44). Increasing 
shades of red indicate a gradient of increasing chemical shift perturbations. Red 
balls indicate residues that show near-complete peak broadening. (PDB 2XNF) 
H1 site H2 site 
Proposed 3rd site 
~90° rotation from H1 site 
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mechanism that is distinct from previously described activator partners. Instead, these 
data suggest that CBP(20-44) could interact at a newly reported third binding site located 
at β2/β4/α2, 90° away from the H2 site.30 An interaction at this site would explain the high 
degree of significantly perturbed residues in that region of the protein. In the event that 
CBP(20-44) does interact at this third binding site, perturbation of residues in the H2 site 
would be explained by allosteric or through-molecule effects. Interestingly, this result is 
unexpected based on the BLAST analysis that demonstrated that CBP(20-44) was 
homologous to VP16 H1. Based on this homology experiment, it might be expected that 
CBP(20-44) would interact at the H1 site of Med25 AcID; That CBP(20-44) does not 
interact specifically at that site suggests that VP16 H1 itself might not be specific for the 
H1 site. Additional experiments described in Chapter 2 (mutagenesis at H1 and H2 
binding sites) and in Chapter 3 (protein-observed 19F NMR) provide additional evidence 
that CBP(20-44) interacts in a manner distinct from activators that directly bind at the H1 
and H2 sites (such as VP16 H1, VP16 H2, ERM) and that it likely binds at the putative 
third site formed by β2/β4/α2.  
 
Characterization of the Med25 AcID-ATF6α protein-protein interaction 
Similar to the N-terminus of CBP, previous reports demonstrated that the N-
terminal 150-residue activation domain of ATF6α interacted with Med25 AcID in vitro.3 
However, the minimal binding region of ATF6α for Med25 AcID was unknown. An analysis 
using BLAST was performed to discover that residues 42-67 of ATF6α shared homology 
(38% identity, 48% similarity) with the VP16 H1 TAD, an interacting partner for Med25 
AcID21–23,33. Critically, this sequence of ATF6α, similarly to VP16 H1, bears a net negative 
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charge (-9 charge for ATF6α compared to -10 charge for the homologous region of VP16 
H1) and is relatively hydrophobic (Figure 2.9).  
 
Again, in similar manner as was performed after discovery of CBP(20-44), a small 
panel of ATF6α-derived peptides surrounding the region homologous to the VP16 H1 
TAD were synthesized. This panel of peptides focused on synthesis of short sequences 
that were richest in negatively charged amino acids (Glu/Asp) and aromatic amino acids 
(Phe/Tyr/Trp) as well as predicted α-helical regions (D28-T39 and E43-A49). Recall that 
high proportion of negatively charged residues, amphipathic character, and a propensity 
to form α-helices are all common characteristics of TADs.34 Seven peptides in total were 
synthesized – ATF6α(13-33), ATF6α(28-49), ATF6α(40-66), ATF6α(52-75), ATF6α(63-
75), and ATF6α(66-80). The peptides of greatest interest at the time of synthesis were 
ATF6α(40-66), designed to capture the entirety of the region homologous to VP16 H1; 
and ATF6α(28-49), designed to encompass each of the predicted α-helices. Each peptide 
was appended with a N-terminal fluorescein and an accompanying β-alanine linker for 
use in FP assays to detect direct binding with Med25 AcID. 
Figure 2.9. Sequence alignment of ATF6α(42-67) and VP16(423-448). A basic 
local alignment search of ATF6α(1-150) demonstrated that ATF6α(42-67) was 
homologous to the VP16 H1 transcriptional activation domain. ATF6α(42-67) shares 
numerous acidic and hydrophobic residues in common with the VP16 sequence. 
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 Each of the peptides synthesized demonstrated single-digit micromolar binding 
affinities towards Med25 AcID. Further, two peptides - ATF6α(40-66) and ATF6α(63-75) 
– exhibited binding affinities in submicromolar range. Collectively, this suggests that the 
ATF6α TAD is quite lengthy, spanning the majority of the 13-80 amino acid region that 
was explored. Since negatively charged and aromatic residues are dispersed throughout 
this ATF6α sequence, this observation is perhaps not unlikely. For future study of the 
Med25-ATF6α PPI, the ATF6α(40-66) peptide was chosen because of its homology with 
VP16 H1 and its tight binding affinity (KD = 0.50 ± 0.02 µM).  
 
 Figure 2.10. Minimal Med25 AcID-interacting sequences of ATF6α. (A) Sequence 
of ATF6α from 13-80. Predicted α-helical regions, from 28-39 and from 43-49, are bold 
and underlined. Synthesized peptides are shown, labeled and depicted as colored 
boxes, beneath their corresponding sequences. (B) Direct binding experiments 
between fluorescein-labeled ATF6α peptides and purified Med25 AcID. Binding curves 
are colored to match the sequences shown in (A). Data curves reported are average 




Next, 1H-15N-HSQC experiments were performed to determine the binding site(s) of 
Med25 AcID responsible for its interaction with ATF6α. Acetylated ATF6α(40-66) peptide 
was titrated into 15N-labeled Med25 AcID at 0, 0.25, 0.5, 1 and 3 equivalents of peptide 
relative to protein (Figures 2.11, 2.12, 2.13). Dose-responsive chemical shift perturbations 
of selected residues demonstrated that Med25 AcID specifically interacts with ATF6α(40-
66) and that the peptide does not destabilize the overall structural fold of Med25 AcID.  
 
Figure 2.12. Chemical shift perturbations within Med25 AcID induced by 
saturating ATF6α conditions. The magnitude of chemical shift perturbations, in Hz, 
are shown upon saturation of 15N Med25 AcID with three equivalents ATF6α(40-66). 
Residues that shift 1-2 standard deviation (SD) above the mean (light blue) and >2 
standard deviations above the mean (dark blue) are considered to be significantly 
affected by ATF6α(40-66). 
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As with CBP(20-44) titration, peaks in all of the collected HSQC spectra were 
assigned to specific residues using both a previously published NMR assignment21 and 
a de novo assignment performed by Andy Henderson (Mapp lab, University of Michigan). 
Notably, only residues of Med25 AcID located on the H2 face are significantly affected by 
the addition of ATF6α(40-66). These affected residues located within the cleft of Med25 
formed by β4/β7/β6, α1, and α2 include G462, L464, R466, V471, H474, G485, R487, 
I488, M489, G490, G492, L513, L514, S516, M523, G524, and L525. The majority of 
these perturbed residues cluster within the H2 site of Med25 AcID in stark contrast to the 
similar experiment performed with CBP(20-44). There are minor, but not significant (>1 
SD chemical shift), perturbations at the H1 face. These minor perturbations are likely a 
result of either a slight conformational change within Med25 AcID or through-molecule 
H1 site 
Figure 2.13. Chemical shift perturbations within Med25 AcID induced by 
saturating ATF6α conditions. Mapped onto the structure of Med25 AcID are 
chemical shift perturbations upon binding to three equivalents ATF6α(40-66). 
Increasing shades of red indicate increasing magnitude of chemical shift; Note that 




effects. These data are consistent with ATF6α(40-66) binding specifically to the H2 site 
of Med25 AcID.  
 
Mutational analysis of Med25 to define binding models 
 Previous studies suggested that the two TADs of VP16 bind opposing faces of 
Med25 AcID. VP16 H1 binds to Med25 AcID at the surface formed by β1–β3–β5 and α223 
and that VP16 H2 binds at the surface formed by α1 and β6–β7–β421. However, the 
specificity of peptides for one site over the other remained an open and unanswered 
question. To better understand the specificity of individual binding partners towards each 
of the two binding sites, it was hypothesized that mutagenesis of specific Med25 AcID 
residues at each binding site could provide a more in-depth picture of these PPIs. Due to 
the observation made by others in the Mapp lab that charge-charge interactions between 
the positively charged Med25 AcID protein and negatively charged peptide ligands is a 
primary driver of these PPIs, most residues were mutated to introduce a negatively 
charged side chain (Glu or Asp). The introduction of negative charge at a single site was 
hypothesized to function as a mechanism to functionally block one site of Med25 while 
leaving the opposite site unaffected. This would allow for a determination of the selectivity 
of each discrete peptide ligands for unique binding sites on Med25 AcID. For example, it 
was anticipated that a Met-to-Glu mutation at residue 523, located in the center of the H2 
face and perturbed by ATF6α in HSQC NMR titrations, would cause a dramatic loss in 
binding affinity for ATF6α(40-66) but have marginal effect on ERM(38-68), a ligand 





Initial residues selected for mutagenesis to introduce a negatively charged residue 
at the H1 binding face - V405, L423, Q451, H499, and R538 -  were chosen based on 
analysis of published HSQC NMR data of the Med25-ERM PPI.17 All mutants, following 
Figure 2.14. Mutagenesis at H1 site of Med25 AcID. (A) Residues selected for 
mutagenesis based on HSQC NMR titrations with ERM peptides. (B) Circular 
dichroism spectra of WT Med25 AcID and H1 site mutants. (C) Binding affinities of 
Med25-interacting peptides for H1 site mutants relative to WT Med25 AcID, as 
measured by FP. Bar graphs represent the average and standard deviations of the 
fold change of three independent experiments performed in triplicate. 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
(𝐾𝐷 for Mutant Med25 AcID-peptide interaction)
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site-directed mutagenesis of a plasmid containing WT Med25 AcID, were expressed and 
purified following standard conditions defined for WT Med25 AcID. Mutant proteins were 
then subjected to a battery of biochemical experiments - FP assays against Med25-
interacting peptide ligands, circular dichroism, and CD-monitored thermal denaturation – 
to determine the functional impact of the mutation (Figure 2.14). Circular dichroism, which 
measures protein secondary structure, suggested that most mutant proteins retained WT-
like secondary structure. L423E and H499E both demonstrated minima at 208 and 228 
nm that were of lesser magnitude than WT Med25 AcID. This suggests that these 
mutations had a slight effect on the helicity of the protein fold. This is not unexpected as 
L423E introduces a negative charge in the proximity of α2 while H499E places a negative 
charge in the proximity of α3. Interestingly, all single-point mutants tested behaved 
similarly in CD-monitored thermal denaturation experiments with 12-15% losses in 
melting temperature (58-60 °C compared to 71 °C for WT Med25 AcID). Taken together, 
these experiments demonstrate that mutations at the H1 face of Med25 AcID could result 
in minor losses in stability but have little effect on the overall structural integrity of Med25 
AcID.  
It had been anticipated that the introduction of glutamic acid within the H1 binding 
face would result in large losses in apparent binding affinity relative to WT Med25 AcID 
for peptides predicted to preferentially bind at the H1 face such as ERM(38-68), VP16 
(438-454) – the helical region of VP16 H1 – and VP16(413-451) – the entirety of the VP16 
H1 TAD. However, FP experiments utilizing these mutants demonstrated that they 
conferred only a modest effect on the binding affinities for Med25-interacting ligands. 
V405E and L423E demonstrated a less than two-fold loss in binding affinity for all peptides 
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tested relative to WT Med25 AcID. This could indicate that these two residues are outside 
of the H1 site, as neither mutation provided significant effects (greater than 3-fold 
change). Q451E, H499E, and R538E all demonstrated a significant effect on the binding 
interaction with ERM(38-68) with 3.0-, 3.5-, and 5.9- fold losses in binding affinity relative 
to WT, respectively. These data are consistent with ERM(38-68) binding preferentially to 
the H1 site.  However, they do suggest that either a single mutation is not sufficient to 
fully block the H1 site or that ERM is capable of compensatory interactions at the H2 site. 
Q451E, H499E, and R538E did not significantly affect any other peptide ligand. 
Collectively, these data suggest that the H1 binding site is less dependent on electrostatic 
interactions and hotspot residues than previously assumed, that a single mutation is not 
sufficient to block the H1 site, and/or that the H1 site could allow for multiple 




Initial residues selected for mutagenesis at the H2 binding face – R466, R469, and 
M523 – were chosen based on HSQC NMR data of the Med25-ATF6α PPI (Figure 2.13). 
Negatively charged amino acids (Glu or Asp) were singly introduced at all three positions. 
A. B. 
C. 
Figure 2.15. Mutagenesis at H2 site of Med25 AcID. (A) Residues selected for 
mutagenesis based on HSQC NMR titrations with ATF6α(40-66). (B) Circular 
dichroism spectra of WT Med25 AcID and H2 site mutants. (C) Binding affinities of 
Med25-interacting peptides for H2 site mutants relative to WT Med25 AcID, as 
measured by FP. Bar graphs represent the average and standard deviations of the 
fold change of three independent experiments performed in triplicate. 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
(𝐾𝐷 for Mutant Med25 AcID-peptide interaction)




All mutants, following site-directed mutagenesis of parent Med25 plasmid, were 
expressed and purified following standard conditions defined for WT Med25 AcID. 
Circular dichroism demonstrated that single-point H2 mutant proteins (R466D, R466E, 
and M523E) retained the core secondary structure of WT Med25 AcID (Figure 2.15) with 
minor differences. CD spectra of R469E does have a minimum at 208 nm that is of 
meaningfully lesser magnitude than WT suggesting that this particular mutation affects 
the helical structure of Med25 AcID, potentially through disruption of α1. Additionally, each 
single-point mutant brought minor losses in protein stability in CD-observed thermal 
denaturation experiments (15-19% decrease in melting temperatures relative to WT 
Med25 AcID).  
Differing from the example of H1 mutations, FP experiments performed with 
R466D, R466E, and M523E demonstrated that introduction of negative charge within the 
predicted H2 binding face had dramatic effects on binding affinity for CBP(20-44), 
VP16(467-488) – the helical region of VP16 H2, and ATF6α(40-66). Specifically, the 
binding affinities of R466E Med25 AcID to CBP(20-44), VP16(467-488), and ATF6α(40-
66) were, respectively 6.7-fold, 14-fold, and 11-fold weaker than the corresponding 
interactions with WT Med25 AcID. The binding affinities of R466D Med25 AcID to 
CBP(20-44), VP16(467-488), and ATF6α(40-66) were, respectively, 8.1-fold, 11-fold, and 
6.3-fold weaker than the corresponding interactions with WT Med25 AcID. Finally, the 
binding affinities of M523E Med25 AcID to CBP(20-44), VP16(467-488), and ATF6α(40-
66) were, respectively, 11-fold, 9.4-fold, and 8.5-fold weaker than the corresponding 
interactions with WT Med25 AcID. These experiments corroborate earlier experiments 
indicating that the H2 site is dependent on electrostatic contacts between positive charges 
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of Med25 AcID and negatively charged TADs. Additionally, these findings suggest that 
the peptides derived from ATF6α, CBP, and VP16 H2 are specific interacting partners at 
the H2 face of Med25. If these peptide ligands could bind equally or nearly as well to the 
H1 face as to the H2 face, there would be a limited reduction in binding affinities to H2 
mutants relative to WT. These three single-point mutants did not show decreases in 
binding affinities that were nearly as dramatic for ERM(38-68), VP16(413-451) or 
VP16(438-454). The lack of large reductions in binding affinity for these peptides, 
particularly ERM(38-68), suggests that the binding interaction of these peptide ligands for 
Med25 is not dependent on the H2 face.  
The R469E mutation brought about a moderate but significant decrease in the 
binding affinity for all tested peptides. The minima observed at 208 nm and 228 nm, which 
represent α-helical character, in the CD spectrum of R469E were of lesser magnitude 
than that of WT Med25 AcID. Taken in concert, FP assays and CD analysis suggests that 
this mutation, with a side chain directed away from the center of the H2 binding face, 
could be affecting the structural integrity of Med25 AcID. It is possible that an introduction 
of negative charge at this position could result in the disruption of either α1 or α3. The 
D529R mutation was designed in part to function as a control mutation. D529 is positioned 
on α3, away from both the H1 and H2 faces, and was not predicted to be involved in any 
PPIs. D529R Med25 AcID retained WT-like secondary structure and showed no effect 






Figure 2.17 Mutagenesis to block H1 and H2 sites simultaneously. (A) Binding 
affinities of putative H1 site peptides for Med25 mutants relative to WT Med25 AcID, 
by FP. Bar graphs represent the average and standard deviations of the fold change 
of three independent experiments performed in triplicate. (B) Binding affinities of 
putative H2 site peptides for Med25 mutants relative to WT Med25 AcID.  
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
(𝐾𝐷 for Mutant Med25 AcID-peptide interaction)





To continue the investigation into peptide selectivity between the putative H1 and 
H2 sites, methods to inhibit function at both sites were desired. Knowledge from the single 
mutagenesis experiments was leveraged to generate two doubly mutated Med25 AcID 
variants - Q451E/M523E and R466D/M523E. 
An attempt to block the H1 and H2 faces simultaneously through the 
Q451E/M523E mutant was successful in corroborating that peptides believed to 
specifically target the H1 face – ERM(38-68) and VP16(413-451) – are capable of 
interacting at the H2 face (Figure 2.17.A). Q451E Med25 AcID bound ERM(38-68) 3.0-
fold less tightly than WT Med25 AcID; Q451E/M523E bound ERM(38-68) 9.9 times less 
tightly than WT Med25 AcID. The single mutants R466D and M523E, as well as double 
mutant R466D/M523E, had no effect on the binding of ERM(38-68). This single mutant 
data suggests that ERM(38-68) has a preference for interaction at the H1 site, as 
evidenced by impact of negative charge at H1 face alone but not at H2 face alone. 
However, the large increase in the magnitude of the effect in the case of Q451E/M523E 
definitively demonstrates that ERM(38-68) must be capable of interacting at the H2 face 
when/if the H1 face is blocked. In the case of the other ligand predicted by NMR to bind 
the H1 face, each of the three single-point mutants (Q451E, R466D, M523E) inhibited 
VP16(413-451) equally well with 3.0- to 4.0- fold losses in binding affinity relative to WT 
Med25 AcID. This suggested that, contrary to published HSQC NMR experiments, 
VP16(413-451) could bind equally well at both the H1 and H2 faces of Med25 AcID. The 
double mutant Q451E/M523E validated this finding, since blocking both sites resulted in 
24-fold loss in binding affinity. 
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The double mutagenesis was also effective at providing corroborating evidence 
that both ATF6α(40-66) and VP16(467-488) are highly selective/specific for the H2 face 
of Med25 AcID (Figure 2.17.B). The double mutant Q451E/M523E had nearly identical 
effects on binding affinity towards ATF6α(40-66) and VP16(467-488) as did M523E itself 
(9.4-fold loss in affinity vs. 8.6-fold loss against ATF6α(40-66); 9.0-fold loss in affinity vs. 
9.1-fold loss against VP16(467-488)). The inability of the H1 mutation to provide 
additional inhibitory benefit relative to a single H2 mutant demonstrates that neither 
peptide is affected by the blocking of the H1 face through the introduction of negative 
charge. Further, as anticipated, the double mutant R466D/M523E was more effective at 
inhibition of ATF6α(40-66) and VP16(467-488) than either single mutant. The CBP(20-
44) peptide, as in HSQC NMR experiments, behaved unlike all others. Neither double 
mutant was more effective at inhibition of CBP(20-44) than either R466D or M523E. In 
fact, Q451E/M523E bound CBP(20-44) more tightly (5.3-fold loss in binding affinity 
relative to WT) than M523E (11-fold loss in binding affinity). It is possible that this data 
suggests, in light of the HSQC NMR experiments, that CBP(20-44) is partially interacting 
at the putative third site of Med25 AcID. If this is the case, the inability of Q451E/M523E 
to replicate the effects of M523E alone could be explained by either a slight 
conformational change in Med25 AcID or an alteration in the orientation of the peptide 
interaction with the protein. 
A secondary method to block both the H1 and H2 faces simultaneously was 
explored using a combination of mutagenesis and covalently tethered peptide ligands. It 
had been discovered that a unique derivative of VP16(438-454) that incorporated a 
cysteine at the G450 position can form a disulfide linkage with C506 of Med25 AcID. C506 
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of Med25 AcID is positioned on a loop nearby the H1 face site and nearly 100% labeling 
with the G450C peptide can be achieved using disulfide Tethering35,36. HSQC NMR 
experiments of WT Med25 AcID tethered to G450C peptide demonstrate that the peptide 
does not destabilize the overall structure of the protein and that it likely interacts with the 
H1 face of Med25 AcID (Figure 2.18). Therefore, it was expected that the G450C peptide 
would function to block, or inhibit, the H1 face of Med25 AcID, likely more efficiently than 
does Q451E, R538E, or H499E.   
 Modifications performed in tandem (G450C peptide at H1 site; mutagenesis at H2 
site) designed to block both faces simultaneously performed similarly to the 
Q451E/M523E double mutation and corroborated the conclusions that were drawn from 
Figure 2.18. Chemical shift perturbations within Med25 AcID induced by 
tethered VP16 G450C peptide. Mapped onto the structure of Med25 AcID are 
chemical shift perturbations caused by formation of a covalent complex with VP16 
G450C peptide. Significantly perturbed residues are depicted in pink (>1 standard 
deviation from mean) and red (>2 standard deviation). Cys506 is depicted with red 
sphere. (PDB 2XNF) 
 
H1 face H2 face 
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Figure 2.19 Mutant Med25-G450C peptide complexes to block H1 and H2 sites 
simultaneously. (A) Binding affinities of putative H1 site peptides for Med25 mutants 
complexed to VP16 G450C relative to WT Med25 AcID, by FP. Bar graphs depict the 
average and standard deviations of the fold change of experiments performed in 
triplicate. (B) Binding affinities of putative H2 site peptides for Med25 mutants 
complexed to VP16 G450C relative to WT Med25 AcID, as measured by FP. 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
(𝐾𝐷 for Mutant Med25 AcID-peptide interaction)






Blocking either the H1 (G450C peptide complex) or H2 face (R466D) had 
negligible impact on the binding affinity of ERM(38-68) relative to WT Med25 AcID. 
However, a complex of R466D Med25 AcID tethered to G450C peptide bound ERM(38-
68) with a 8.8-fold weaker binding affinity than WT Med25 AcID. Blocking the H1 face 
(G450C peptide complex) caused a 13-fold loss in binding affinity towards VP16(413-
451); blocking the H2 face (R466D or M523E) caused a 4.0- to 5.5- fold loss in affinity. 
However, blocking both faces with mutant proteins, R466D and M523E, complexed to 
G450C peptide led to 67- and 77- fold losses in binding affinity, respectively. For each of 
these peptides, as had been shown in the Q451E/M523E set of experiments, these 
results add to the mountain of evidence suggesting that neither of ERM(38-68) nor 
VP16(413-451) binds exclusively to the H1 face. 
 Again, as had been shown in Q451E/M523E experiments, VP16 H2 is more 
specific for the H2 site than any of the presumed H1 peptides are for the H1 site. However, 
blocking the H1 site with G450C peptide proved to be more effective than the Q451E 
mutation. In the Q451E/M523E experiments, no additional inhibitory benefit against 
VP16(467-488) had been attributed to the Q451E mutation. However, the addition of 
G450C peptide to H2 mutant proteins did produce a more pronounced effect on the 
binding affinity of VP16(452-490) than R466D or M523E alone. R466D-G450C peptide 
complex bound VP16(452-490) with 23-fold decrease in binding affinity relative to WT 
Med25 AcID; R466D gave a 11-fold decrease. M523E-G450C peptide complex bound 
VP16(452-490) with 33-fold decrease in binding affinity relative to WT Med25 AcID; 
R466D gave a 23-fold decrease. This loss in specificity for the H2 site could be explained 
by a change in the peptide used during these experiments. VP16(452-490), the peptide 
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used in the mutant-G450C peptide experiments, is a larger VP16 H2-derived peptide than 
used in single and double mutagenesis work previously described. It is highly possible 
that the N-terminal portion of this construct is beginning to wrap around Med25 AcID and 
contacting the H1 site directly while the C-terminal portion is contacting the H2 site. The 
final peptide tested in this set of experiments, VP16(438-490), contains the helical region 
of VP16 H1 and the entirety of VP16 H2. It is known to interact with both the H1 and H2 
sites21 simultaneously. Each of the three single-site inhibitory methods – R466D, M523E, 
and G450C peptide – cause a significant loss in binding affinity relative to WT Med25 
AcID (8.9-, 15-, and 6.0- fold losses respectively). As anticipated, blocking both sites has 
a dramatic effect on binding to this particular peptide – R466D complexed with G450C 
peptide experienced a 46-fold loss in binding affinity relative to WT Med25 AcID and 
M523E complexed with G450C peptide experienced a 117-fold loss in binding affinity 
relative to WT Med25 AcID. 
  
D. Conclusions and future directions  
 Through the work outlined in this chapter, I set out to expand the understanding of 
the molecular underpinnings of the interactions between Med25 AcID and its binding 
partners. Previous literature reports had demonstrated that Med25 AcID contains two 
binding sites that interact with VP16 TADs and ERM(38-68)17,21,23. Additional data from 
the Mapp lab had determined that Med25 AcID-VP16 PPIs were dependent on 
electrostatic interactions between acidic TADs and basic amino acids on the surface of 
the AcID motif. However, the selectivity of unique activator ligands for single sites within  
Med25 AcID remained an open question at the beginning of this Chapter. In addition, the 
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minimal interacting regions of two Med25 AcID binding partners (CBP and ATF6α) had 
not yet been identified and the PPIs had not been biochemically characterized.  
 Using basic local alignment searches coupled with peptide synthesis and FP 
assays, the minimal regions of CBP and ATF6α that interact specifically with Med25 AcID 
were determined. Subsequent HSQC NMR suggested that CBP(20-44) bound Med25 
AcID did not interact specifically at one of the two previously reported binding sites for 
VP16 and that ATF6α(40-66) likely interacted at the H2 site of Med25 AcID.   
 The H1 and H2 sites of Med25 AcID were also investigated by selectively blocking 
each interface through the introduction of negative charges at the H1 and H2 sites using 
protein mutagenesis and the addition of a Tethered VP16 G450C peptide at the H1 site. 
Collectively, experiments to block the H2 site suggested that binding at the H2 site is 
more dependent on electrostatic interactions and ‘hot spot’ residues than the H1 site. 
Additionally, these data demonstrated that ATF6α and VP16 H2 preferentially interact at 
the H2 site. However, peptides predicted to bind the H1 site by HSQC NMR17,23 – ERM 
and VP16 H1 – did not demonstrate similar selectivity for the H1 site. Instead, ERM and 
VP16 H1 were both capable of binding to the H2 site when the H1 site was blocked, as 
demonstrated by the double H1/H2 site inhibition experiments.  
While the mutagenesis study and 1H, 15N-HSQC NMR experiments within this 
chapter and in the literature, are consistent in loosely describing the multi-site binding 
model of Med25 AcID, there remained uncertainty regarding the specific differences 
between discrete Med25 AcID binding partners. Each of the described binding sites are 
very large (estimated at ~1800 Å2), as determined by HSQC NMR, which leads to several 
questions. Does every protein partner orient itself in the same direction within a binding 
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site? Do protein ligands associate with the entirety of a binding site or just a portion of it? 
Furthermore, it has been suggested in this chapter that some peptide ligands (e.g. VP16 
H1) are capable of binding at the H1 and the H2 sites. What does this supposition mean 
for binding stoichiometry and the relative affinities that a ligand might have towards one 
binding site over another? Are some peptides capable of binding with >1:1 stoichiometry?  
 Many of these next-level mechanistic questions require higher levels of sensitivity 
than can be provided using either HSQC NMR or fluorescence polarization experiments. 
To overcome this sensitivity problem and to answer many of the questions posed above, 
protein-observed 19F-NMR of Med25 AcID and its PPI network will be described in 
Chapter 3. This burgeoning technique involves the incorporation of site-selective 19F 
nuclei into the side chains of Med25 AcID for the direct observation of individual protein-
protein and protein-ligand interactions. These 19F-incroporated residues are well-
dispersed across the binding sites of Med25 and allow for precise determination of 
binding locations, relative affinities between differing binding sites, and binding 





E. Materials and methods 
Reagents and Instrumentation 
Unless otherwise noted, chemical and biological reagents were obtained from commercial 
sources and were used without additional modification. Protein, peptide, and DNA 
concentrations were determined using a NanoDrop ND-1000 UV-Vis Spectrophotometer 
and/or a Beckman Spectrophotometer.  
 
Plasmids  
pET21b-Med25(394-543)-His6 was provided by Patrick Cramer. Mutant Med25 AcID 
plasmids Point mutations of pET21b-Med25(394-543)-His6 were generated using 
standard molecular biology protocols.  
 
Expression of Med25 AcID and Med25 AcID mutants  
All WT Med25 AcID and Med25 AcID mutants were expressed as follows. pET21b-
Med25(394-543)-His6 was transformed into chemically competent Rosetta pLysS cells 
(Novagen), plated onto LB/ampicillin/chloramphenicol agar, and incubated at 37 °C 
overnight. In the morning, agar plates were placed at 4 °C until further use. In the evening, 
a single colony from the transformed plate was placed into 25 mL Luria Broth with 0.1 
mg/mL ampicillin and 0.034 mg/mL chloramphenicol and incubated at 37 °C overnight at 
≥200 RPM. The following morning, 5-20 mL from the starter culture was added to 1 L 
Terrific Broth with 0.1 mg/mL ampicillin and bacteria were grown at 37 °C at ≥200 RPM 
to an OD600 of 0.8-1.0. Temperature was reduced to 20 °C for a minimum of thirty minutes 
prior to induction of protein expression with 0.2-0.5 mM IPTG. Bacteria were shaken 
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overnight at 20 °C at ≥200 RPM. The following morning, bacterial cultures were 
centrifuged at 7000 x g for 20 mins at 4 °C. Cell pellets were then stored at -80 °C prior 
to protein purification. 
 
Expression of 15N-labeled Med25 AcID 
pET21b-Med25(394-543)-His6 was transformed into chemically competent Rosetta 
pLysS cells (Novagen), plated onto LB/ampicillin/chloramphenicol agar, and incubated at 
37 °C overnight. In the morning, agar plates were placed at 4 °C until further use. In the 
evening, a single colony from the transformed plate was placed into 25 mL Luria Broth 
with 0.1 mg/mL ampicillin and 0.034 mg/mL chloramphenicol and incubated at 37 °C 
overnight at ≥200 RPM. The following morning, 5-20 mL from the starter culture was 
added to 1 L Terrific Broth with 0.1 mg/mL ampicillin and bacteria were grown at 37 °C at 
≥200 RPM to an OD600 of 0.8-1.0. Cells were centrifuged and washed with M9 minimal 
media. Cells were then resuspended in 1 L M9 minimal media with ampicillin and 2-3 mL 
BioXpress (Cambridge Isotope Laboratories) was added. Cultures were incubated at 37 
°C overnight at ≥200 RPM for one hour reducing the temperature to 20 °C. After 30-45 
minutes, 0.5 mM IPTG was added. Bacteria were shaken overnight at 20 °C at ≥200 RPM. 
The following morning, bacterial cultures were centrifuged at 7000 x g for 20 mins at 4 




Purification of Med25 AcID and Med25 AcID mutants 
The purification of Med25 AcID proteins was completed using two different 
protocols – one that used a Ni-NTA 5 mL HiTrap FPLC column and the other that used 
Ni-NTA resin (Qiagen). Both are described below. 
  
1. Ni-NTA 5 mL HiTrap FPLC column 
Cell pellets were thawed and resuspended with 30-35 ml Lysis Buffer (50 mM 
phosphate, 300 mM NaCl, 10 mM imidazole, pH 7.2). β-mercaptoethanol, at 1:1000 
dilution, and one cOmplete, Mini, EDTA-free Protease Inhibitor tablet (Sigma-Aldrich) 
were added to the resuspended cell pellet. To lyse, the cells were sonicated on ice for 
4-6 min (Cycle - 3 seconds on, 7 seconds off) and/or until the cells had observable 
change in color (lighter brown) and viscosity. Following sonication, the lysed pellet in 
50 mL conical tube(s) was centrifuged at 9,500 RPM for 30 min at 4 °C. The supernatant 
was decanted into fresh 50 mL conical tubes, the pellet was discarded, and the 
supernatant was centrifuged at 9,500 RPM for 10 min at 4 °C. After this second 
centrifugation step, the supernatant was filtered using a 0.2 µm or 0.45 µm syringe filter 
(Whatman). This filtered supernatant was then purified over a Ni-NTA 5 mL HiTrap 
column using an AKTA pure FPLC chromatography system. The gradient used for the 
purification is as follows: 1) Load protein onto the column (All flow rates during the 
purification at 2.5 mL/min); 2) Wash with 5 column volumes of Buffer A; 3) Wash with 5 
column volumes at 10% Buffer B (90% Buffer A); 4) Wash with 5 column volumes at 15% 
Buffer B (85% Buffer A); 5) Gradient from 15-100% Buffer B relative to Buffer A over the 
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course of 10 column volumes; 6) Wash with 5 column volumes at 100% Buffer B. The 
composition of Buffers A is 50 mM phosphate, 300 mM NaCl, 30 mM imidazole, pH 7.2; 
Buffer B is 50 mM phosphate, 300 mM NaCl, 400 mM imidazole, pH 7.2. Fractions that 
contain Med25 AcID were combined and diluted by 4-fold with cold DI water or 50 mM 
phosphate buffer. 1 mM DTT was added to this protein solution. The protein was then 
purified over Source S 5 mL HiTrap column using an AKTA pure FPLC chromatography 
system. The gradient used for the purification is as follows: 1) Load protein onto the 
column (All flow rates during the purification at 2.5 mL/min); 2) Wash with 5 column 
volumes of Buffer A; 3) Gradient from 0-100% Buffer B relative to Buffer A over the course 
of 10 column volumes; The composition of Buffer A is 50 mM phosphate, 1 mM DTT, pH 
7.2; Buffer B is 50 mM phosphate, 1 M NaCl, 1 mM DTT, pH 7.2. To check for purity after 
the purification, SDS-PAGE of eluted fractions was then performed (1X MES running 
buffer; 8-12% acrylamide gels). Fractions of pure protein (>95% pure by SDS-PGAE 
analysis) were combined and buffer exchanged into storage buffer (10 mM phosphate, 
100 mM NaCl, 10% glycerol, 1 mM DTT, pH 6.8) using either overnight dialysis, a PD-10 
column, or the concentrate-dilute-concentrate method. Protein concentration was 
determined by UV-Vis spectroscopy using an extinction coefficient, ε = 22,460 M-1cm-1 
and samples were taken for mass spectroscopy analysis prior to storage of protein 
aliquots (300-400 µL at 100-150 µM concentration) at -20 °C. 
 
2. Ni-NTA resin (Qiagen) 
 Cell pellets were thawed and resuspended with 30-35 ml Lysis Buffer (50 mM 
phosphate, 300 mM NaCl, 10 mM imidazole, pH 7.2). β-mercaptoethanol, at 1:1000 
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dilution, and one cOmplete, Mini, EDTA-free Protease Inhibitor tablet (Sigma-Aldrich) 
were added to the resuspended cell pellet. To lyse, the cells were sonicated on ice for 
4-6 min (Cycle - 3 seconds on, 7 seconds off) and/or until the cells had observable 
change in color (lighter brown) and viscosity. Following sonication, the lysed pellet in 
50 mL conical tube(s) was centrifuged at 9,500 RPM for 30 min at 4 °C. Concurrent with 
centrifugation of cells, 750 μl of Ni-NTA resin per 12 mL of cell lysate were washed three 
times with DI water. After centrifugation of the cell lysate, the supernatant was added to 
the washed Ni-NTA resin (Qiagen) and incubated for 1 hour at 4 °C. The resin was then 
centrifuged at 2500 RPM for 2 min at 4 °C before being washed five times with wash 
buffer (50 mM phosphate, 300 mM sodium chloride, 30 mM imidazole, pH 6.8). The resin 
was centrifuged at 2500 RPM for 1 min at 4 °C between washes. After the washing step, 
protein was incubated with 1 mL of elution buffer (50 mM phosphate, 300 mM sodium 
chloride, 400 mM imidazole, pH 6.8) per 750 μl of Ni-NTA resin for 30 min at 4 °C. The 
resin was centrifuged at 2500 RPM for 1 min at 4 °C and the protein supernatant 
containing Med25 AcID was saved. This elution step was repeated a total of three times. 
Fractions containing Med25 AcID were pooled and subjected to further purification using 
a Source S 5 mL HiTrap column using an AKTA pure FPLC chromatography system, as 
previously described.  
 
Mass spectroscopy of proteins 
Samples were not prepared. Protein was analyzed by mass spectrometry using an Agilent 
QTOF LC/MS following a partial separation with a Poroshell 300SB C8 reverse-phased 
HPLC column (5-100% acetonitrile with 0.1% formic acid over five minutes). Resultant 
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MS data was analyzed using Agilent software (Qualitative Analysis) with background 
subtraction and deconvolution settings for an intact protein of 10-30 KDa.  
 
Solid-phase peptide synthesis and subsequent HPLC purification 
Peptides were synthesized on CLEAR amide resin (Peptides International) using 
standard HBTU/HOBT/DIEA coupling conditions as previously described37. TFA cleaved 
peptides were purified using reverse-phase HPLC (Agilent 1260) on a C18 Poroshell 
column (Agilent) using ammonium acetate/acetonitrile solvent systems. The 
concentration of fluorescein labeled peptides was then determined by UV-Vis 
spectroscopy following 1:500 dilution of DMSO stock solutions into 10 mM PBS, pH 7.4 
using ε = 72,000 M-1cm-1, per the manufacturer (Pierce). Acetylated peptides, if they did 
not contain a native Tyr/Trp, were synthesized with a N-terminal Tyr residue next to a β-
alanine linker prior to the start of desired sequence in order to allow for determination of 
the concentration of stock peptides by UV/VIS. Peptide identity was confirmed by 
electrospray mass spectrometry; peptide purity was determined by analytical HPLC. 
 
Fluorescence polarization binding assays  
Fluorescence polarization binding assays were performed in triplicate with a final sample 
volume of 16 μL in a low volume, non-binding, 384-well black plate (Corning). Peptides 
that were N-terminally labeled with fluorescein were diluted in assay buffer (5 mM 
HNa2PO4, 5 mM NaH2PO4, 100 mM NaCl, 10 % glycerol, pH 6.8) to 50 nM. Med25 AcID 
(16 µL per replicate) was serially diluted two-fold with assay buffer going down the 
columns of the 384-well plate (This allowed for eight total protein-peptide experiments on 
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a single plate). The final well, in Row P, was a negative control (no-protein, peptide-only). 
8 µL of the diluted fluorescent peptide stock was then added to each well of protein for a 
final peptide concentration of 25 nM. Plates were then incubated for 30 minutes at room 
temperature before fluorescence polarization was measured on either a Tecan Genios 
Pro or PHERAstar plate reader (polarized excitation at 485 nm and emission intensity 
measured through a parallel and perpendicularly polarized 535 nm filter). A binding 
isotherm that accounts for ligand depletion (assuming a 1:1 binding model of peptide to 
protein) was fit to the observed polarization values as a function of ACID to obtain the 
apparent equilibrium dissociation constant, C where ‘a’ and ‘x’ are the total concentrations 
of fluorescent peptide and protein, respectively; ‘y’ is the observed polarization at a given 
protein concentration; ‘b’ is the maximum observed polarization; ‘c’ is the minimum 
observed polarization value.     
 
Each KD is the average and standard deviation of three technical replicates. For the 
mutagenesis study, the fold change in binding affinity for mutants relative to WT Med25 
AcID is calculated using the following: 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
(𝐾𝐷 for Mutant Med25 AcID-peptide interaction)
(𝐾𝐷 for WT Med25 AcID-peptide interaction)
 
 
Fluorescence polarization competition assays 
Inhibition assays were performed in triplicate with a final sample volume of 20 μL in a low 
volume, non-binding, 384-well black plate (Corning). A complex of the indicated 
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fluorescent peptide and protein was prepared at a two-fold the concentrations of protein 
and peptide to achieve 50% of the tracer bound during the assay. For peptide-based 
competition assays, an N-terminally acetylated variant of peptide was diluted in assay 
buffer (5 mM HNa2PO4, 5 mM NaH2PO4, 100 mM NaCl, 10 % glycerol, pH 6.8) to 
100-1000 µM compound and serially diluted was serially diluted two-fold with assay buffer 
going down the columns of the 384-well plate (This allows for eight total protein-peptide 
experiments on a single plate). The final well, in Row P, was a negative control (protein-
peptide, no inhibitor). 10 µL of the pre-formed fluorescent peptide-protein complex was 
then added to each well for a final volume of 20 µL. Samples were incubated for thirty 
minutes at room temperature before fluorescence polarization was measured a Tecan 
Genios Pro or PHERAstar plate reader (polarized excitation at 485 nm and emission 
intensity measured through a parallel and perpendicularly polarized 535 nm filter). 
Polarization values were converted to relative fraction bound and plotted against 
log[inhibitor]. Inhibition curves were fit with a non-linear regression using Prism’s 
‘log(inhibitor) vs response – variable slope’ equation from which the IC50 value was 
calculated.  
 
1H, 15N-HSQC NMR of Med25 AcID 
Samples of purified 15N-labeled Med25 AcID (50-100 µM) were complexed with molar 
equivalents of N-terminally acetylated peptides at 10% D2O (final concentration) with 
NMR buffer (20 mM sodium phosphate buffer, pH 6.5, 150 mM NaCl, 3 mM DTT). HSQC 
experiments were completed by Felicia Gray (University of Michigan) using an Avance 
Bruker 600 MHz NMR spectrometer equipped with a 5 mm cryogenic probe.  Data was 
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processed and analyzed by Matt Beyersdorf using TopSpin. Chemical shift analysis for 
individual peaks was quantified using the following:  
Chemical shift = SQRT((abs(Δδ15N)2)+ (abs(Δδ1H)2)) 
 
Circular dichroism of Med25 AcID 
Circular dichroism spectra of Med25 AcID and mutants were acquired on a J-715 
spectropolarimeter (Jasco Inc) using a 1 mM pathlength quartz cuvette. Protein was 
dialyzed into CD buffer (5 mM HNa2PO4, 5 mM NaH2PO4, 100 mM NaF, pH 6.8) 
overnight before analysis. Data was collected from 260-180 nm in 1 nm increments at a 
scanning speed of 100 nm/min. A background scan was performed using buffer only.  
Data, after subtraction of the background scan, were converted to mean residue ellipticity 
according to the following equation where Ψ is the CD signal in degrees, n is the number 
of amides, l is the path length in centimeters, and c is the concentration in decimoles per 
cm3: 
 
Each spectrum reported is the average of 8 scans. 
 
Circular dichroism-observed thermal melt 
CD-observed thermal melts were collected following collection of CD spectra; See above 
for instrument/buffer/etc. Using the ‘Variable temperature’ module, thermal melts were 
observed by CD. Protein was heated from 20-100 °C at a gradient of 1 °C/min; data was 
acquired by monitoring the molar ellipticity at 208 nm and 222 nm. Molar ellipticity was 
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collected at every third degree from 20-35 °C and at every degree from 35-100 °C. Molar 
ellipticity values were converted to Fraction Unfolded and Tm was determined by fitting 
data with Prism’s ‘log(inhibitor) vs response – variable slope’ equation. 
 
Tethering with VP16 G450C peptide 
The cysteine of VP16 G450C peptide (sequence: ALDDFDLDMLGDCDSPG) was 
capped with cysteamine by Andy Henderson. A two-fold molar excess of 
cysteamine-capped VP16 G450C in presence of 100 µM β-mercaptoethanol was 
incubated  with WT or mutant Med25 overnight, shaking, at room temperature. During the 
following day, the protein-peptide complex was purified away from excess peptide using 
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Defining binding mechanisms of Med25 AcID and its protein-protein interaction 
network using protein-observed 19F-NMR 
 
A. Abstract 
 The structural study of coactivator-activator interactions has long been considered 
challenging due to the transient and dynamic natures of these interactions, weak-to-
moderate binding affinities, and abilities of both coactivators and activators to bind 
multiple targets.1–3 However, NMR techniques offer excellent methodologies to 
investigate protein dynamics due to their sensitivity and resolution.4,5 In particular, protein-
observed fluorine (PrOF) NMR is desirable for the study of these interactions due to the 
short amount of time required for experimental and data analysis, the high sensitivity 
provided by the 19F nucleus, and the lack of 19F in naturally-occurring proteins.6,7 Previous 
work in the literature and in Chapter 2 of this thesis demonstrated the Med25 AcID 
contains multiple binding sites, each of which is suggested to be targeted by specific 
Med25-interacting proteins.8–12 However, many questions regarding the mechanisms of 
recognition between Med25 AcID and its protein partners remained. This chapter set out 
to answer several of those mechanistic questions using PrOF NMR, an emerging 
technique to study protein-protein interactions. This chapter precisely describes the 
inherent differences between each unique Med25 AcID protein-protein interaction 
including differences in binding selectivity towards AcID binding sites, relative affinities, 
                                            
Several collaborators provided research assistance throughout Chapter Three. Prof. William Pomerantz 
and Clifford Gee (University of Minnesota) assisted with initial efforts to incorporate 19F into Med25 AcID 
and resonance assignment of 3-fluorotyrosine Med25 AcID. Andy Henderson (University of Michigan) 
collected HSQC NMR of several Med25-activator complexes that were useful in describing binding 
models for discrete Med25 AcID protein-protein interactions. Drs. Paul Bruno and Steve Sturlis (University 
of Michigan) identified and characterized norstictic acid as an inhibitor of Med25 AcID. Andy Henderson 
identified fragment A6 in a Tethering screen against Med25 AcID; Dr. Clint Regan (University of Michigan) 
synthesized A6 and all A6 derivatives. 
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and binding stoichiometry. These observed differences in binding modes range from the 
subtle (ATF6α and VP16 H2, both selectively for the H2 binding site, position themselves 
differently across this interface) to the highly dramatic (ERM, highly selective for the H1 
site, appears capable of achieving a 2:1 binding stoichiometry). Finally, the mechanism 
of action for two recently identified small molecules (norstictic acid and the fragment A6) 
that target Med25 AcID is described, as determined using PrOF NMR of Med25 AcID. 
  
B. Introduction 
Limitations of 1H, 15N-HSQC NMR in study of protein-protein interactions 
Protein-observed NMR has been extensively utilized to study protein-protein 
interactions (PPIs) and protein-ligand interactions for decades.4 1H, 15N-HSQC NMR is 
the most commonly used technique and, as described in Chapters 2 and 4 of this thesis, 
has been effective in mapping the binding interactions between Med25 AcID and its native 
and small molecule ligand partners. However, this two-dimensional technique has several 
practical and experimental limitations. Long instrumental time (e.g. 90-100 minutes for a 
single 1H, 15N-HSQC NMR Med25 AcID experiment), the need for expensive isotopic 
reagents to produce 15N-labeled protein, and time-intensive analysis of resulting 2-D NMR 
spectra complicate data collection and interpretation.13 Incomplete assignment of all 
resonances in 1H, 15N-HSQC NMR (e.g. Only 103 of the 151 residues of Med25 AcID can 
be definitively assigned) limits the depth of the analysis of the protein-of-interest, including 
difficulty in differentiation of orthosteric and allosteric effects.14 This lack of depth is 
especially problematic for the study of activator-coactivator interactions because these 
interactions are transient, weak affinity, and involve proteins that are highly dynamic and 
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often intrinsically disordered.2,3,15 Additionally, coactivator proteins often contain multiple 
binding sites with many protein partners; differentiation of these binding sites and binding 
partners is imperative for proper understanding of coactivator-activator function. Finally, 
this technique detects chemical shift perturbations of amide N-H bonds and thus offers 
little insight into side chain interactions.4     
  
Protein-observed 19F-NMR for study of protein-protein interactions 
Protein-observed 19F-NMR (PrOF NMR), a 1-D NMR experiment that 
complements 1H, 15N-HSQC NMR, can overcome some of the inherent limitations of 
HQSC NMR. PrOF NMR is desirable for a its short experimental time6, simple and quick 
analysis of 1-D spectra, and ability to observe side chain interactions of a select number 
of residues. Inherent advantages also offered by the 19F nucleus include its native isotopic 
abundance (100%), magnetic sensitivity (83% as sensitive as 1H), and its low background 
signal in protein NMR (19F does not occur naturally in proteins)7. PrOF NMR has been 
effectively utilized to study several protein-protein and protein-ligand interactions 
including those involving the glucose- and galactose-binding protein16, avian lysozymes17, 
dihydrofolate reductase18, the aspartate receptor19, the coactivator domain CBP20,21, and 
bromodomains22,23.  
 Incorporation of 19F for PrOF NMR can be done using biosynthetic methodologies 
to integrate fluorinated amino acids into a protein-of-interest or through chemical 
modification to covalently label a residue onto the protein-of-interest with a fluorinated 
molecule.24,25 The most utilized amino acids for PrOF are fluorinated versions of tyrosine, 
tryptophan, and phenylalanine, all of which can be incorporated by auxotrophic bacterial 
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strains.26 These aromatic amino acids are selected due to their range of native structural 
environments from conformationally dynamic loops to α-helical and β-sheet structures 
and at PPI interfaces.27–30 Additionally, aromatic amino acids are desirable due to their 
low abundance, which minimizes the total number of 19F nuclei that are incorporated into 
protein, simplifying the subsequent PrOF spectrum.31 This also lessens the likelihood of 
significant effects of the fluorinated amino acids on protein structure and function. 
Common fluorinated variants of aromatic amino acids for direct incorporation into the 
primary structure of proteins include 3-fluorotyrosine, 2/3/4-fluorophenylalanine, and 
4/5/6-fluorotryptophan. Alternatively, fluorine-containing small molecules can be 
incorporated into a protein after expression. This is typically accomplished through 
covalent modification of cysteine residues. Common molecules that have been 
successfully utilized for the methodology include 3-bromo-1,1,1-trifluoroacetone, 3-
bromo-1,1,1-trifluoropropanone, and 2,2,2-trifluoroethanethiol, all of which are cysteine-
reactive.32–35  
 
PrOF NMR for study of Med25 AcID and its protein-protein interaction network 
PrOF NMR of Med25 AcID was pursued to complement 1H, 15N-HSQC NMR 
experiments and the mutagenesis study described in Chapter 2 to test the proposed 




Incorporation of 3-fluorotyrosine (3FY) was proposed to provide NMR reporters of 
the H2 site of Med25 AcID due to the dispersed placement of Tyr residues across the H2 
and third sites of Med25 (Figure 3.1). Y528 is located on the loop between β7 and α3 with 
its side chain situated at the base of the H2 site. Y487 and Y515, thought to be a 
hydrogen-bonded pair, are situated at the opposite edge of the H2 site from Y528, on α2 
and β5 respectively. Finally, Y432 is situated within the putative third site and in proximity 
of the H2 site, near the C-terminal end of β2. Notably, as shown in the image of the H1 
Figure 3.1. 3FY Med25 AcID structures. (A) Surface renderings of the H2 site (left) 
and H1 site (right) of Med25. Tyr residues are colored – Y528 (red), Y432 (green), 
Y487/Y515 (orange). (B) Cartoon images of the H2 site (left) and putative third site 










Putative third site 
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site in Figure 3.1.A, none of the Tyr residues are situated proximal to the H1 site. It was 
hypothesized that PrOF NMR of 3FY Med25 AcID would provide corroborating evidence 
regarding the selectivity of VP16 H2 and ATF6α for the H2 site of Med25 site, could 
definitively demonstrate the ability of ERM and VP16 H1 to bind at both the H1 and 
H2sites, and would provide additional evidence of the putative third site that CBP was 
proposed to bind in HSQC NMR experiments.  
 
Incorporation of 5-fluorotryptophan (5FW) was proposed to function as a NMR 
reporter system to allow for observation of the H1 site of Med25 AcID. All three Trp 
residues of Med25 AcID are near to the H1 site on Med25 AcID (Figure 3.2). W402 and 
W444 are part of an aromatic triad (along with F500) within the core of the β-barrel and 
form an edge-to-face π-π stacking interaction with one another. W408 is located near the 
C-terminal end of β1 and, with α2, forms a cleft at the “top” of the β-barrel. This residue 
Figure 3.2. 5FW Med25 AcID structure. Cartoon (left) and surface (right) images of 
the H1 site of Med25 AcID. All three residues are near the H1 site and the side chains 
of W402/W444 are not solvent-exposed. (PDB 2XNF) 
 
H1 site H1 site 
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is thought to be the most sensitive reporter of the three towards H1 ligands. It was 
hypothesized that PrOF NMR of 5FW would corroborate evidence that VP16 H2, 
ATF6α(40-66), and CBP(20-44) do not interact with the H1 site, even at high 
concentrations of peptide. Furthermore, it was thought that PrOF NMR analysis would 
corroborate the working model that ERM, while capable of binding to the H2 site, interacts 
preferentially at the H1 site. 
 
C. Results and discussion 
Biochemical characterization of fluorinated Med25 variants 
Fluorinated variants of Med25 were expressed using an auxotrophic bacterial 
strain, adapted from published expression conditions for other proteins.36 3-fluorotyrosine 
(3FY) expression resulted in high yields (35-40 mg protein per liter bacterial culture) with 
>99% 19F incorporation, as determined by mass spectrometry (Figure 3.3). Note that in 
all cases, the percentage of 19F incorporation was calculated by dividing the total peak 
areas of deconvoluted proteins in mass spectrometry by the sum of peak areas of all 
proteins that contain at least one 19F atom.36 Furthermore, ~80% of 3FY Med25 AcID had 
3FY incorporated at all four Tyr residues. 5-fluorotryptophan (5FW) expression resulted 
in lower yields (10-15 mg protein per liter bacterial culture) and lower incorporation of 19F 
(90% by mass spectrometry) than 3FY. However, protein quality and quantities were 
sufficiently high to perform subsequent experiments. The third amino acid, 
4-fluorophenylalanine (4FF), provided poor results in terms of yield (<<5 mg protein per 
liter bacterial culture) and 19F incorporation (~70% labeled; however, most of the protein 




Circular dichroism (CD) and fluorescence polarization (FP) were used to assess 
effects of the unnatural amino acids on Med25 AcID structure and function (Figure 3.4 
and Table 3.1). CD spectra indicated that fluorine incorporation resulted in minimal 
perturbation of the secondary structure relative to WT. CD-observed thermal denaturation 
indicated that 3FY Med25 AcID was marginally more stable than WT Med25 AcID (67.0 
± 0.5 °C vs 64.8 ± 0.3 °C). Finally, FP assays demonstrated that 3FY Med25 AcID and 
5FW Med25 AcID maintained similar function to WT. All tested peptides bound 3FY and 
5FW Med25 with less than three-fold loss in binding affinity relative to WT.  
Figure 3.3. Mass spectrometry of fluorinated Med25 AcID variants. Deconvoluted 
mass spectra of A) 3-fluorotyrosine, (B) 5-fluorotryptophan, and (C) 4-
fluorophenylalanine Med25 AcID with corresponding 19F-containing amino acid 
structure. Red squares represent the number of incorporated 19F-containing amino 
acids (+18 amu per 19F). The percentage of 19F incorporation was calculated by 
dividing the total peak areas of deconvoluted proteins in mass spectrometry by the 
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Figure 3.4 Structural stability of fluorinated Med25 AcID variants. (A) Circular 
dichroism spectra of 3FY, 4FF, and 5FW Med25. (B) CD-observed thermal 
denaturation of 3FY Med25 and WT Med25. Fraction unfolded was determined from 
circular dichroism measurements at 222 nm as protein samples were heated from 20-
100 °C. 
Table 3.1 Dissociation constants for Med25-interacting peptides to 3FY Med25 
AcID. Each KD was determined using FP assays performed in triplicate.   
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Following this initial suite of experiments to characterize the fluorinated Med25 
AcID variants, each variant was independently subjected to PrOF analysis (Figure 3.5). 
The PrOF NMR spectrum of 3FY Med25, which contains four Tyr residues, provided four 
well-resolved resonances with excellent signal-to-noise in 1200-1600 total NMR scans 
(experimental time of 11-15 minutes). 5FW Med25 AcID provided two overlapped and 
broad resonances at -126.8pm with another resonance ~1.5 ppm upfield in 2400 scans 
(experimental time of ~20 minutes). The PrOF NMR spectrum of 4FF Med25 AcID was 
not well-resolved (up to five resonances overlapped from -116 to -118 ppm). Furthermore, 
6000 scans (~1 hr of experimental time) were required to acquire a 4FF spectrum of the 
quality shown in Figure 3.5. 4FF Med25 AcID was not further pursued for PrOF NMR of 





Figure 3.5. 19F-NMR spectra of fluorinated Med25 AcID variants. (A) NMR spectra 
of 3-fluorotyrosine Med25 AcID; All four Tyr residues, shown in blue, are solvent 
exposed and located within or near the H2 site. (B) NMR spectra of 5-fluorotryptophan 
Med25 AcID; All three Trp residues, shown in blue, located in proximity of the H1 site. 
Only the side chain of W408 is solvent exposed. (C) NMR spectra of 
4-fluorophenylalanine Med25 AcID; Only two of seven Phe residues, shown in blue, 







Assignment of 3FY resonances 
 Prior to functional ligand studies, the 19F-NMR resonances of 3FY Med25 needed 
to be independently assigned to specific residues of the protein. To accomplish this, four 
Tyr-to-Phe mutants were generated (Y432F, Y528F, Y487F, and Y515F Med25 AcID). 
Each mutant was successfully cloned, expressed and purified in low-to-moderate yield. 
Mass spectrometry of each mutant verified that a single mutation had been performed 
and that 19F incorporation was sufficiently high for PrOF NMR analysis (Figure 3.6).  
 
Subsequent PrOF NMR spectra of Y432F Med25 AcID demonstrated that the 
resonance at -135.57 ppm was Y432 based on the absence of that peak from the 
collected spectra (Figure 3.6). Similarly, PrOF NMR spectra of Y528F Med25 AcID 
Figure 3.6. Assignment of Y432 and Y528 resonances of 3FY Med25. Tyr-to-Phe 
mutations at residues 432 and 528 allowed for the assignment of these 19F-NMR 
resonances at -135.57 ppm and -137.48 ppm, respectively. Note that signal-to-noise 
of both Y432F and Y528F Med25 AcID spectra are low in part because each was 
expressed on small-scale (100 mL bacterial culture), resulting in low total protein. 
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demonstrated that the resonance at -137.48 ppm was Y528 based on the absence of that 
peak from the collected spectra. PrOF spectra of Y487F and Y515F Med25 AcID gave 
inconclusive results, possibly because these two Tyr residues might be engaged in a 
hydrogen bond interaction with one another. While the distances between the oxygen of 
one Tyr and the hydrogen of another are never closer than 3.5 Å in NMR structures (PDB 
2XNF, 2KY6, 2L6U), these side chains are oriented such that they could be engaged in 
a transient hydrogen bond.  
To assign the final two tyrosine residues, Y487 and Y515, which represent the 
most upfield resonances of the WT spectra, the “nudge” mutational method was utilized.37 
This methodology involves a soft mutation of a residue located in the physical proximity 
of a single target Tyr. This “nudge” mutation should then affect the local environment of 
only that target Tyr and perturb a single 19F-NMR resonance. The perturbed resonance 
can then be assigned to the Tyr residue near the nudge mutation. 3FY-containing K484R 
Med25 was generated in hopes of “nudging” Y487 and perturbing a single resonance 
(Figure 3.7). This residue was selected for mutation because it was near Y487 only and 
was solvent exposed, and therefore expected to have minimal effect on Med25 structure. 
PrOF spectrum of K484R Med25 allowed for the assignment of Y487 to be the resonance 
at -137.95 ppm in the WT spectra. The K484R mutation led to a 0.025 ppm shift in the 
resonance at -137.95 ppm while leaving the resonance at -138.26 ppm unperturbed. This 






PrOF NMR titrations with Med25-interacting peptides against 3FY Med25 AcID 
With assignments of 3FY Med25 AcID completed, PrOF NMR was used to define 
interactions between Med25 AcID and native peptide ligands. Titrations were performed 
with acetylated variants of the Med25-interacting peptides (the same peptide ligands used 
during previous mutagenesis and HSQC NMR work in Chapter 2).  
 
  
    
Figure 3.7. Assignment of Y487 and Y515 resonances of 3FY Med25. The nudge 
mutation method was used to assign these two Tyr residues. A K484R mutation 
perturbed the resonance at -137.95 ppm, indicating that it represents Y487. 19F-NMR 





An acetylated variant of VP16(413-451) (7.5 µM, 18.75 µM, 37.5 µM, 56.25 µM, 
75 µM, 93.75 µM, 112.5 µM and 150 µM) was complexed with 3FY Med25 AcID (75 µM) 
and subjected to PrOF NMR (Figure 3.8). The most significantly perturbed resonances 
corresponded to the Y487/Y515 pair, as these two peaks merged to form an overlapping 
resonance at -137.08 ppm in the spectra of 3FY Med25 with two equivalents of VP16(413-
451), the H1 TAD of VP16. This new resonance represented an upfield shift of 0.12 ppm 
for Y487 and a downfield shift of 0.18 ppm for Y515. Additionally, starting at 0.5 and 
higher equivalents of VP16 H1, Y528 was perturbed (0.03 ppm downfield shift at 2 eq. 
Figure 3.8. PrOF NMR of 3FY Med25 AcID-VP16 H1 complexes. Spectral analysis 
of 3FY Med25 AcID in the presence of increasing concentrations of VP16(413-451), 
the H1 TAD of VP16, demonstrated that VP16 H1 only perturbs the Y487/Y515 pair, 
in a dose-responsive manner. The resonance corresponding to Y528 is initially 




peptide). VP16 H1 had a much more significant impact on the Y487/Y515 than any of the 
H2/third site peptides - VP16 H2, ATF6α, and CBP. This is consistent with an alternative 
mode of interaction. The effect on Y487/Y515 could be explained by an interaction 
between VP16 H1 and β5, located at the center of the H1 cleft. A tight association with 
β5 would likely cause a conformational change in α2, the helix on which Y487 resides. 
The lack of perturbations at Y528 at 0.1 and 0.25 eq VP16 H1 along with the complete 
lack of perturbations at Y432 are consistent with the H2 site not being the primary target 
for VP16 H1 binding to Med25 AcID. However, the perturbation of Y528 at elevated 
concentration of VP16 H1 does corroborate mutagenesis data that suggests that VP16 




Increasing concentrations of VP16 H2 (residues 452-490 of VP16) (7.5 µM, 
18.75 µM, 56.25 µM, 75 µM, and 150 µM) were then complexed with 3FY Med25 AcID 
(75 µM) and subjected to PrOF NMR (Figure 3.9). VP16(452-490), which comprises the 
entirety of the VP16 H2 TAD, significantly affected both Y432 (upfield shift of 0.05 ppm at 
2 eq. peptide) and the Y487/Y515 pair (0.05 ppm downfield and 0.09 ppm upfield shifts 
at 2 eq. peptide). This result suggests that VP16 H2 binds at the H2 site, as expected by 
HSQC NMR8 and mutagenesis work. However, the difference in perturbed residues 
between VP16 H2 and ATF6α(40-66) suggests that these two H2 site peptides interact 
Figure 3.9. PrOF NMR of 3FY Med25 AcID-VP16 H2 complexes. Spectral analysis 
of 3FY Med25 AcID in the presence of increasing concentrations of VP16(452-490), 




differentially with Med25 AcID. While PrOF and HSQC data suggest that ATF6α binds 
perpendicular to the β-barrel and interacts with the C-terminal end of α1, this PrOF result 
suggests that VP16 H2 likely extends towards the N-terminal end of the α1 and proximal 
to α2.   
 
 Acetylated VP16(438-490) (7.5 µM, 37.5 µM, 56.25 µM, 75 µM, 93.75 µM, 
112.5 µM and 150 µM) was complexed with 3FY Med25 AcID (75 µM) and subjected to 
PrOF NMR (Figure 3.10). Based on the PrOF data for VP16(452-490), it is unsurprising 
that an extended VP16 construct, VP16(438-490), also perturbs Y432 (0.06 upfield shift 
Figure 3.10. PrOF NMR of 3FY Med25 AcID-VP16(438-490) complexes. Spectral 
analysis of 3FY Med25 AcID in presence of increasing concentrations of VP16(438-
490), the helical region of VP16 H1 and the entirety of VP16 H2, demonstrated 
perturbations of all four Tyr residues.  
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at 2 eq. peptide) and the Y487/Y515 pair (0.13 ppm downfield and 0.05 ppm upfield) in 
similar ways. However, an interesting difference between these two PrOF titrations is that 
VP16(438-490) also perturbs Y528 in a dose-responsive manner (0.07 ppm downfield 
shift at 2 eq. peptide). These data are consistent with a more complex binding mode for 
VP16(452-490) relative to VP16(438-490).  For instance, VP16(438-490), which binds 
Med25 AcID much more tightly than VP16(452-490) (KD of 82 nM for Med25-VP16(438-
490) vs. 605 nM for Med25-VP16(452-490) in FP assays), could potentially bind twice to 
Med25, either at both the H1 and H2 sites simultaneously or twice at the H2 site itself. 
The N-terminal portion of VP16(438-490) which represents the helical region of the VP16 
H1 TAD, could bind to the H1 face concurrent to the C-terminal portion’s interaction with 
the H2 site. If this second scenario is true, the PrOF data, particularly the perturbation of 
Y528, would suggest that VP16(438-490) wraps around either α1 and α3 or “underneath” 




 As performed with CBP(20-55), ATF6α(40-66) peptide (8.75 µM, 35 µM, and 
70 µM) was complexed with 3FY Med25 AcID (35 µM) and subjected to PrOF NMR 
(Figure 3.11). ATF6α(40-66) caused dose-responsive shifts in both Y432 and Y528, with 
the highest concentration (2 eq peptide relative to 3FY Med25 AcID) providing upfield 
0.12 ppm and 0.11 ppm shifts respectively. These data corroborate HSQC NMR evidence 
that ATF6α(40-66) binds the H2 site at the cleft formed by β6/β7/β4 and α1 and suggests 
that the peptide does not directly bind to α2, where Y487 is located. 
Figure 3.11. PrOF NMR of 3FY Med25 AcID-ATF6α(40-66) complexes. Spectral 
analysis of 3FY Med25 AcID in presence of increasing concentrations of ATF6α(40-
66) demonstrated that ATF6α(40-66) perturbs Y432 and Y528, each of which are 




Increasing concentrations of acetylated CBP(20-55) peptide (7.5 µM, 15 µM, 
30 µM , and 60 µM) were complexed with 3FY Med25 AcID (50 µM) and subjected to 
PrOF NMR (Figure 3.12). Only Y432 was significantly perturbed in a dose-responsive 
Figure 3.12. PrOF NMR of 3FY Med25 AcID-CBP(20-55) complexes. Spectral 
analysis of 3FY Med25 AcID in presence of increasing concentrations of CBP(20-55) 
demonstrated that CBP(20-55) specifically perturbs Y432. A binding isotherm for the 
Med25-CBP interaction can be determined using the chemical shift perturbation at 
Y432 with respect to [CBP(20-55)].   
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manner. At the highest concentration (1.2 eq. CBP peptide relative to 3FY Med25 AcID), 
there was a 0.06 ppm upfield shift the Y432 resonance. The specific perturbation of this 
residue without affecting the other resonances suggests that CBP(20-55) does not bind 
directly to the H2 site. Instead, these data corroborate HSQC NMR evidence that 
suggested that CBP bound to Med25 by wrapping itself perpendicular to the β-barrel 
along β4/β2/β1 in a binding mode that was unique compared to the Med25-interacting 
ligands. 
A binding isotherm for the Med25-CBP PPI was determined using the dose-
responsive chemical shift perturbation at Y432 to determine a binding affinity of 
35 ± 7 µM. This result provided an additional validation that 3FY Med25 AcID functioned 
similarly to Med25 AcID, with a KD approximately ten-fold higher than measured by FP. 
This loss in binding affinity can be explained by the lack of the hydrophobic N-terminal 
fluorescein in the acetylated CBP(20-55) peptide. A similar ten-fold loss in binding affinity 
was demonstrated in FP-based competition experiments (Figure 2.3). Notably, this PPI 
was the only interaction for which an appropriate KD with minimal error could be 
measured. This could be explained if the Med25-CBP PPI occurs with different kon/koff 
values and/or exchange rates (kex)38. For interactions that occur on fast exchange 
regimes (high kex), titrations of one ligand into protein will provide NMR resonances that 
shift proportionally from the unbound state to the bound state.5 However, in the case of 
protein-ligand interactions that occur under intermediate exchange rates, the chemical 
shift is not necessarily proportional from the unbound state to the bound state. It is likely 
that the Med25-CBP PPI is operating in the fast exchange regime while the other Med25 











Finally, ERM(38-68) peptide (7.5 µM, 18.75 µM, 37.5 µM, 56.25 µM, 75 µM, 
93.75 µM, 112.5 µM and 150 µM) was titrated with 3FY Med25 AcID (75 µM) and 
subjected to PrOF NMR in order to test the working hypothesis that ERM is the most 
selective peptide for the H1 site and also interacts at the H2 site with weaker affinity 
(Figure 3.13). Titration of 3FY Med25 AcID with ERM(38-68) demonstrated biphasic 
character. At substoichiometric concentrations of peptide (Figure 3.13.A), none of the 3FY 
resonances is shifted; The only effect that substochiometric ERM(38-68) provides is a 
slight broadening of the resonance at Y515. Similar to VP16 H1, this difference could be 
explained by a slight conformational change in the protein that results from ERM(38-68) 
binding to the H1 site. The second phase of 3FY Med25 AcID induced by ERM(38-68) 
occurs at 1, 1.5, and 2 eq. of peptide relative to protein (Figure 3.13.B). These three 
spectra (1, 1.5, and 2 eq. ERM) overlap with each of the four resonances experiencing 
nearly identical downfield shifts relative to WT. These data suggest that either Med25 
binds ERM peptide at two sites with measurably different affinities or that ERM binds at 
the H1 site and induces a significant conformational change in Med25 that causes uniform 
shifting in 3FY resonances after ERM saturation. Taken together with previous 
mutagenesis data demonstrating that ERM(38-68) is capable of binding Med25 even if 
the H1 site is inhibited, the first scenario is most consistent.  
 
Figure 3.13. PrOF NMR of 3FY Med25 AcID-ERM(38-68) complexes. (Figure on 
previous page); Spectral analysis of 3FY Med25 AcID in the presence of increasing 
concentrations of ERM(38-68) demonstrates biphasic character. At substoichiometric 
concentrations (A), shown in blue, ERM(38-68) causes no significant chemical shifts 
but does broaden the Y515 resonance. At and above stoichiometric equivalents (B), 
shown in green, ERM(38-68) causes a downfield perturbation in all four Tyr residues.  
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PrOF NMR titrations with Med25-interacting peptides against 5FW Med25 AcID 
 3-fluorotyrosine provided excellent reporters of ligand binding and conformational 
change at the H2 and third sites of Med25 AcID while also offering some nuance towards 
definition of the H1 site. However, for continued study of the H1 site using PrOF NMR, 
further development of a system that provided direct reporters within the H1 site was 
desired. Since 5-fluorotryptophan Med25 AcID was obtainable in high yields (10-15 mg 
protein per liter bacterial culture) at high 19F incorporation and provides direct reporters 
at the H1 site, this reagent was used in similar peptide titrations as performed with 3FY 
Med25 AcID.  
Site-directed mutagenesis to assign the resonances in 5FW Med25 AcID were 
unsuccessful. None of the attempted mutants – W402F, W408F, and W444F – could be 
expressed. This inability to express W-to-F mutants likely results from the side chains of 
each of these Trp residues not being solvent exposed and thus potentially critical for 
protein folding and structure. However, for the scope of this work, independent 
assignment was thought to be unnecessary, in part because W402 and W444 are direct 
interaction partners. It is thought that the overlapped resonances from -126.3 to -127.3 
ppm, which integrate for two fluorine atoms, likely represent the W402-W444 dyad. 
Furthermore, all three Trp residues are positioned near the H1 site, contain side chains 
that are not solvent exposed, and are presumed to be integral to Med25 structure. 
Therefore, it was hypothesized that 5FW resonances would be sensitive to only the most 





Figure 3.14. PrOF NMR of 5FW Med25 AcID complexes. (A) Spectral analysis of 
5FW Med25 AcID in the presence of increasing concentrations of VP16(413-451), the 
H1 TAD of VP16. No Trp residue is significantly affected. This titration is representative 
of similar titrations of 5FW Med25 performed with VP16 H2, ATF6α(40-66), and 
CBP(20-44), which also showed no effect. (B) Spectral analysis of 5FW Med25 in 
presence of highest concentrations of peptides tested, 
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  Similar to the described experiments with 3FY Med25 AcID, peptide ligands that 
interact with Med25 AcID – CBP(20-44), ATF6α (40-66), VP16 H1, and VP16 H2 – were 
incubated with 5FW Med25 AcID (Figure 3.14). 5FW Med25 was held constant at 75 µM 
and peptide ligands were added at 18.75 µM, 37.5 µM, 75 µM, and 150 µM for PrOF NMR 
spectral analysis. Note that the VP16 H1 titration did not include the 150 µM data point. 
None of these four peptide ligands had any effect on the 5FW Med25 spectra, indicating 
that none of them contacted, or caused a conformational change in, any of the three Trp 
residues. These results were expected for the CBP, ATF6α, and VP16 H2 peptides, none 
of which appear to significantly interact at the H1 site. However, the lack of perturbation 
of W408 by VP16 H1 was puzzling as it was expected that VP16 H1 interacted with the 
loop between β1 and β2. This result suggests instead that VP16 H1 likely interacts with 
the H1 site parallel to, and up against α3.  
 
Figure 3.15. PrOF NMR of 5FW Med25 AcID in complex with 1 eq ERM(38-68). 
ERM(38-68) causes a significant perturbation (0.83 ppm shift) in the resonance 
centered around -126.7 ppm in spectra of 5FW Med25 AcID while not affecting the 
resonance at -128.3 ppm. 5FW Med25 complexed to ERM(38-68) shown in blue; 5FW 
Med25 only shown in red.  
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In contrast to the results of the H2/third site interacting peptides and the VP16 H1 
experiments, the addition of 1 eq ERM(38-68) to 5FW Med25 AcID caused a dramatic 
perturbation of 5FW resonances (Figure 3.15). Specifically, ERM(38-68) caused a ~1 
ppm downfield shift of the resonance at -126.7 ppm. As previously noted, this broad 
resonance integrates for two 19F atoms and is proposed to represent the W402/W444 
dyad. This result corroborates previous evidence that ERM(38-68) binds to the H1 site in 
a unique manner and quite differently than VP16 H1. In particular, when considering the 
lack of perturbations at α2 in 3FY PrOF experiments at substochiometric ERM conditions, 
this result suggests that ERM(38-68) might bind perpendicular to the β-barrel at the H1 
site. 
 
Binding models for unique peptide interactions with Med25 AcID  
 At this stage, each discrete interaction between Med25 AcID and its protein 
interaction partners have been subjected to extensive analysis including 1H, 15N-HSQC 
NMR, the mutational study described in Chapter 2, and protein-observed 19F NMR. 
Collectively, these data have informed proposed binding models to describe each of the 
known Med25 AcID PPI. Each methodology has its limitations (e.g. HSQC NMR cannot 
necessarily differentiate between allosteric and orthosteric effects) however, they are 
incredibly complementary, with each providing unique insights (e.g. PrOF NMR can 




In the mutagenesis study, blocking both the H1 and H2 sites with negative charge 
(Q451E/M523E mutant) resulted in a 24-fold loss in binding affinity for VP16 H1 relative 
to WT; Blocking either the H1 site (Q451E) or the H2 site (M523E) alone provided 
relatively minor losses in binding affinity (2.9-fold and 4.3-fold losses, respectively). This 
suggested that VP16 H1 could either bind at both the H1 and H2 sites or that VP16 H1 is 
an allosteric regulator of Med25 function; HSQC NMR data were consistent with these 
two possibilities. PrOF NMR of 3FY Med25 AcID suggested that VP16 H1 binding occurs 
“high” in the H2 site, near α2, as only the Y487/Y515 pair were significantly perturbed. 
The lack of perturbations in the PrOF NMR of 5FW Med25 (which provides NMR reporters 
at the H1 site only) indicated that the H1 site is not the sole target for binding to Med25 
Figure 3.16. Model of the Med25 AcID-VP16 H1 PPI. Proposed binding locations of 
Med25 AcID for VP16(413-451) are highlighted by golden circles. Residues of Med25 
AcID that are significantly perturbed by VP16 H1 peptide in HSQC NMR are colored 
in teal (2 standard deviations) and pale blue-green (1 standard deviation); Tyr residues 
that are affected in PrOF NMR experiments are shown as sticks in black; Residues 
where introduction of negative charge significantly inhibited the PPI are shown as 
sticks in dark blue. HSQC NMR performed by Andy Henderson. (PDB 2XNF) 
H1 site H2 site 
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AcID, diminishing allosteric effects as the cause for H2 site perturbations in other 
experiments. Collectively, these data suggest that VP16 H1 binds at the H2 site with an 
affinity equivalent to that at the H1 site. It remains unknown however if multiple copies of 
the peptide are capable of binding to the protein simultaneously (Figure 3.16). 
 
HSQC NMR of the Med25 AcID-VP16 H2 demonstrated significant perturbations 
at the H1 and H2 sites, suggesting that the peptide might bind at both locations. However, 
the mutational and PrOF NMR studies were more definitive in demonstrating that VP16 
H2 binds selectively to the H2 site. Mutagenesis to block the H2 site was incredibly 
effective at inhibiting VP16 H2 (R466D and M523E provided 11-fold and 23-fold losses in 
binding affinity relative to WT, respectively) while blocking the H1 site through 
H2 site H1 site 
Figure 3.17. Model of the Med25 AcID-VP16 H2 PPI. The proposed binding location 
of Med25 AcID for VP16(452-490) is highlighted by the golden circle within the H2 site. 
Residues of Med25 AcID that are significantly perturbed by VP16 H2 in HSQC NMR 
are colored in red (2 standard deviations) and pink (1 standard deviation); PrOF NMR 
experiments of 3FY Med25 AcID caused perturbations in Y432 and the Y487/Y515 
pair (sticks in black); Introduction of negative charge at R466 and M523 (sticks in blue) 
caused significant inhibition of the Med25 AcID-VP16 PPI. HSQC NMR performed by 
Andy Henderson. (PDB 2XNF) 
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mutagenesis was ineffective at inhibiting VP16 H2. PrOF NMR studies of the Med25 
AcID-VP16 H2 localized the VP16 H2 interaction to occur “high” in the H2 site, near α2, 
and likely extending perpendicular to the β-barrel towards Y432 (Figure 3.17). 
 
Like VP16 H2, HSQC NMR of VP16(438-490), which contains the α-helical region 
of VP16 H1 and the entirety of VP16 H2, demonstrated significant chemical shift 
perturbations at both the H1 and H2 sites of Med25 AcID. However, the mutagenesis 
work and PrOF NMR could differentiate VP16 H2 from VP16(438-490), as VP16(438-
490) had more dramatic impact within both studies. PrOF NMR of 3FY Med25 AcID 
perturbed all four Tyr residues dispersed among the H2 site. Individual inhibition of either 
H2 site H1 site 
Figure 3.18. Model of the Med25 AcID-VP16(438-490) PPI. Proposed binding 
locations of Med25 AcID for VP16(438-490), which contains the α-helical region of 
VP16 H1 and the entirety of VP16 H2, are highlighted by golden circles. Residues of 
Med25 AcID that are significantly perturbed by VP16 H1 peptide in HSQC NMR are 
colored in orange (2 standard deviations) and yellow (1 standard deviation); Tyr 
residues that are affected in PrOF NMR experiments are shown as sticks in black; 
Shown as sticks in dark blue are residues at which introduction of negative charge to 
block the H2 site (R466 and M523) or tethering with a peptide to block the H1 site 
(C506) significantly inhibited the Med25-VP16(438-490) PPI. HSQC NMR performed 
by Andy Henderson. (PDB 2XNF) 
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the H2 site through introduction of negative charge (R466D and M523E provided 8.9-fold 
and 15-fold losses in binding affinity relative to WT, respectively) or the H1 site through 
Tethering of VP16 G450C peptide (WT-VP16 G450C peptide provided a 6.0-fold loss in 
binding affinity relative to WT) significantly reduced binding affinity. Furthermore, blocking 
the H1 and H2 sites simultaneously had dramatic effects (R466D and M523E Tethered 
to VP16 G450C peptide provided 46-fold and 117-fold losses in binding affinity to WT, 
respectively). Collectively, these data suggest that VP16(438-490) likely binds to both the 
H1 and H2 faces simultaneously. It is likely that C-terminal portion, containing VP16 H2, 
interacts at the H2 site while the N-terminal binds at the H1 site (Figure 3.18). While the 
order in which these interactions occur is unknown, the first binding event would make 
the second binding event highly favorable, as the entropic cost of the second interaction 
would be lowered. This mechanism of action provides an explanation of why the 
VP16(438-490) peptide binds Med25 AcID with >7-fold higher affinity than VP16 H2 (KD 




 HSQC NMR of the Med25 AcID-ERM PPI, reported in the literature10 and 
performed in the Mapp lab, demonstrated significant chemical shift perturbations at the 
H1 site. Additional residues were significantly perturbed at the H2 site, opening the 
possibility that ERM(38-68) could behave like VP16 H1 and bind at both sites with similar 
affinities. However, both the mutagenesis study and PrOF NMR indicated that this is not 
the case. In the mutagenesis study, ERM was the only peptide that was significantly 
Figure 3.19. Model of the Med25 AcID-ERM PPI. The proposed primary binding 
location of Med25 AcID for ERM(38-68) is highlighted by the golden circle at the H1 
site. A proposed secondary binding location, thought to represent a weaker affinity 
interaction, is highlighted by the tan circle at the H2 site. Residues of Med25 AcID that 
are significantly perturbed by saturation with ERM peptide in HSQC NMR are colored 
in teal (2 standard deviations) and pale blue-green (1 standard deviation). Shown as 
sticks in dark blue are residues (Q451, H499, and R538) at which introduction of 
negative charge to block the H1 site significantly inhibit ERM binding (These residues 
are also significantly perturbed in HSQC NMR experiments.). At the H1 site, Trp 
residues that are affected in PrOF NMR experiments are shown as sticks in black; At 
the H2 site, Tyr residues, shown as sticks in gray, are perturbed in PrOF NMR only at 
and above stoichiometric equivalents; Introduction of negative charge at M523, shown 
as sticks in light blue, inhibits ERM binding only if the H1 site is also blocked with 
Q451E (H1 site) mutation. HSQC NMR performed by Andy Henderson. (PDB 2XNF)  
H1 site H2 site 
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affected by the introduction of negative charge at Q451, H499, and R538 (3.0-fold, 3.5-
fold, and 5.9-fold losses in binding affinity to ERM(38-68) relative to WT, respectively). 
Furthermore, ERM(38-68) was the only interaction partner that perturbed 5FW Med25 
resonances in PrOF NMR, all of which are located near the H1 site, and did not perturb 
any 3FY Med25 resonances at substochiometric equivalencies. Collectively, these data 
demonstrated that ERM binds selectively at the H1 site when relative levels of ERM 
peptide are low (Figure 3.19).  
Additional evidence suggested that ERM likely binds to the H2 site with a lesser 
relative affinity when the H1 site is already occupied with another copy of the peptide 
ligand. In PrOF NMR, 3FY Med25 resonances are unaffected by ERM until the 
concentration of ERM peptide is equal or, or greater than, the concentration of protein at 
which point all resonances become significantly perturbed. The mutational study provided 
additional evidence of a weak, second interaction between ERM and the H2 site. 
Inhibition of the H2 site through introduction of negative charge at M523 alone does not 
affect ERM binding (1.2-fold change relative to WT) however blocking both the H1 and 
H2 sites with the Q451E/M523E mutation provides 9.9-fold loss in binding affinity relative 





 Like VP16 H2, all experimental data suggest that ATF6α binds selectively at the 
H2 site. HSQC NMR demonstrated that vast majority of significantly perturbed residues 
are within or near the H2 site; Inhibition at the H1 site through mutagenesis had no effect 
on the Med25-ATFα interaction however H2 site mutants provided large effects (M523E, 
R466D, and R466D/M523E provided 8.8-, 12-, and 16-fold losses in binding affinity 
relative to WT). PrOF NMR did however demonstrate that ATF6α does interact differently 
with the H2 site than does VP16 H2. These data suggest that ATF6α binds at the ‘bottom’ 
of the H2 site, away from α2 and near the C-terminal end of α1 (Figure 3.20). 
Y528 
R466 
Figure 3.20. Model of the Med25 AcID-ATF6α PPI. The proposed binding location of 
Med25 AcID for ATF6α(40-66) is highlighted by the golden circle within the H2 site. 
Residues of Med25 AcID that are significantly perturbed by ATF6α peptide in HSQC 
NMR are colored in red (2 standard deviations) and pink (1 standard deviation); R466 
and Y528 (labeled) were also perturbed by >2 SD in HSQC NMR. PrOF NMR 
experiments of 3FY Med25 AcID caused perturbations in Y528 and Y432 (sticks in 
black). Finally, introduction of negative charge at R466 and M523 (sticks in blue) 





 The Med25 AcID-CBP PPI is unique from all Med25-activator PPIs, based on the 
data. HSQC perturbation patterns differ from all other peptides, providing significant 
chemical shift perturbations within the H2 site and at a cleft in the protein that could 
represent a third binding site formed by β2/β4/α2, 90° away from the H2 site. Notably, 
CBP(20-44) is the only tested peptide to perturb several residues in this region of the 
protein away from the H2 site. A recent report has suggested that the DNA-binding 
domain of ETV4 likely occupies this similar position on Med25 AcID.39 Additional evidence 
that CBP(20-44) resides at this newly identified cleft of the protein and not at the H2 site 
comes from the PrOF NMR titration of 3FY with CBP. Only Y432, a residue that is situated 
between the H2 site and this putative third site, is perturbed by CBP. It should be noted 
H2 site Third site 
Figure 3.21. Model of the Med25 AcID-CBP PPI. The proposed binding location of 
Med25 AcID for CBP(20-44) is highlighted by the golden circle at the third site. 
Residues of Med25 AcID that are significantly perturbed by CBP peptide in HSQC 
NMR are colored in bright green (2 standard deviations) and dull green (1 standard 
deviation); Y432, the single Tyr residue that is perturbed in PrOF NMR experiments is 
shown as sticks in black; Residues where introduction of negative charge significantly 




that it is unknown where the H2 site ends and this potential third site would begin (Figure 
3.21). However, critically, the NMR binding signatures for the Med25-CBP(20-44) PPI are 
unique and unlike any other peptide ligand (as described) or small molecule ligand (to be 
described). This stark difference in binding signature could have important implications 
on Med25 AcID function. This newly identified site, if verified, could represent an interface 
that Med25 might exploit for allosteric purposes or to link activators to the master 
coactivator CBP/p300. 
 
Protein-observed 19F-NMR experiments demonstrate model of Med25 AcID inhibition 
induced by norstictic acid 
Norstictic acid is a single-digit micromolar inhibitor of Med25 AcID PPIs, and 
functions through formation of reversible covalent imine adducts with lysine residues of 
Med25 AcID. Site-specific mutations of lysine with arginine eliminated the possibility for 
covalent-adduct formation while maintaining positive charge. A single set of mutations – 
K518R/K519R/K520R, located on the H2 site – had negligible effects on native Med25-
peptide interactions but strongly reduced inhibition by norstictic acid of Med25-VP16 H1 
and Med25-VP16 H2 interactions. This suggested that norstictic acid covalently binds 
with these specific lysine residues within the H2 site however secondary evidence was 
desired. This Med25 AcID-ligand interaction offered an excellent opportunity to leverage 
the PrOF NMR system and knowledge gained during the PrOF analyses of Med25 PPIs 




 Norstictic acid was incubated with 3FY Med25 AcID, at four different 
concentrations relative to Med25, for four hours at room temperature prior to reduction of 
the resultant imine with sodium borohydride. Following a buffer exchange, these protein 
samples were then subjected to mass spectrometric analysis to demonstrate the 
formation of covalent Med25-norstictic acid adducts (Figure 3.22). Incubation of 3FY 
Med25 with 0.5 eq. norstictic acid provided 39% singe-labeled protein (18557.59 Da) and 
6% double-labeled protein (118912.52 Da). 3FY Med25 incubated with 1 eq. norstictic 
acid (47% single-, 21% double-, and 3% triple-labeled) and 2 eq. norstictic acid (45% 
single-, 37% double-, and 8% triple-labeled) both provided protein samples that were 
primarily labeled as a single adduct. Unsurprisingly, incubation with 4 eq. norstictic acid 
Figure 3.22. Labeling of 3FY Med25 AcID with norstictic acid. 3FY Med25 (75 µM) 
was incubated with 0.5, 1, 2, and 4 eq. of norstictic acid for four hours at room 
temperature before mass spectrometry and PrOF NMR analysis. Red squares indicate 
number of covalent norstictic acid; Each norstictic acid provided +354 mass units. 
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gave the highest degree of labeling with > 50% of the total protein covalently bound with 
three or more norstictic acid molecules (6% single-, 19% double-, 24% triple-; 32% 4x-, 
14% 5x-, 5% 6x-labeled).  
 
  After mass spectroscopy and a buffer exchange to remove excess norstictic acid, 
each sample was subjected to PrOF NMR analysis (Figure 3.23). The resultant spectra 
demonstrated that labeling with norstictic acid dramatically affects the tyrosine residues 
of 3FY Med25. The Med25 AcID sample incubated with 0.5 eq. norstictic acid was either 
unlabeled (55% by MS) or single-labeled (39% by MS). This single adduct caused a 
splitting of both the Y432 and Y487 resonances, as evidenced by the downfield shoulders 
Figure 3.23. PrOF NMR of 3FY Med25 AcID labeled with norstictic acid. Spectral 
analysis of 3FY Med25 AcID incubated with 0.5, 1, 2, and 4 eq. of norstictic acid. 
Labeling with norstictic acid causes chemical shift perturbation at Y487 at 0.5 eq. and 
subsequent perturbations of Y432 and Y515 as [norstictic acid] increases. 
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of the WT resonances at -134.5 and -136.9 ppm. These new peaks become more 
apparent in the 1 eq. norstictic acid sample, likely due to its lower % unlabeled by MS 
(29%). In the PrOF spectrum of the Med25 AcID sample incubated with 2 eq. norstictic 
acid sample, which contained significant amount of protein with two covalent adducts 
(37% double-labeled), both the Y487 and Y515 resonances were completely shifted 
downfield from their WT chemical shifts. The PrOF spectrum of the final sample, Med25 
AcID incubated with 4 eq. norstictic acid, demonstrated significant broadening of all 
resonances in the noise, with peaks indistinguishable for Y432, Y487, and Y515. This 
could indicate that each of these tyrosine residues are near norstictic acid when Med25 
AcID is labeled with more than one norstictic acid or that multiple-labeled adducts induce 
large conformational changes (Only 6% of this sample contained fewer than two adducts). 
The resonance for Y528, while broadened slightly, remained in its WT location.  
 Collectively, these PrOF experiments with Med25 AcID covalently labeled to 
increasing amounts of norstictic acid demonstrated that norstictic acid likely binds the 
protein in proximity of the Y487/Y515 pair and Y432 (Figure 3.24). Since it is known that 
the molecule forms a covalent adduct with the side chains of lysine, this PrOF data 
suggested that norstictic acid is likely to preferentially bind one of the lysine residues in 
the 6-7 loop (K518/K519/K520) at least once, and potentially twice, before reacting with 
other residues. These are the only lysine residues in proximity of each of the Y487/Y515 
and Y432 residues that are influenced by norstictic acid in PrOF experiments. This 
analysis is consistent with, and corroborates, previous Lys-to-Arg mutational work that 
demonstrated that K518/K519/K520 were critical for the inhibitory activity of norstictic 
acid40. In addition to providing corroboration of the location of the Med25-norstictic acid 
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interaction, this result demonstrated that PrOF NMR of fluorinated Med25 variants offers 
a unique method of studying Med25-ligand interactions in addition to Med25 PPIs  
 
PrOF NMR allows for characterization and development of a small molecule fragment 
that targets Med25 AcID 
The Med25 AcID-ERM PPI had been screened against a library of 1600 small 
molecule fragments maintained by the Wells lab at the University of California – San 
Francisco using the FP Tethering approach (Andy Henderson, University of Michigan and 
Zach Hills, UCSF).41,42 This methodology allows for the discovery of fragments that 
undergo disulfide exchange with solvent exposed cysteine residues of a protein-of-
interest. Med25 AcID contains two such cysteines – C497, located in the center of the H1 
site, and C506, located on a loop near the base of the H1 site. Thus, this methodology 
Figure 3.24. Model of norstictic acid labeling of Med25 AcID. PrOF NMR analysis 
corroborated that K518/K519/K520 (shown in red) on loop between β6-β7 is likely 
primary target for covalent labeling of norstictic acid for Med25 AcID. Dark blue 
residues indicate 3FY residues perturbed in PrOF experiments; pink represents 
additional Lys residues; Light blue represents Y528, which is not affected by norstictic 





was anticipated to discover molecules that inhibited Med25 AcID at the H1 site. Following 
screening of the Med25-ERM complex at three different stringencies (0.2 mM, 1 mM, and 
5 mM β-mercaptoethanol) and removal of fluorescent artifacts, thirty-one unique 
compounds were discovered to significantly inhibit Med25-ERM. One of the most potent 
fragments discovered, termed A6, was independently synthesized (Clint Regan, 
University of Michigan) containing an irreversible iodoacetamide electrophile in place of 
the disulfide used during the Tethering screen (Figure 3.25). As with norstictic acid, it was 
hypothesized that PrOF NMR could be leveraged to provide mechanistic understanding 
of the interaction of this fragment small molecule with Med25 AcID.  
 
Med25 AcID was incubated with four equivalents of A6-iodoacetamide fragment 
for six hours, resulting in a protein sample that was singly labeled (>95% by mass 
spectroscopy). Longer incubation times and/or higher equivalencies of A6 did produce 
Figure 3.25. Structures of fragment A6. A6 is shown with a right-side terminal 
disulfide (structure of originally discovered molecule in Tethering screen; allows for 
reversible disulfide exchange with cysteine) and with a right-side terminal 
iodoacetamide (allows for covalent labeling at cysteine residues) 
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Med25 AcID that was doubly labeled; however, this second labeling event was much 
slower than the first. Labeling studies with C506A and C497A mutants were used to 
determine which of the two solvent exposed cysteines was the preferred target for 
A6-iodoacetamide (Andy Henderson, University of Michigan). These experiments 
demonstrated that A6-iodoacetamide efficiently labels C497A Med25 AcID but does not 
label C506A Med25 AcID, a result indicating that the Cys at 506 is the likely target of 
A6-iodoacetamide. 
 The ability of A6 to inhibit binding of peptide ligands to the H1 site of Med25 was 
investigated using WT Med25 AcID and Med25 mutants that block the H2 site (R466D, 
and M523E), in similar manner as performed with VP16 G450C peptide (Figure 3.26). It 
was hypothesized that A6 would be capable of moderate and significant inhibition of the 
Med25-VP16 H1 PPI based on the effects of VP16 G450C peptide when tethered to C506 
of Med25 AcID. Tethering of VP16 G450C peptide to WT Med25 AcID caused a 12.8-fold 
loss in VP16 H1 binding affinity while Tethering of VP16 G450C peptide to R466D had 
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Figure 3.26. Mutant Med25-A6 complexes fail to block H1 and H2 sites 
simultaneously. Binding affinities of VP16 H1 and VP16 H2 peptides for Med25 




caused a 67-fold loss in VP16 H1 binding affinity. These results had demonstrated that 
the combination of an H2 site mutant and VP16 G450C peptide appended to the H1 site 
was capable of successfully blocking the H1 and H2 sites simultaneously. Considering 
these large inhibitory effects provided by VP16 G450C, it was hypothesized that the small 
molecule fragment A6 Tethered to the same C506 residue of Med25 AcID would be 
capable of comparable inhibitory effects.  
For all three Med25 AcID variants (WT, R466D, and M523E), excess A6-
iodoacetamide was incubated with protein until >95% single labeling was achieved 
according to MS analysis. Binding affinities of labeled and unlabeled protein to VP16 H1 
and VP16 H2 were then measured by FP. WT Med25 AcID bound VP16 H1 and VP16 
H2 with a KD of 1.7 ± 0.1 and 0.6 ± 0.1 µM, respectively; Tethering of A6 to WT Med25 
AcID had a minimal effect on the affinity towards VP16 H1 (2.7-fold loss; 
KD = 4.6 ± 0.3 µM) and VP16 H2 (1.6- fold loss; KD = 0.9 ± 0.1 µM). Labeling of R466D 
and M523E, two mutants that block the H2 site, with A6-iodoacetamide did not improve 
the capability of parent proteins to block VP16 H1 or VP16 H2 interactions. In fact, R466D 
Med25 labeled with A6 bound VP16 H1 and VP16 H2 with slightly tighter affinities than 
WT Med25 AcID (e.g. R466D Med25 AcID bound VP16 with KD of 9.9 ± 0.9 µM compared 
to a KD of 8.5 ± 0.8 µM for WT Med25 AcID).  
 PrOF NMR of Med25 AcID, utilizing both VP16 G450C and A6 tethered to C506, 
was then pursued to determine why A6 was incapable of successfully blocking the H1 
site even while being tethered to C506. It was hypothesized that differences in binding 
locations of VP16 G450C and A6 to Med25 AcID as determined using PrOF NMR could 
explain their differences in efficacy. 3FY Med25 was independently labeled with VP16 
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G450C peptide and fragment A6 before being subjected to PrOF NMR analysis (Figure 
3.27)  
 
 As expected, VP16 G450C caused chemical shift perturbations in each tyrosine 
residue in 3FY Med25 relative to unlabeled 3FY Med25. This result was consistent with 
VP16 G450C likely inducing a conformational change in Med25 AcID when 100% bound 
to the protein. The large effects on Y432 and the Y487/Y515 pair indicate that VP16 
G450C is likely extending across the H1 site from C506 up to α2 of Med25 AcID. Finally, 
Y528 was the least perturbed resonance of the four tyrosines in 3FY Med25 AcID, further 
corroborating that VP16 G450C extends into the H1 site and thus away from Y528. Of 
Figure 3.27. PrOF NMR of 3FY Med25 AcID labeled with VP16 G450C peptide or 
fragment A6. Spectral analysis of 3FY Med25 AcID covalently tethered to either VP16 
G450C peptide or A6 at C506.  
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note for this discussion – The side chain of Y528 is only 12-18 Å away from the sulfur 
atom of C506 in every published NMR structure. 
 Differing from the PrOF NMR spectra of 3FY Med25-VP16 G450C, which 
demonstrated chemical shifts for all resonances, the PrOF NMR spectrum of 3FY Med25 
AcID was dramatically perturbed at a single resonance by labeling with A6. The 
resonance attributed to Y528, at -137.5 ppm, was completely broadened into noise in the 
3FY Med25-A6 PrOF spectra. The lack of major perturbations in the Y487/Y515 pair and 
Y432 suggests that, unlike VP16 G450C peptide, A6 does not extend into the H1 site 
towards α2 of Med25 AcID when tethered to C506. Instead, the broadening of the Y528 
resonance suggested that A6 is likely interacting with the ‘bottom’ of the β-barrel, away 
from the H1 site, and could be making direct contact with Y528. Further, it was proposed 
that the 5-methoxy-indole of A6 could be forming a π-π interaction or hydrogen bond with 
the side chain of Y528 or a nearby residue. Based on molecular distances, this hypothesis 
is plausible. A6 is predicted to extend ~20 Ǻ from end-to-end in its lowest energy 
structure, longer than the distance (12-18 Ǻ) between C506 and Y528.  
 To investigate the hypothesis that the 5-methoxy-indole of A6 interacted with the 
base of the β-barrel and thus diminished its ability to inhibit Med25 PPIs similarly to VP16 
G450C, A6 was chemically modified to remove hydrogen bonding and/or aromatic 
character (Figure 3.28). Syntheses of an A6 derivative that replaced the 5-methoxy-indole 
with benzene and another that replaced the 5-methoxy-indole with cyclohexane were 






Following synthesis of the A6 derivatives, samples of 3FY Med25 AcID were 
independently labeled with each molecule to >95% singly labeled by MS and then 
subjected to PrOF NMR analysis (Figure 3.29). PrOF NMR spectrum of 3FY Med25 AcID 
tethered to the A6 benzene derivative demonstrated a partial recovery of the Y528 
resonance relative to the 3FY Med25-A6 spectrum and a ‘new’ resonance at -136.8 ppm. 
This peak and the Y528 resonance at -136.5 ppm both integrate for ~0.6 19F relative to 
the Y432 resonance (the Y487/Y515 pair integrate for 2.05 19F) suggesting that these 
resonances represent two distinct conformers of Y528, a WT-like state and another in 
which Y528 is interacting with the A6 benzene derivative. Additionally, moderate 
perturbations in the Y487/Y515 pair suggest that α2, located on the opposite end of the 
β-barrel from C506, is affected by the A6 benzene derivative. Collectively, this result 
indicated that the A6 benzene derivative was likely interacting with the bottom of the β-
Figure 3.28. Structures of A6 derivatives. Two derivatives of A6 were designed to 
investigate the hypothesis that the 5-methoxy-indole of A6 interacts with the base of 
the β-barrel to significantly broaden the Y4528 resonance in PrOF NMR. 
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barrel about 50% as tightly or consistently as A6 and that the A6 benzene derivative was 
partially adopting VP16 G450C character. 
 
PrOF NMR spectrum of the A6 cyclohexane derivative demonstrated nearly 
complete recovery of the resonance at Y528. The chemical shift of the doubled peak is 
significantly perturbed relative to WT, however the peak itself has recovered signal-to-
noise and integrates for 1.1 19F relative to Y432. This result suggests that the A6 
cyclohexane derivative no longer significantly interacts with Y528 and the bottom of the 
β-barrel, likely due to the replacement of the 5-methoxy-indole functionality of A6 with a 
saturated cyclohexane ring incapable of π-π stacking or hydrogen bond formation. It is 
Figure 3.29. PrOF NMR of 3FY Med25 AcID labeled with A6 or A6 derivatives. 
Spectral analysis of 3FY Med25 AcID covalently tethered to A6 or A6 derivatives at 
C506. As proposed, chemical modification of the 5-methoxy-indole of A6 to remove 




possible that the molecule could now be occupying the H1 site instead even though the 
A6 cyclohexane derivative does not perturb the Y487/Y515 pair, which are affected by 
VP16 G450C peptide.  
 This chemical modification and subsequent PrOF NMR strategy was successful in 
demonstrating that the inability of the parent fragment A6 to significantly inhibit Med25 
PPIs when fully bound at C506 likely results from its binding location on Med25 AcID. 
This strategy demonstrated that by removing the aromatic and hydrogen bond 
donators/acceptors at the end of this molecule, the fragment started to bind at the H1 site 
in a manner similar to VP16 G450C, a highly effective inhibitor of Med25 PPI at the H1 
site, as opposed to associating with the bottom of the β-barrel and apart from any of the 
putative Med25 AcID binding sites. While it is yet unknown if these modified fragments 
will be useful Med25 inhibitors, this study should provide future guidance in the rational 
development of Med25 fragments that target the H1 site. Additionally, this study 
demonstrated the power and utility of PrOF NMR in the development and characterization 
of small molecule modulators of Med25 AcID.  
 
D. Conclusions and future directions 
In this chapter, I hypothesized that protein-observed 19F-NMR of Med25 AcID 
would be a useful methodology for the study of Med25 and its protein-protein interaction 
network that would complement previously performed 1H, 15N-HSQC NMR from the 
literature and Chapter 2 of this thesis.8–10,39 Previous data demonstrated that Med25 AcID 
contained two or three discrete binding interfaces. Additionally, the H1 site was 
determined to be less dependent on hotspot residues and electrostatic interactions than 
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the H2 site and that several Med25-interacting partners that bound at the H1 site were 
proposed to be capable of compensatory interactions at the H2 site.  
Two unique PrOF NMR strategies were developed to specifically differentiate 
between the H1 and H2/third sites of Med25 AcID. The incorporation of 3-fluorotyrosine 
into Med25 AcID was hypothesized to allow for precise study of the H2 and ‘third’ sites 
due to the dispersion of four solvent-exposed Tyr residues surrounding the putative 
bounds of the H2 site. The incorporation of 5-fluorotryptophan into Med25 AcID was 
hypothesized to allow for direct observation of the H1 site. 3FY Med25 and 5FW Med25 
AcID were biosynthesized in high yields and subjected to PrOF NMR analysis. 3FY 
Med25 AcID provided four well-resolved resonances that were independently assigned 
to each of the four Tyr residues using Y-to-F and ‘nudge’ mutagenesis strategies. 5FW 
Med25 AciD provided an interpretable spectrum in a reasonable timeframe (~20 minutes 
of experimental time) however resonances were assigned to specific Trp residues. 
Subsequent titrations of each Med25-interacting peptide ligand with 3FY Med25 
AcID and 5FW Med25 AcID were analyzed by PrOF NMR. The titration of peptide ligands 
previously proposed to bind specifically at the H2 site (ATF6α and VP16 H2) caused 
significant chemical shift perturbations in multiple 3FY Med25 resonances while not 
affecting any resonances of 5FW Med25 AcID. PrOF NMR of CBP(20-55) in complex with 
3FY Med25 AcID demonstrated a significant chemical shift in a single residue (Y432) 
located along the nebulous barrier between the H2 site and the third site. This 
demonstrated that CBP binds Med25 AcID in a manner unlike other Med25-interacting 
ligands and likely associates directly at the third site located along β4/β2/β1 and the N-
termini of α2. PrOF NMR demonstrated significant differences in the binding modes of 
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the two previously proposed peptides (ERM and VP16 H1) that were thought to be 
somewhat selective for the H1 site. Increasing concentrations of VP16 H1 were found to 
cause significant chemical shift perturbations in the Y487/Y515 pair of residues in 3FY 
Med25 AcID while having no impact on resonances of 5FW Med25 AcID. However, 
increasing concentrations of ERM(38-68) had no impact on 3FY Med25 AcID at 
substochiometric equivalencies while causing a significant shift in 5FW Med25 AcID. This 
suggested that while VP16 H1 might be equally capable of binding to the H1 or H2 sites, 
ERM is highly selective for the H1 site at substochiometric concentrations. Collectively, 
these analyses of Med25 PPIs by PrOF NMR coupled with experiments performed in 
Chapter 2 and by another member of the Mapp lab (Andy Henderson) allowed for the 
generation of hypothesized models to describe each of the binding interactions for Med25 
AcID and its discrete protein partners. 
In addition to the study of Med25 and its PPI network, PrOF NMR was successful 
applied to the characterization of two small molecules discovered by other members of 
the Mapp lab. PrOF NMR spectra of 3FY Med25 AcID samples labeled with norstictic acid 
provided decisive evidence regarding norstictic acid’s mode of inhibition. This primary 
binding of this molecule, previously known to function through covalent adduct formation 
with lysine residues of Med25 AcID, was localized to the 6-7 loop of H2 site. PrOF NMR 
was also successfully utilized to suggest the reason for the inability of a molecule that 
binds Med25 AcID to significantly inhibit Med25 AcID function. This molecule, a fragment 
termed ‘A6’ was discovered by a Tethering screen against Med25 AcID. However, even 
when fully bound to the protein, A6 offered minimal inhibitory effects. PrOF NMR of 3FY 
Med25 labeled with A6-iodoacetamide demonstrated that the 5-methoxyindole 
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functionality of this fragment was likely forming a π-π interaction or hydrogen bond with 
a region of Med25 AcID that directed the molecule away from the H1 binding site. 
Removal of that 5-methoxyindole functionality provided A6-derivatives that are thought to 
bind into the H1 site in a manner similar to a known peptide-based inhibitor of the H1 site, 
VP16 G450C. This study could provide future guidance in the rational development of 
Med25 inhibitors that target the H1 site.  
Future work to develop additional fluorinated variants of Med25 AcID for the study 
of the H1 site could be beneficial. Only a single peptide, ERM(38-68) was capable of 
perturbing any of the resonances of 5FW Med25 AcID. However, while this result was 
incredibly useful in demonstrating the unique binding mode of ERM towards Med25 AcID, 
recall that at least two of the Trp residues within Med25 AcID are not solvent-exposed. It 
is thought that more environmentally sensitive 19F reporters could be useful in detecting 
weak interactions of other peptide ligands with the H1 site. To this end, future PrOF NMR 
experiments could be pursued using Med25 AcID labeled with trifluoroacetone. 
Preliminary work has demonstrated that the solvent-exposed cysteines (C497 and C506) 
of Med25, both of which reside within the H1 site, can both be reacted with 3-bromo-
1,1,1-trifluoroacetone to generate a Med25 AcID covalently linked to two trifluoroacetone 
molecules (Figure 3.30). A subsequent PrOF NMR spectrum provided three distinct 
resonances, indicating that the trifluoroacetone bound to each Cys residue are resolved. 
Three NMR resonances, as opposed to the anticipated two, suggests that one of the two 
cysteine-trifluoroacetone species likely exists in multiple conformations. Assignment of 
these resonances should be possible by labeling C497A and C506A Med25 mutants with 






Figure 3.30. PrOF NMR of Med25 AcID labeled with trifluoroacetone. (A) Med25 
was reacted with 3-bromo-1,1,1-trifluoroacetone to covalently label C497 (orange) and 
C506 (red) with trifluoroacetone. (B) Mass spectroscopy of Med25-trifluoroacetone 
sample demonstrated that Med25 AcID was 16% singly labeled and 83% double 
labeled. (C) PrOF NMR spectra of Med25-trifluoroacetone sample provided three 





E. Materials and methods  
Plasmids  
pET21b-Med25(394-543)-His6 was provided by Patrick Cramer. Mutant Med25 AcID 
plasmids. Point mutants of pET21b-Med25(394-543)-His6 were generated using 
standard molecular biology protocols.  
 
Previously described methods 
Relevant methods that were previously described in Chapter Two include Med25 AcID 
purification, mass spectroscopy of proteins, FP binding experiments, circular dichroism, 
thermal melts, and solid-phase peptide synthesis. 
 
Expression of 19F-labeled Med25 AcID 
pET21b-Med25(394-543)-His6 was transformed into chemically competent DL39(DE3), 
plated onto LB/ampicillin agar, and incubated at 37 °C overnight. In the morning, agar 
plates were placed at 4 °C until further use. In the evening, a single colony from the 
transformed plate was placed into 25 mL Luria Broth with 0.1 mg/mL ampicillin and 
incubated at 37 °C overnight at ≥200 RPM. The following morning, 5-20 mL from the 
starter culture was added to 1 L Luria Broth with 0.1 mg/mL ampicillin and bacteria were 
grown at 37 °C at ≥200 RPM to an OD600 of ~0.8. Cells were centrifuged and supernatant 
was decanted. Cells were then resuspended in 0.5-1 L of the minimally defined media, 
as described36 with minor changes as noted. For the expression of 3FY Med25, media 
was supplemented with either 48 mg/L L-3-fluorotyrosine (Alfa Aesar) or 
96 mg/mL DL-3-fluorotyrosine (Sigma Aldrich). For the expression of 5FW Med25, media 
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was supplemented with either 60 mg/L L-5-fluoroindole (Alfa Aesar) or 
120 mg/mL DL-5-fluoroindole (Sigma Aldrich). For the expression of 4FF Med25, media 
was supplemented with either 29 mg/L L-4-fluorophenylalanine (Alfa Aesar) or 
58 mg/mL DL-4-fluorophenylalanine (Sigma Aldrich). Cultures were incubated at 37 °C 
overnight at ≥200 RPM for 90 minutes before reducing the temperature to 20 °C. After 30 
minutes, 0.5 mM IPTG was added. Bacteria were shaken overnight at 20 °C at ≥200 RPM. 
The following morning, bacterial cultures were centrifuged at 7000 x g for 20 mins at 4 
°C. Cell pellets were then stored at -80 °C prior to protein purification (performed as done 
with unlabeled Med25 AcID, described in Chapter Two) 
 
1-D 19F-NMR of 19F-labeled Med25 AcID 
To prepare for PrOF NMR,19F-labeled Med25 AcID was dialyzed into PrOF buffer (50 mM 
HEPES, 100 mM NaCl, 1 mM DTT, pH 7.2). All PrOF experiments were performed with 
10% D2O and 0.01% trifluoroacetic acid (TFA) as an internal 19F reference. PrOF NMR 
data were acquired on a Varian 500 MHz NMR spectrometer with a Varian 5 mm PFG 
OneNMR Probe. Spectra were obtained without proton decoupling. NMR pulse 
parameters - D1 relaxation time of 1 sec and an acquisition time of 0.6 sec with a 10 ppm 
sweep width (centered on −136 ppm for 3FY Med25, −125 ppm for 5FW Med25, and 
−117 ppm for 4FF Med25). 1200-1600 total scans were collected for experiments with 
3FY Med25 AcID; 2400 scans for 5FW Med25 AcID; 6000 scans for 4FF Med25 AcID. 
For each protein sample, a second TFA reference experiment was also performed (32 




Labeling of 3FY Med25 AcID with norstictic acid 
Varying molar equivalents of norstictic acid were added to 3FY Med25 AcID, in PrOF 
buffer. The protein-small molecule mixture was incubated for 4 hours at room temperature 
with gentle shaking using an orbital shaker. The protein was then reduced with excess 
sodium borohydride for 1 hour at room temperature with gentle shaking using an orbital 
shaker. After reduction, the protein was buffer exchanged in PrOF buffer and prepared 
for PrOF NMR analysis. 
 
Labeling of Med25 AcID with A6 and its derivatives 
A four-fold molar excess of compound was incubated with WT, mutant, or 19F-labeled 
Med25 for four hours, or until >95% single-labeled protein was obtained by mass 
spectroscopy. The protein-small molecule complex was incubated at room temperature 
with gentle shaking using an orbital shaker. After labeling, the protein was centrifuged 
and buffer exchanged into either FP assay or PrOF buffer.  
 
Labeling of Med25 with 3-bromo-1,1,1-trifluoroacetone 
A five-fold molar excess of compound was incubated with WT Med25 overnight. The 
protein-small molecule complex was incubated at room temperature with gentle shaking 
using an orbital shaker. After labeling, the protein was centrifuged and buffer exchanged 
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Small molecule inhibition of Med25-activator interactions 
 
A. Abstract 
 Med25 AcID, a structurally unique and dynamic transcriptional coactivator, makes 
critical contacts with several transcriptional activators that are critical for normal cellular 
processes and certain disease states, including the oxidative stress response factor 
ATF6α and the ETV/PEA3 family of transcription factors.1,2 Previous work had 
demonstrated that Med25 contains two discrete binding sites, one of which demonstrates 
high selectivity for interaction with ATF6α while the other is moderately selective for the 
ETV5/ERM activator. It is proposed that small molecule inhibition of Med25 AcID and its 
protein-protein interaction (PPI) network would be beneficial in studying the function of 
Med25 in a cellular context and could be beneficial in the study of cancer progression and 
metastasis through inhibition of ETV- and ATF6α-mediated transcriptional activation. Two 
distinct strategies to develop and characterize small molecules that selectively target 
Med25 AcID in vitro and in cellulo are described herein. A pilot fragment screening effort 
that utilized PrOF NMR of Med25 identified nine preliminary compounds that target the 
AcID motif. Additionally, a novel natural product compound, termed 34913 lipopeptide, 
has been identified as a potent and selective inhibitor of Med25 AcID. This molecule, 
thought to mimic the structure of a transcriptional activation domain, interacts with the H2 
site of Med25 AcID in a binding mode that is nearly identical to that of the ATF6α activation 
                                            
Several collaborators provided research assistance throughout Chapter Four. Andy Henderson 
(University of Michigan) identified EN300-51104 in a HSQC fragment screening effort; Julie Garlick 
(University of Michigan) collected the inhibition data presented in Figure 4.2. Dr. Ashootosh Tripathi and 
Pam Schultz (University of Michigan) purified 34913 lipopeptide; Dr. Tripathi elucidated the structure of 
34913 lipopeptide. Brian Linhares (University of Michigan) collected HSQC NMR data of the Med25 AcID-
34913 lipopeptide interaction. 
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domain. Furthermore, the 34913 lipopeptide exhibited dose-dependent inhibition of a 
critical ATF6α gene product, GRP78, in a cellular environment. Collectively, this chapter 
represents a key advance in the discovery of small molecules that modulate Med25 AcID 
function and should allow for future determination of the role of Med25 and its PPI network 
in several disease contexts. 
 
B. Introduction 
Difficulties in targeting protein-protein interactions  
Protein-protein interactions (PPIs), particularly those in the transcriptional 
activator-coactivator class, have long been characterized as “undruggable”.3,4 The 
contact interfaces of PPIs are generally large (1500 – 3000 Å2) and shallow, lacking a 
traditional binding pocket present in protein-ligand interactions.4,5 Activator-coactivator 
interactions bring an additional set of difficulties. These PPIs are transient, moderate-
affinity interactions (binding affinities range from 500 nM to 100 µM) and each protein 
involved is structurally dynamic, often intrinsically disordered, and uses the same binding 
surface to interface with a large number of interaction partners.6–8 
 
Natural products for the inhibition of protein-protein interactions 
As a result of the inherent character of activator-coactivator interactions described 
above, traditional screening, medicinal chemistry efforts and rational design 
methodologies have led to limited success towards targeting this class of PPIs.9 Natural 
products, however, offer promise towards targeting this class of PPIs, and several natural 
products have recently been developed as tool compounds to target PPIs.10–14 These 
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natural product compounds derive great utility from their inherent structural complexity, 
ability to maintain high degrees of rigidity and chirality, and their vast diversity of molecular 
structure and scaffolds.15 In fact, nearly 40% of compounds represented in the Dictionary 
of Natural Products contain unique structural elements that are not otherwise represented 
in purely synthetic compounds.16,17 Furthermore, it is thought that the scientific community 
has discovered small fractions of the total chemical matter that nature has designed, 
particularly from the marine environment.18,19 Resulting from recent advances in 
fermentation, sample collection techniques, and structural elucidation technologies, 
natural product exploration into the marine environment (and other underutilized 
biological sources) has become more accessible.20,21 
 An excellent example of natural product inhibition of a PPI was demonstrated by 
Majmudar and coworkers in their discovery of depsides and depsidones that inhibited the 
KIX transcriptional coactivation domain of CBP and its transcriptional activation network.8 
Two unique compounds, sekikaic acid (depside) and lobaric acid (depsidone), were 
capable of inhibition of CBP KIX and were highly selective for this coactivator motif relative 
to transcription factor-DNA interactions and related coactivator-activator PPIs 
(Figure 4.1). Molecular dynamics simulations of sekikaic acid demonstrated that this 
molecule adopts an amphipathic structure that mimics an α-helix, suggesting that 
depsides and depsidones might be privileged scaffolds for the inhibition of PPIs. 
 
Molecular inhibition of Med25 AcID for study of disease 
 The ETV/PEA3 family of transcriptional activators and the oxidative stress 
response activator ATF6α represent emerging targets for disease, particularly metastatic 
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cancers.22,23 The Mediator subunit Med25, a common transcriptional interaction partner 
of these two TADs, represents a potential target for small molecule intervention of these 
activators and their downstream gene products.1,2 
 Under normal cellular conditions, the transcriptional activator ATF6α is a 
transmembrane protein found in the endoplasmic reticulum (ER). However, conditions of 
oxidative stress cause cleavage of ATF6α and subsequent translocation to the nucleus.24 
Once in the nucleus, ATF6α interacts with promoters that contain endoplasmic reticulum 
stress response elements and activates pro-survival and anti-apoptotic genes associated 
with the unfolded protein response (UPR), most notably the chaperone protein 
GRP78.25,26 As a critical component of the UPR, induction of GRP78 acts to suppress 
oxidative stress and misfolding of proteins to protect the cell from apoptosis during times 
of external stress, particularly in cancerous tumors.27,28 It is hypothesized that selective 
disruption of ATF6α activity through inhibition of the Med25-ATF6α PPI could be 
therapeutically beneficial in downregulating GRP78 and related gene targets. 
Additionally, small molecule inhibition of the Med25-ATF6α PPI would be incredibly 
beneficial in determining the role of Med25 in the ATF6α pathway, the UPR, and the role 
of the UPR in cancer progression.29 
 The ETV family of transcriptional activators (ETV1/ER81, ETV4/PEA3, and 
ETV5/ERM) are involved in the transition into a metastatic phenotype across several 
cancer types.22,30–32 Overexpression of the ETV activators has been correlated with an 
invasive cancer phenotype and shRNA knockdown of all three ETV activators has been 
shown to decrease the transcription of genes associated with cancer metastasis.33,34 It is 
hypothesized that targeting Med25 AcID with small molecules would function similarly to 
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shRNA knockdown of the ETVs and downregulate cancer metastasis genes (e.g. Matrix 
metalloprotease I).   
 
Initial success in demonstrating that Med25 can be targeted with small molecules 
Similar to CBP KIX, depsidone scaffolds have been discovered that selectively 
inhibit Med25 AcID PPIs (relative to other coactivator-activators interactions.35 Two 
compounds, norstictic acid and psoromic acid, are capable of targeting Med25 AcID in 
cellulo with specific inhibition of the Med25-ATF6α PPI having been demonstrated 
through downregulation of GRP78. Additionally, these compounds decreased the 
migratory ability of breast cancer cells, presumably by downregulating the expression of 
Matrix metalloprotease I, an ETV gene product.  
 
 However, these small molecules bring inherent issues that could hamper their 
usefulness as molecular probes to study Med25 function in more complicated cellular 
experiments. First, each molecule contains an aldehyde functionality that has been shown 
to efficiently and covalently label Med25 AcID in vitro. Second, each molecule is highly 
oxygenated and presumed to be highly redox active. Each of these two characteristics 
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(covalent mode of action and redox activity) lessen their likely utility as molecular probes 
in cellulo. 
 Additional tools will be required for a more complete understanding of Med25 
function both in cellulo and in vivo. This chapter will highlight the methodologies (fragment 
discovery, natural product discovery) that have been pursued to discover novel small 
molecules that target Med25 AcID and lack one or both undesirable qualities of norstictic 
and psoromic acids. Additionally, through biochemical and biophysical techniques, we 
sought to find small molecule ligands that could function to selectively target a single 
binding site within Med25 AcID. This would allow for future work in dissecting the relevant 
roles that each individual binding site plays within the context of the cell.  
 
C. Results and discussion 
NMR fragment screening allows for rapid discovery of weak-to-moderate affinity ligands  
 NMR screening has been successfully used to identify fragments that interact with 
a protein-of-interest with weak-to-moderate binding affinity in a medium-throughput 
manner.36–38 NMR as a screening methodology for fragments provides two essential 
benefits – differentiation of multiple binding sites and preliminary characterization of 
binding mechanism during the screening process and a high degree of sensitivity for 
molecules that interact weakly with the protein-of-interest.37,39 These discovered 
fragments have been successfully used to study underlying biochemical mechanisms of 
their target proteins and, in several cases, have ultimately led to the generation of lead 
clinical target molecules.40–42 PrOF NMR strategies were pursued for the discovery of 
novel fragments that bind Med25 AcID.  
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 A previous 1H 15N-HSQC NMR screen of 15N-labeled Med25 AcID against a 
medium-sized fragment library (532 total compounds) maintained by the Cierpicki lab at 
the University of Michigan discovered a single hit fragment (Andy Henderson, 
University of Michigan). This hit rate of 0.2% was incredibly low and unfortunately 
provided few lead fragments for molecule discovery, indicating that chemical shift 
perturbations induced in HSQC NMR of Med25 AcID are not sensitive enough to detect 
weak binding fragment molecules. Subsequent FP inhibition assays with this fragment, 
EN300-51104, demonstrated that this fragment inhibited Med25 AcID-VP16 H1 with an 
IC50 value of 139 ± 10 µM and Med25 AcID-VP16 H2 with an IC50 value of 79 ± 7 µM 
(Figure 4.2). 
 
PrOF NMR presents a sensitive screening methodology for the discovery of small 
molecule fragments that target Med25 AcID 
The weak inhibitor EN300-51104 provided an excellent positive control for 
determining the sensitivity of 3FY Med25 AcID in PrOF NMR experiments for weak 
fragments (Figure 4.3). All PrOF experiments performed with 3FY Med25 AcID had 
Figure 4.2. Fragment EN300-51104 is a weak inhibitor of Med25 AcID. This 
fragment, identified in a HSQC NMR screen against Med25 AcID inhibits the Med25 
AcID-VP16 H1 PPI with an IC50 value of 139 ± 10 µM and the Med25 AcID-VP16 H2 




previously been performed with peptide and small molecule ligands that bound WT 
Med25 AcID with single-digit micromolar binding affinities. It should be noted that the 
HSQC NMR screen was run at 1 mM fragment. It was thus hypothesized that if EN300-
51104 caused a significant chemical shift perturbation in 3FY Med25 AcID at ≤1 mM 
concentration that PrOF NMR would represent a potentially successful screening 
strategy. 
 
PrOF NMR of 3FY Med25 with increasing concentrations of EN300-51104 
demonstrated dose-dependent chemical shift perturbations of Y487/Y515 resonances. 
Additionally, at higher equivalencies of the fragment, perturbations at both Y432 and Y528 
Figure 4.3. PrOF NMR of 3FY Med25 AcID in presence of EN300-51104. These 
data, demonstrating a dose-dependent shift in 3FY resonances and significant (>0.03 
ppm) chemical shifts below 1 mM (10 eq.), suggested that PrOF NMR of 3FY Med25 
AcID represented a viable screening strategy. 
 
Y432 Y528 Y487 Y515 
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are observed; It would not be surprising if, at high concentrations, that the fragment would 
be capable of binding multiple times to the protein. Critically, the fragment did 
demonstrate a chemical shift perturbation well below the concentration of molecule 
relative to protein that was screened in the HSQC NMR screen (1 mM fragment; which in 
these experiments is closest to 12 eq relative to Med25 AcID). Furthermore, a significant 
chemical shift perturbation (>0.03 ppm shift) in the Y487/Y515 pair was detected at an 
even lower concentration (3 eq. relative to protein) than the HSQC NMR screen was 
performed. This suggests that a PrOF NMR screen with 3FY Med25 AcID would be as 
sensitive, if not more sensitive, than an HSQC NMR screen with 15N Med25 AcID.  
 
A pilot, small-scale fragment screening effort using PrOF NMR against 3FY Med25 
was performed (Figure 4.4). To maximize the potential for the discovery of Med25-
interacting fragments, we leveraged knowledge of functional groups that had either 
previously been found in Med25-interacting ligands (peptides, norstictic acid, fragment 
A6, EN300-51104) or are known to be commonly found in PPI inhibitors.8,43–45 A 
commercially available fragment library (Asinex Navigator) maintained by the Center for 
Chemical Genomics was mined for all fragments that contained functional groups 
contained within Med25 AcID inhibitors (carboxylic acid, amide, indole, highly oxygenated 
Figure 4.4. Generation of fragment library for PrOF NMR screening. Flowchart to 
describe methodology behind the generation of a selected number of fragments to test 




groups) in addition to other common functional groups (e.g. piperazine, nipecotic acid, 
morpholine, sulfonamide) to provide 927 unique compounds. A second filtering step, a 
requirement that all fragments contain at least two of these “desirable” functional groups 
for PPI inhibition, trimmed the potential list to 168 total fragments. Finally, sixty unique 
fragments to be screened by PrOF NMR were randomly selected from this shortlist of 168 
fragments with two or more “desirable” functional groups.    
 The sixty fragments selected for screening were combined into fifteen unique 
mixtures (termed Mix 1 through Mix 15) at a stock concentration of 25 mM per compound 
in DMSO. All mixtures were subsequently screened at 750 µM compound and 3% DMSO 
(9 µL fragment mixture into 300 µL final sample volume) in the presence of 75 µM 3FY 
Med25 AcID. All experiments were performed using 1600 scans and required less than 
15 min of instrumental time (240 min total instrument time to screen all 15 mixtures and 






Figure 4.5. PrOF NMR of fragment mixtures not classified as hits. Overlay of 3FY 
Med25 AcID in presence of fragment mixtures that did not significantly perturb any 3FY 
resonances relative to average chemical shift of all fragment mixtures. Note that Mixt 
13 contained a fluorine-containing small molecule that is presumed to give the large 






Figure 4.6. PrOF NMR of fragment mixtures classified as hits. Overlay of 3FY 
Med25 AcID in presence of fragment mixtures 5, 2, 4, 6, 3, and 14 with 3% DMSO 
control. Mix 5 was classified as a hit based on significant (>1 standard deviation in 
magnitude relative to average chemical shift of screened fragment mixtures) 
perturbation of Y528 and Y487 (green asterisks); Mixes 2, 4, and 6 were classified as 
hits based on significant perturbation of Y432 (red asterisk). Mixes 3 and 14 were 




 Following the initial screening of the fragment mixtures using PrOF NMR, the 
chemical shifts of resonances for each spectrum was determined to calculate the absolute 
magnitude of the chemical shift perturbation relative to the 3% DMSO. From there, 
mixtures were scored as hits if the chemical shift of one of their resonances was perturbed 
by more than one standard deviation greater than the mean perturbation for that residue 
(Figure 4.7). This strategy found six fragment mixtures to contain at least one statistically 
significant chemical shift perturbation – Mix 2, Mix 3, Mix 4, Mix 5, Mix 6, and Mix 14 
(Figure 4.6). Mixes 3 and 14 were classified as hits based on the downfield perturbation 
Figure 4.7. Chemical shift perturbations of 3FY Med25 AcID residues in PrOF 
NMR fragment screening. The chemical shift perturbations induced by each fragment 
mixture are shown. Mixtures that were classified as hits are depicted in colors that 
correspond to the residue that is significantly perturbed. The statistical cutoff to 
designate a significant chemical shift (1 standard deviation above average chemical 
shift perturbation of all mixtures) for each 3FY residue is shown with a colored line. 
(e.g. Mixture 2, shown in dark red, was classified as a hit as a result of significant 




of Y487, indicating that these mixtures contain at least one fragment capable of binding 
to Med25 AcID near α2 at either the H1 or H2 sites. Mixes 2, 4, and 6 were classified as 
hits based on perturbation at Y432 and, in the case of mixes 4 and 6, at Y515. This result 
would indicate that these mixtures contain at least one fragment that binds either high in 
the H2 site, near α2, or at the putative third site. Finally, Mix 5 was classified as a hit due 
to perturbation at Y528 and Y487, indicating that this mixture likely contains at least one 
fragment that binds at the H2 site and would likely be an orthosteric inhibitor of H2 site 
peptides such as ATF6α(40-66). Most fragment mixtures were not classified as hits 
because none of their resonances were significantly perturbed (Figure 4.5). 
 
 
This initial screening of this sixty-compound library narrowed potential Med25-
interacting fragments to 24 unique compounds. To rapidly perform a secondary 
screening/filtering step, these 24 compounds were tested for inhibition of Med25 PPIs in 
an FP assay (Figure 4.8) This yielded nine potential inhibitors of Med25 AcID for further 
investigation in PrOF NMR titrations with 3 FY Med25 AcID (Figure 4.9).  
 
Figure 4.8. Secondary screening of PrOF NMR fragment mixtures. The individual 
fragments that comprised the six hit fragment mixtures were all tested for inhibition of 
Med25 AcID-VP16 H2 in FP assays. Weak inhibition of nine fragments was 
demonstrated; These fragments represent potential Med25 inhibitors and require 




 As anticipated, preliminary fragments from the PrOF NMR screen include a couple 
of carboxylic acid-containing molecules. Interestingly, two of these fragments – A12 and 
E8 – are highly similar molecules. Both fragments the same pyridylalanine core; this could 
represent an excellent starting point for rational design of downstream Med25 ligands. 
Four of the nine potential Med25 fragments contain an acetamide functionality and a 
saturated ring system with two heteroatoms. Each of these nine potential Med25 fragment 
Figure 4.9. Structures of discovered fragments in PrOF NMR screen of Med25 
AcID. Nine fragment molecules have been classified as preliminary hit molecules in a 
PrOF NMR screen of 3FY Med25. This set includes three carboxylic acid-containing 
and four acetamide-containing fragments. All molecules require additional 




molecules, while apparent weak inhibitors of Med25 AcID, represent an opportunity to 
pursue rational design of novel Med25 PPI inhibitors pending independent verification of 
binding to Med25 AcID in PrOF and 1H 15N-HSQC NMR experiments.  
 
A naturally occurring lipopeptide demonstrates selective inhibition of Med25 AcID 
 As discussed, the binding sites of Med25 are large (1500 – 3000 Å2) and shallow 
with moderate-affinity interactions with several TADs. Additionally, Med25 AcID has been 
demonstrated to be structurally dynamic and many of its interacting partners are 
intrinsically disordered. Collectively, these features make targeting Med25 AcID with high-
affinity small molecules difficult. However, as has been shown with norstictic acid and 
garcinolic acid, natural product compounds present great utility for Med25 AcID inhibition. 
Natural products possess high degrees of structural complexity that offer high rotational 
and conformational plasticity that are thought to be beneficial in inhibition of transcriptional 
PPIs. It was hypothesized that natural products discovery towards Med25 AcID inhibition 
could be beneficial in targeting Med25 without some of the challenges presented by 
previously identified molecules (e.g. Norstictic acid functions through covalent adduct 
formation and has redox reactivity, both impediments for study of Med25 function in 
cellular context). 
 Concurrent with the follow-up and deconvolution of a high-throughput screen 
(HTS) of a natural product extracts library (described in the Appendix), a previously 
unidentified lipopeptide was isolated from a cyanobacterial strain. This cyanobacterial 
strain, hereby referred to using its internal identification number 34913, had demonstrated 
~20% inhibition of the Med25-ERM PPI in the aforementioned HTS, below the arbitrary 
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cutoff (30% inhibition) for a hit extract. The novel lipopeptide from strain 34913 consists 
of a D-amino acid-containing heptapeptide (Glu-Asp-Leu-Leu-Leu-Leu-Val) connected to 
a lipophilic alkyl chain via an amide bond (Figure 4.10). This structure was determined 
using high-resolution mass spectrometry, to provide an exact mass of 1054.6982 Da, and 
rigorous 1-D and 2-D NMR analysis (Ashu Tripathi, University of Michigan). I noted that 
the lipopeptide appeared to mimic the structural elements of a transcriptional activator 
and decided to test the novel molecule for activity against Med25 AcID and its PPI 
network. 
  
FP-based inhibition experiments demonstrated that the 34913 lipopeptide is a 
potent inhibitor of Med25 AcID with a Ki of 8.8 ± 0.6 µM against the Med25-ATF6α PPI 
Figure 4.10. 34913 lipopeptide is a potent inhibitor of the Med25-ATF6α PPI. The 
34913 lipopeptide, consisting of an acidic, D-amino acid heptapeptide connected 
through an amide linkage to a branched lipophilic alkyl chain, is thought to function 
as a TAD mimetic. It demonstrates single-digit micromolar inhibition of the Med25-
ATF6α PPI (Ki of 8.8 ± 0.6 µM) 
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and a Ki of 11 ± 2 µM against the Med25-ERM PPI. Each of the amino acids in the peptide 
portion of this small molecule are D-amino acids, a potentially beneficial structural aspect 
for in cellulo  and in vivo studies as D-amino acids are less prone to proteolysis than L-
amino acids46. Taking the free carboxy terminus of the peptide portion into account, this 
molecule has a net -3 charge. A net negative charge would be expected for a potent 
inhibitor of Med25 AcID PPIs. The alkyl moiety consists of an eleven-carbon chain with 
four methyl branches and a single hydroxyl group gamma to the carbon of the amide bond 
that connects the alkyl chain to the peptide portion of the molecule.  
 Following the discovery of this novel natural product and its potent single-digit 
micromolar inhibition of Med25 AcID PPIs, FP-based inhibition assays against CBP KIX 
were performed to test for selectivity of the molecule towards Med25 AcID (Figure 4.11). 
The lipopeptide did successfully inhibit CBP KIX function (Ki values of ~25 µM for all three 
canonical CBP KIX-TAD PPIs tested). Critically, this indicates that the 34913 lipopeptide 
is three times more active against the Med25 AcID-ATF6α PPI than against CBP KIX, 
Figure 4.11. Inhibitory effects of 34913 lipopeptide against CBP KIX. The 34913 
lipopeptide demonstrates inhibition of Med25 AcID that is approximately 3-fold 
stronger than CBP KIX (Ki of 9 µM for Med25 AcID versus 25 µM for CBP KIX), as 
measured by FP. 
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providing a window of selectivity that is necessary and beneficial to study Med25 AcID 
function in cellulo and in vivo. 
 
 With a selective molecule in hand, biophysical experiments – 1H 15N-HSQC and 
PrOF NMR experiments –  were performed to map the binding location of the 34913 
lipopeptide onto Med25 AcID. Based on the slight increase in potency towards the 
Med25-ATF6α PPI (specific for the H2 site) compared to the Med25-ERM PPI (the most 
specific H1 site peptide ligand), it was proposed that the 34913 lipopeptide would be a 
H2 site binding ligand and thus an orthosteric inhibitor of the ATF6α TAD. 
 1H-15N-HSQC experiments were performed in which 34913 was complexed with 
15N-labeled Med25 AcID at 0, 1, 2, and 4 equivalents of small molecule relative to protein. 
Figure 4.12. 1H-15N-HSQC NMR spectra of Med25 AcID in complex with 34913 
lipopeptide. Overlay of the HSQC spectra of 15N-labeled Med25 AcID with DMSO 
(black), 1 eq. molecule (light blue), 2 eq. (dark blue), and 5 eq. (pink) is shown. Inserts 
show selected resonances have been significantly perturbed including H2 site residues 
(L513, G524, and L464) and H1 site residues (C497). 
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These data demonstrated that the molecule bound to Med25 AcID in a specific orientation 
and did not cause significant protein unfolding or aggregation as several resonances 
corresponding to specific residues were perturbed in a dose-dependent manner (Figures 
4.12 4.13, 4.14). Peaks in each of the collected spectra were assigned to specific residues 
using a previously published NMR assignment47 and a recent assignment performed in 
the Mapp lab (Andy Henderson, University of Michigan).   
 
Saturation of the 34913 lipopeptide onto Med25 AcID caused significant 
chemical shift perturbations (>2 standard deviations above the mean) in selected 
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Figure 4.13. Chemical shift perturbations within Med25 AcID induced by 
saturating 34913 lipopeptide. The magnitude of chemical shift perturbations, in Hz, 
are shown upon saturation of 15N Med25 AcID with 4 eq. 34913 lipopeptide. Residues 
that shift 1-2 standard deviation (SD) above the mean (light blue), >2 SD (dark blue), 
and broadened into noise level (red) are significantly perturbed. 
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residues located in the H2 site of the protein along α1 and β6/β7/β4. All perturbed shifts 
reside at the ‘bottom’ of the H2 site, away from α2. These statistically significant chemical 
shift perturbations specifically correspond to Q455, G462, L464, R469, M470, V471, 
L513, and G524. Additionally, the residue R466, located at the C-terminus of α1 and 
known to be critical for H2 site peptide ligand binding based on mutagenesis work 
performed in Chapter 2, was broadened into the noise level at all concentrations of 34913 
lipopeptide tested. This suggested that this residue is likely in direct contact with the 
molecule when the lipopeptide is bound to Med25 AcID. These data are consistent with 
the 34913 lipopepetide functioning as an orthosteric inhibitor of ATF6α(40-66) at the base 
of the H2 site. Furthermore, the residues that are significantly perturbed by binding of 
34913 lipopeptide represent many of the same residues that are significantly perturbed 
by ATF6α(40-66) (Figure 4.15). In addition to H2 site perturbations, the HSQC data also 
demonstrates that a small number of residues at the H1 site are significantly perturbed 
(T421, C497, V508). The C497 residue, in particular, is located in the center of the H1 
site and is among those residues significantly perturbed by ERM peptide ligands in HSQC 
NMR experiments48. This could suggest that the 34913 lipopeptide is capable of allosteric 





Figure 4.14. Chemical shift perturbations induced by 34913 lipopeptide mapped 
on Med25 AcID. Residues are colored with increasing shades of red to indicate a 
gradient of increasing chemical shift perturbations. These data suggest that 34913 
lipopeptide interacts specifically with the H2 face of Med25 AcID. 
Figure 4.15. Overlay of ATF6α(40-66)-induced and 34913 lipopeptide-induced 
Med25 AcID chemical shifts in HSQC NMR. Residues of Med25 AcID that are 
significantly affected by both ATF6α and 34913 lipopeptide are shown in red. These 
data demonstrate that 34913 lipopeptide binds to the H2 site in a binding mode very 
similar to that of ATF6α, suggesting that the lipopeptide is an orthosteric inhibitor of 
the Med25-ATF6α PPI. Residues significantly affected by 34913 lipopeptide only are 




Concurrent with HSQC analysis, PrOF NMR experiments were also performed to 
characterize the Med25 AcID interaction with the 34913 lipopeptide. Increasing 
concentrations of 34913 lipopeptide (0, 0.25 eq., 0.5 eq., 1 eq. relative to protein) were 
complexed with 3FY Med25 AcID and subjected to PrOF NMR analysis (Figure 4.16).   
 The HSQC data also demonstrates that the 34913 lipopeptide affects the Tyr 
residues of 3FY Med AcID in a similar manner as does ATF6α(40-66) peptide. All four 
residues are perturbed in a dose-dependent manner; however the intensity of the 
observed chemical shift perturbations is less than with ATF6α peptide. This could be 
explained by the large difference in size between the 34913 lipopeptide and the 25-
residue ATF6α peptide particularly if the lipopeptide binds specifically at the ‘bottom’ of 
the H2 site and away from α2 (on which Y487 is located), as predicted by HSQC NNMR.  
  
Figure 4.16. PrOF NMR of 3FY Med25 AcID in complex with 34913 lipopeptide. 
Spectral analysis of 3FY Med25 AcID in presence of increasing concentrations of 
34913 lipopeptide corroborated HSQC NMR evidence that 34913 binds Med25 AcID 




The 34913 lipopeptide is an effective inhibitor of Med25 function in a cellular context  
With structural characterization of the molecule and biochemical assessment of its 
interaction with Med25 AcID completed, experiments were pursued to demonstrate 
inhibition of Med25 function in cellulo. It was hypothesized that the 34913 lipopeptide 
could traverse the cellular membrane based on its amphipathic nature (lipophilic portion 
attached to linear peptide chain) and, once inside the cell, interact specifically with Med25 
AcID (based on observed 3-fold selectivity against CBP KIX).  
Previous literature on Med25 function reported an interaction between the retinoic 
acid receptor and the nuclear receptor box of Med25 in order to recruit Med25 and the 
Mediator complex to retinoic acid receptor promoter elements.49 A subsequent 
interaction, as has been described in Chapter 2, between Med25 AcID and CBP(20-44), 
results in the recruitment of CBP to the same retinoic acid promoter. This set of 
interactions was then leveraged to design a luciferase reporter to observe the Med25 – 
CBP – retinoic acid receptor interactions in cellulo.49 HEK293T cells were transfected with 
a luciferase reporter driven by a retinoic acid receptor element promoter in addition to a 
constitutively expressed β-galactosidase (for normalization purposes). Concurrent with 
stimulation of the luciferase reporter gene using retinoic acid, cells were co-dosed with 
increasing concentrations of the 34913 lipopeptide (Figure 4.17). It was hypothesized that 
the 34913 lipopeptide would be capable of inhibition of the luciferase output by direct 
inhibition of the Med25 AcID-CBP PPI. Disruption of this interaction should disrupt 
formation of the pre-initiation complex and binding of RNA polymerase II to the retinoic 




Figure 4.17. Inhibition of a Med25-dependent luciferase reporter by the 34913 
lipopeptide. (A) Schematic of the RARα-luciferase reporter assay. RARα binds to a 
RARE promoter on the luciferase reporter plasmid following stimulation with retinoic 
acid and recruits the Mediator complex through an interaction with the NR region of 
Med25. The AcID domain of Med25 then recruits CBP to the promoter, which can then 
modify upstream histones using its histone acetyltransferase domain, resulting in 
elevated expression of luciferase. (B) The 34913 lipopeptide demonstrated a dose-
dependent reduction in the transcriptional activation of a luciferase reporter driven by 
the retinoic acid receptor. This luciferase inhibition is presumed to occur through direct 
inhibition of the Med25 AcID-CBP PPI, which leads to a lowered recruitment of the 
master coactivator CBP to the promoter elements of the retinoic acid receptor. All 
luciferase signals were normalized to β-gal activity and represent the mean and 





  The 34913 lipopeptide was capable of dose-dependent inhibition in this Med25-
dependent luciferase reporter assay. These data demonstrated that this molecule can 
cross the cell membrane and target Med25 AcID in the cellular milieu. Excitingly, the 
molecule provided complete inhibition of normalized luciferase output at 200 µM with 
nearly 50% inhibition at 50 µM.  
 Following these successful preliminary cellular experiments, we were interested in 
the potential for 34913 lipopeptide to inhibit the Med25-ATF6α PPI, an interaction thought 
to be important in the unfolded protein response and hypoxia.1,50 This PPI leads to the 
activation of  pro-survival and anti-apoptotic genes associated with the UPR under 
hypoxic conditions.25,26 The most notable of these ATF6α-regulated genes is GRP78 
(also known as HSPA5), a chaperone protein that suppresses oxidative stress, prevents 
misfolding of proteins, and stabilizes intracellular calcium levels during periods of 
hypoxia.51,52 To test for inhibition of the Med25-ATF6α PPI, we measured the effects of 
increasing doses of 34913 lipopeptide on GRP78 expression levels after thapsigargin-
induced hypoxic stress, as previously described for inhibition of Med25- ATF6α, using 
qPCR for analysis1. HeLa cells were dosed with 34913 lipopeptide for three hours prior 
to induction of hypoxic stress with thapsigargin dosing for another three hours 
(Figure 4.18). It was hypothesized that the lipopeptide would be capable of 
downregulating GRP78 expression levels through the inhibition of the Med25 AcID-





Figure 4.18. Inhibition of the Med25 AcID-ATF6α PPI in a cellular context by the 
34913 lipopeptide. (A) Schematic of the activation of GRP78. The transcriptional 
activation domain of ATF6α recruits the Mediator complex through a specific protein-
protein interaction with Med25 AcID to activate expression of GRP78. (B) The 34913 
lipopeptide downregulated the production of GRP78, an ATF6α gene product, in a 
dose-dependent manner, as assessed by qPCR. This downregulation is presumed to 
occur through orthosteric inhibition of the Med25 AcID-ATF6α PPI. Expression levels 
of GRP78 were normalized to expression levels of RPL19. All signals represent the 






GRP78 gene output, as assessed by qPCR, was inhibited by 34913 lipopeptide in 
a dose-dependent manner with ~50% inhibition achieved at 50 µM molecule. 
Interestingly, 34913 lipopeptide at 75 µM did not inhibit GRP78 more efficiently than the 
50 µM dosage. This could indicate that the lipopeptide is at saturating levels in the cell at 
50 µM or, that GRP78 is being produced in compensatory mechanisms that are not 
Med25-dependent. If the latter is true, the 34913 lipopeptide could be a useful as a 
synergistic inhibitor of molecules known to target other proteins involved in hypoxia and 
the unfolded protein response. Collectively, these data demonstrate that this novel 34913 
lipopeptide is capable of on-target inhibition of a potential therapeutic gene target. Based 
on biochemical evidence that the 34913 lipopeptide interacts with the H2 site of Med25 
AcID in a similar fashion to ATF6α(40-66), this inhibition of GRP78 is presumably a result 
of direct inhibition of Med25 AcID in cellulo.  
 
D. Conclusions and future directions 
The overarching hypothesis of this work is that the discovery and characterization 
of small molecules that inhibit Med25 AcID function could provide molecular probes for 
the study of disease through inhibition of the Med25-ERM and Med25-ATF6α PPIs. 
Specifically, with respect to ERM/ETV5, these molecules could be useful towards a better 
understanding of ETV5 and related ETV activators and their role in cellular processes 
related to cancer progression and metastasis. With respect to ATF6α, molecules that 
inhibit Med25 PPIs could be therapeutically beneficial in downregulating ATF6α gene 
products, such as GRP78, and could useful in determining the role of Med25 in the ATF6α 
pathway, the unfolded protein response, and the role of the unfolded protein response in 
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cancer progression.29 In this chapter, we developed and characterized several small 
molecules that inhibit Med25 AcID function. These molecules were discovered using 
multiple screening strategies, from fragment identification by Tethering and NMR 
methodologies to natural products isolation following competition-based fluorescence 
polarization assays.  
PrOF NMR of Med25 AcID was developed to allow for a pilot screening effort of a 
small fragment library. This technique is uniquely sensitive for the detection of weakly 
binding fragment molecules as NMR allows for screening of high [compound] in a 
multiplexed format. Furthermore, PrOF NMR, a 1-D methodology, specifically offers short 
experimental and analysis timeframes as well as high native abundance of the 19F 
isotope, high magnetic sensitivity (83% as sensitive as 1H), low background signal and 
low background signal. Using a PrOF NMR screen of 3FY Med25 AcID, nine compounds 
were discovered as preliminary hits against Med25 AcID. These fragments represent 
excellent compounds for future biochemical and NMR characterization with Med25 AcID 
and could demonstrate novel scaffolds for rationally designed fragment inhibitors. 
A novel lipopeptide isolated from cyanobacteria has been discovered as a potent 
single-digit micromolar inhibitor of the Med25-ATF6α PPI in FP assays that demonstrates 
three-fold selectivity for Med25 AcID relative to CBP/p300 KIX. HSQC and PrOF NMR 
demonstrated that this lipopeptide binds at the H2 site of Med25 AcID in a binding mode 
nearly identical to that of the ATF6α transcriptional activator. In cellular experiments, 
GRP78 gene output, as assessed by qPCR, was downregulated by the novel lipopeptide 
in a dose-dependent manner with ~50% inhibition achieved at 50 µM compound. 
Critically, this novel natural product represents the first highly selective, potent, and non-
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covalent small molecule that targets Med25 AcID function both in vitro and in cellulo. It 
demonstrates tremendous promise as a lead candidate for future study of the roles that 
Med25 AcID plays in disease contexts, particularly cancer metastasis and tumor 
progression. 
Going forward, we are developing two strategies for future production of this novel 
lipopeptide and related compounds. The cyanobacterial strain, 34913, that produces this 
compound will be engineered to produce the compound in higher yields using ribosomal 
and/or metabolic strategies.53,54 Concurrently, synthetic derivatives of this lipopeptide are 
being generated that incorporate aromaticity into the peptide portion and vary the alkyl 
chain (Figure 4.19). If a similar compound with similar inhibitory properties can be readily 
synthesized, this would represent the route with highest potential throughput for cellular 








Figure 4.19. Structures and activity of 34913 lipopeptide derivatives. (A) Four 
34913 lipopeptide derivatives are provided. The peptide portion has been synthesized 
with all D-amino acids and with all L-amino acids; Both peptides has been derivatized 
with a ten-carbon chain appended to its N-terminus. (B) Inhibition of the Med25-ATF6α 
PPI by 34913 derivatives. 
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E. Materials and methods 
Previously described methods 
Relevant methods that were previously described in Chapter Two include Med25 AcID 
purification, mass spectroscopy of proteins, FP binding experiments, FP competition 
experiments, production of 15N-labeled protein, HSQC NMR and solid-phase peptide 
synthesis. 
Relevant methods that were previously described in Chapter Three include the production 
of 19F-labeled protein and PrOF NMR. 
 
PrOF NMR screening 
The sixty fragments selected for screening were combined into fifteen unique mixtures 
(termed Mix 1 through Mix 15) at a stock concentration of 25 mM per compound in DMSO. 
All mixtures were subsequently screened at 750 µM compound and 3% DMSO (9 µL 
fragment mixture into 300 µL final sample volume) in the presence of 75 µM 3FY Med25 
AcID. All experiments were performed using 1600 scans.  
 
Expression and purification of CBP KIX 
CBP KIX was expressed and purified according to previously published protocols55. 
 
Med25-CBP-RARα luciferase reporter assay  
The RARα luciferase reporter plasmid containing 3 tandem RARα promoter elements 
(termed ‘pRARE-luc’) was obtained from Addgene. A constitutively active β-galactosidase 
coding plasmid driven by a CMV promoter (termed ‘CMV β-Gal’) was provided by Dr. 
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Jorge Iñiguez-Lluhí (University of Michigan). pCDNA3, a non-coding vector, used for 
transfection controls was provided by Dr. Jorge Iñigues:Lluhí. All cells were maintained 
in 5% CO2 at 37°C. HeLa cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM, Invitrogen) supplemented with 10% FBS. For luciferase assays, 4x105 cells were 
plated in a 6-well dish and allowed to adhere overnight. The media was removed and 
cells were transfected in OptiMEM (Invitrogen) with 1 μg RARα:luc, 200 ng CMV:β:Gal, 
and 800 ng pCDNA using Lipofectamine 2000 (Life Technologies) according to 
manufacturer’s instructions. After 4.5 hours, transfection solution was removed and 
replaced with DMEM containing 10% FBS. At 24 h after transfection, cells were 
trypsinized and resuspended in DMEM supplemented with 10% FBS before plating into 
a 96-well plate at a density of 15x103 cells per well. After an additional 16 hours, media 
was removed and replaced with OptiMEM containing DMSO control or 34913 lipopeptide 
and 1 µM retinoic acid.  After cells 16 hours, media was removed and cells were lysed 
with 60 μL of passive lysis buffer. Luciferase and β:Galactosidase activities were 
determined as previously described56. RARα luciferase activity and response curve 
analysis was performed using GraphPad software. 
 
RT-qPCR analysis of GRP78 gene expression  
For endogenous gene expression analysis, 1x105 HeLa cells were plated into a 24-well 
plate and allowed to adhere overnight. Media was removed and replaced with OptiMEM 
containing DMSO control or 34913 lipopeptide. After incubating for 2 hours, cells were 
treated with 500 nM thapsigargin. After 2 h, the media was removed and total RNA was 
isolated using RNeasy Plus RNA isolation kits (Qiagen) according to manufacturer’s 
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instructions. Each RNA sample was used to synthesize cDNA using iScript cDNA 
synthesis kits (Bio-Rad). RT-qPCR reactions were carried out in duplicate in an Applied 
Biosystems StepPlusOne instrument using SYBR green master mix and primers for: 
human RPL19 F pr. 5’:ATGTATCACAGCCTGTACCTG:3’; R Pr., 5’:TTCTT 
GGTCTCTCTTCCTCCTTG:3’) and GRP78 (F Pr., 5’:CTGGGTACATTTGATCTGACTG 
G:3’; R Pr., 5’: CTTACCGACCTTTCGGTGGTCCTACG:3’). RT-qPCR analysis was 
carried out using the comparative CT Method (ΔΔCT Method) to estimate GRP78 mRNA 
levels relative to the reference RPL19 mRNA levels.   
 
Synthesis of 34913 derivatives  
34913-derived peptide were synthesized using solid-phase peptide synthesis, as 
described in Chapter Two. ‘34913 D-peptide+decane’ and ‘34913 L-peptide+decane’ were 
synthesized using standard peptide coupling, on solid phase resin, between the 
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Conclusions and future directions 
 
A. Summary 
Historically, targeting protein-protein interactions (PPIs) with small molecule 
modulators has been a significant challenge.1,2 This difficulty has been especially true 
with regards to transcriptional PPIs which are transient, weak-to-moderate affinity, and 
for which structural studies have been limited. However, there have been recent 
successes born from the field of natural products and from screening strategies that utilize 
protein-observed 19F-NMR (PrOF NMR) towards the identification of small molecule 
modulators that target transcriptional PPIs.3–6 
This dissertation sought to leverage natural products and PrOF NMR for the 
identification and characterization of selective small molecule inhibitors that target the 
activator interaction domain (AcID) of Med25 and its PPI network. Molecular inhibition of 
Med25 AcID is desired as a potential avenue for the investigation of the ETV/PEA3 family 
of transcriptional activators and the oxidative stress response activator ATF6α in disease, 
such as metastatic cancer.7,8 Towards this end, we first sought to better understand the 
mechanistic details between Med25 and its binding partners. This was accomplished 
using a mutagenesis strategy designed to selectively inhibit a single Med25 binding, 
PROF and HSQC NMR methodologies. Through this process, we demonstrated that 
discrete protein partners of Med25 AcID interact with unique binding profiles and 
signatures that could be exploited during the small molecule discovery process. Following 
these analyses, several small molecules that target Med25 AcID were characterized and 
developed as inhibitors of this coactivator motif. These identified molecules will enable 
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for future study of the role of Med25 AcID in cellular contexts, including in model systems 
of cancer and disease.  
 
B. Conclusions 
The bulk of this thesis, as described in Chapters Two and Three, has focused on 
the investigation of Med25 AcID and its underlying mechanistic biochemistry. Prior to this 
dissertation, structural data of Med25 AcID in complex with the two canonical VP16 TADs, 
termed VP16 H1 and VP16 H2, had been reported.9,10 These data demonstrated that 
Med25 AcID contained two putative binding sites, termed the H1 and H2 sites. Chapter 
Two identified the minimal regions of ATF6α and CBP that bind Med25 AcID and 
subsequent HSQC NMR suggested that ATF6α(40-66) likely bound at the H2 site of 
Med25 AcID while CBP(20-44) did not interact specifically at either one of these two 
previously reported H1 or H2 binding sites. Chapter Two then described a strategy to 
selectively inhibit the H1 and H2 sites of Med25 AcID. Inhibition at the H1 site was 
accomplished through the introduction of negative charge using protein mutagenesis and 
peptide Tethering at a solvent-exposed cysteine near the H1 site; The H2 site was 
inhibited using protein mutagenesis to introduce negative charge. Collectively, 
experiments to block the H2 site suggested that binding at the H2 site is more dependent 
on electrostatic interactions and ‘hot spot’ residues than the H1 site. This suggests that 
the H2 is likely to be a more druggable interface than the H1 site. 
 Chapter Three described a strategy for studying Med25 AcID and its protein-
protein and protein-ligand interactions using PrOF NMR. 3-fluorotyrosine (3FY) and 
5-fluorotryphtophan (5FW) were successfully incorporated into Med25 AcID, providing 
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two model systems for study. The precise refinement of binding locations, relative 
affinities between differing binding sites, and binding stoichiometry for each Med25 AcID 
interaction were described using PrOF NMR, HSQC NMR, and analyses from the 
mutagenesis study to block the H1/H2 sites. These data demonstrated that Med25 AcID 
interacts with discrete activators using multiple mechanisms. As demonstrated in Figure 
5.1, ERM binds selectively at the H1 site of Med25 AcID at substochiometric 
concentrations; ATF6α binds selectively at the H2 site of Med25 AcID; VP16 binds at both 
sites simultaneously. The observed level of selectivity between the two sites demands 
logical questions to be answered in the future. Are the two sites differentially regulated in 
normal tissues? In disease states? Can multiple activators bind to the protein 
simultaneously in the cell?  
Chapters Three and Four described the identification and biochemical 
characterization of several small molecules that target Med25 AcID and its PPI network. 
PrOF NMR was leveraged to gain mechanistic insight into the Med25-related function of 
the small molecule fragment, A6, and a natural product compound, norstictic acid. 
Additionally, PrOF NMR of 3FY Med25 AcID was utilized for the screening of a small 
molecule fragment library that identified nine lead compounds for future study. Finally, a 
novel natural product, termed 34913 lipopeptide, was identified as a potent and selective 
inhibitor of Med25 AcID. This molecule, thought to mimic the structure of a transcriptional 
activation domain (TAD), interacts with Med25 AcID in a binding mode that is nearly 
identical to that of the ATF6α activation domain. Furthermore, it demonstrates effective 
inhibition of the Med25-ATF6α PPI in a cellular context, indicating that it could be 




Figure 5.1. Three critical activators bind Med25 AcID in three unique binding 
modes. For each Med25-activator interaction shown, proposed bindind locations are 
shown by golden circles. Data that informs the conclusions presented are indicated as 
Med25 residues that are significantly perturbed in HSQC NMR (VP16 – shades of 
orange; ERM – shades of teal; ATF6α – shades of pink), PrOF NMR (black, as sticks), 
and in the mutagenesis study (dark blue, as sticks) are shown. Detailed figure captions 
and discussions can be found in Chapter Three (Fig 3.18, 3.19, 3.20) (PDB 2XNF) 
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C. Future Directions 
34913 lipopeptide will be used to study the role of Med25 in ATF6α transcriptional 
processes the unfolded protein response  
Under normal cellular conditions, the transcriptional activator ATF6α is a 
transmembrane protein found in the endoplasmic reticulum (ER). However, conditions of 
oxidative stress cause cleavage of ATF6α and subsequent translocation to the nucleus.11 
Once in the nucleus, ATF6α activates pro-survival and anti-apoptotic genes associated 
with the unfolded protein response (UPR), most notably GRP78.12,13 As a key player in 
the UPR, induction of GRP78 acts to suppress oxidative stress and misfolding of proteins 
while stabilizing intracellular calcium levels.14 Collectively, these actions lead to protection 
of the cell from apoptosis during times of external stress. It is thus unsurprising that 
expression of GRP78 is held at low levels under normal cellular conditions while being 
strongly overexpressed in many disease states, such as in cancerous tumors.15,16 This 
overexpression represents an inherent mechanism through which cancer cells can resist 
apoptosis; indeed, GRP78 overexpression resulting from increased ATF6α activity 
protects cancer cells from apoptosis in model systems.17 Additionally, increased activity 
of ATF6α and expression of GRP78 has been indicated in both metastasis and disease 
relapse in Hodgkin’s lymphoma, breast, and liver cancers.18–21 Thus, disruption of ATF6α 
activity and the anti-apoptotic pathways of the UPR through small molecule inhibition of 
the Med25-ATF6α could be therapeutically beneficial in sensitizing cancer cells towards 




As described in Chapter 4, we have identified a novel natural product, termed the 
34913 lipopeptide, as a potent and selective inhibitor of Med25 AcID in vitro that binds to 
the AcID domain with a binding signature that is nearly identical to that of the ATF6α TAD. 
Additionally, we have demonstrated that this molecule inhibits the expression of the 
ATF6α target gene GRP78 under hypoxic conditions. To test the hypothesis that the 
34913 lipopeptide is functioning by specifically targeting the Med25-ATF6α PPI (as 
opposed to causing downregulation of GRP78 through some other avenue), we plan to 
test the inhibitory capability of 34913 lipopeptide towards additional ATF6α gene products 
A. 
B. C. 
Figure 5.2. Activation of ATF6α and GRP78 (A) Under normal cellular conditions, 
ATF6α is a transmembrane protein found in the endoplasmic reticulum (ER). (B) 
Oxidative stress, such as hypoxia in cancer cells, causes ATF6α to translocate to the 
nucleus where it binds to ERSE promoters. An interaction between ATF6α and 
Med25 leads to activation of anti-apoptotic genes associated with the UPR, notably 
GRP78.  (c) It is hypothesized that molecular inhibition of the Med25-ATF6α PPI 
represents a viable target for the inhibition of ATF6α-related, anti-apoptotic pathways 
of the UPR in hypoxic cancers and would sensitize cancer cells to apoptosis.   
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that are involved in the unfolded protein response (e.g. p58, HYOU1, CRT-1, and 
GRP9449)8. Selectivity for targeting the Med25-ATF6α PPI in the context of the unfolded 
protein response (UPR) will then be assessed by determining the effects of the 34913 
lipopeptide towards gene targets that are upstream of IRE1 and PERK, the other primary 
transcriptional activators involved in the UPR22. It is expected that the lipopeptide will 
show no effect on these pathways, indicating that it functions to selectively target the 
Med25 AcID-ATF6α PPI.  
We also plan to assess the ability of 34913 lipopeptide to decrease cancer cell 
viability and proliferation as determined using WST-1 assays, cellular migration as 
determined using a wound healing assay, and cancer invasion as determined using a 
Matrigel invasion assay. Since the UPR is ubiquitous in cancer cells and its role in differing 
cell types is not well understood, it would be useful to perform these phenotypic assays 
in multiple cancer cell types (e.g breast, liver, Hodgkin’s lymphoma, and head and neck). 
Additionally, 34913 lipopeptide could be tested for its ability to sensitize hypoxic cancer 
cells towards apoptosis through combination treatments with common cytotoxic agents 
(e.g. cisplatin, doxorubicin) in common cancer cell lines as well as drug-resistant cell lines 
(e.g. cisplatin-resistant A2780 cells23).  
 
The role of PTOV1 will be determined through the biochemical study of its AcID domains  
The AcID motif is highly unique to Med25; Based on primary structure, only one 
other protein, Prostate Tumor Overexpressed factor 1 (PTOV1), has been proposed to 
contain an AcID domain. However, unlike Med25, PTOV1 contains two AcID domains in 
tandem (Figure 5.3). PTOV1 was originally reported as a protein that was overexpressed 
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in primary tumors of advanced and early prostate cancer patients24,25. It has been since 
been discovered that PTOV1, while undetectable in most normal cell tissues, is 
overexpressed in a wide variety of early- and late-stage cancer types26. Reports suggest 
that PTOV1 functions as a negative regulator of Med25 AcID  function by competing for 
interaction with the N-terminal region of CBP27. These publications demonstrate that a 
chemical biology-focused study of the AcID motifs of PTOV1 could provide excellent 
insight into Med25 function and its mechanisms of regulation within normal and disease 
contexts. Additionally, the PTOV1 AcID domains could represent an excellent model 
system against which to study selectivity within this unique structural class of coactivation 
domains. However, prior to this dissertation, the excised AcID domains of PTOV1 had not 
been biochemically characterized. 
 
The AcID motifs of PTOV1, termed AcID-A (residues 88-235) and AcID-B 
(residues 253-398) share homology with the AcID motif of Med25 (81% identity to AcID-
A and 72% to AcID-B). However, many of the differences between the primary sequences 
of Med25 AcID and the PTOV1 AcID domains lie within the H1 and H2 binding sites. We 
Figure 5.3. Domain architecture of PTOV1 and structure of the AcID motif. At left, 
domain architecture of Med25 (one AcID motif) and PTOV1 (two AcID motifs). At right, 
cartoon image of Med25 AcID to demonstrate central β-barrel with three surrounding 
α-helices. (PDB 2XNF) 
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plan to investigate the role of PTOV1 and its interplay with Med25, biochemical 
characterization of each of the two AcID motifs, AcID-A and AcID-B, was desired. Neither 
domain had been previously expressed as a standalone protein construct.  
 Multiple attempts to express and purify PTOV1 AcID-A and AcID-B were 
unsuccessful. A variety of gene constructs of differing lengths and with a variety of 
solubility tags (e.g. Glutathione S-transferase) were attempted. In the end, codon-
optimized genes for each PTOV1 AcID motif were designed into pET21-b plasmids and 
purchased (Genscript). As demonstrated in Figure 5.4, this strategy provided purified 
PTOV1 AcID-A and PTOV1 AcID-B that was well-folded according to circular dichroism. 
Additionally, both PTOV1 AcID motifs demonstrated equivalent stability relative to Med25 
AcID in thermal melting experiments (Tm of 63 ± 1 °C and 66 ± 1 °C for AcID-A and 
AcID-B, respectively, compared to 65 ± 1 °C for Med25 AcID). Preliminary FP assays with 
both PTOV1 AcID domains suggest that both bind each of the Med25 AcID-interacting 
peptide ligands with similar affinities to Med25 AcID. 
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 These data demonstrating the production of functional AcID domains from PTOV1 
offer a new avenue for future investigation into the AcID domain. While it currently 
unknown whether these excised domains can recapitulate the function of full-length 
PTOV1 either alone or in trans, this represents a critical first step towards answering this 
question. Future work will be performed to study the excised PTOV1 AcID domains using 
HSQC and PrOF NMR to assess any minor differences from the Med25 AcID structure. 
In addition, these AcID motifs will be valuable in small molecule inhibition studies to 




Figure 5.4. Production of PTOV1 AcID-A and AcID-B. (A) Deconvoluted mass 
spectra of PTOV1 AcID-A and AcID-B. (B) Circular dichroism spectra of all three 





D. Materials and Methods 
Plasmids 
pET21b plasmids that encoded for PTOV1(88-235), termed ‘PTOV1 AcID-A’, and 
PTOV1(253-398), termed ‘PTOV1 AcID-B’, were purchased from Genscript. 
 
Previously described methods 
Relevant methods that were previously described in Chapter Two include mass 
spectroscopy of proteins, FP binding experiments, circular dichroism, thermal melts, and 
solid-phase peptide synthesis. 
 
Expression and purification of PTOV1 AcID domains 
Protein expression was completed as described for Med25 AcID. 
Cell pellets were thawed and resuspended with 30-35 ml Lysis Buffer (50 mM phosphate, 
300 mM NaCl, 10 mM imidazole, pH 7.2). β-mercaptoethanol, at 1:1000 dilution, and one 
cOmplete, Mini, EDTA-free Protease Inhibitor tablet (Sigma-Aldrich) were added to the 
resuspended cell pellet. To lyse, the cells were sonicated on ice for 4-6 min 
(Cycle - 3 seconds on, 7 seconds off) and/or until the cells had observable change in color 
(lighter brown) and viscosity. Following sonication, the lysed pellet in 50 mL conical 
tube(s) was centrifuged at 9,500 RPM for 30 min at 4 °C. Concurrent with centrifugation 
of cells, 500 μl of TALON Cobalt resin per 12 mL of cell lysate were washed three times 
with DI water. After centrifugation of the cell lysate, the supernatant was added to the 
washed TALON Cobalt resin and incubated for 1 hour at 4 °C. The resin was then 
centrifuged at 2500 RPM for 2 min at 4 °C before being washed five times with wash 
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buffer (50 mM phosphate, 300 mM sodium chloride, 30 mM imidazole, pH 6.8). The resin 
was centrifuged at 2500 RPM for 1 min at 4 °C between washes. After the washing step, 
protein was incubated with 1 mL of elution buffer (50 mM phosphate, 300 mM sodium 
chloride, 400 mM imidazole, pH 6.8) per 500 μl of TALON Cobalt resin for 30 min at 4 °C. 
The resin was centrifuged at 2500 RPM for 1 min at 4 °C and the protein supernatant 
containing PTOV1 AcID was saved. This elution step was repeated a total of three times. 
Fractions containing PTOV1 AcID were pooled and subjected to further purification using 
a Source S 5 mL HiTrap column using an AKTA pure FPLC chromatography system, as 
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A. The identification of a CBP-CBP protein-protein interaction presents a potential 
mechanism for the regulation of CBP function 
 In Chapter Two of this dissertation, the identification of an N-terminal sequence of 
CBP that interacts specifically with Med25 AcID was described. This sequence of CBP 
shares high homology with the transcriptional activation domain (TAD) of VP16 and, as a 
result, was suspected to function as a TAD mimic (Figure A.1).  
 
Following the investigation of the CBP(20-44) and its proximal downstream 
residues and its interaction with Med25 AcID, it was hypothesized that this TAD-like 
sequence of CBP could also function to interact specifically with other coactivation 
domains. A panel of CBP-derived peptides, labeled with N-terminal fluorescein, were 
synthesized and tested for binding to CBP KIX, as had been performed with Med25 AcID 
(Figure A.2). The supposition that CBP(20-44) could interact specifically with CBP KIX 
was demonstrated to be correct, as CBP(20-44) and CBP(20-55) bound to the CBP KIX 
domain with dissociation constants of 37 ± 2 µM and 49 ± 6 µM, respectively, by 
fluorescence polarization (FP). 
Figure A.1. Sequence alignment of CBP(20-44) and VP16(454-486). A basic local 
alignment search of CBP(1-460) demonstrated that CBP(20-44) was homologous to 
the VP16 H2 transcriptional activation domain. CBP(20-44) shares numerous acidic 




Several TADs have been shown to interact with CBP KIX through a 
phosphorylation-dependent mechanism, including the KID domain of CREB, p53, and 
FOXO3a.1–4 Each of these proteins interact with CBP with relevant affinities after their 
TAD sequences have become phosphorylated. Noting that the CBP(20-44) sequence 
contained two Ser residues that are part of predicted recognition sites for casein kinase 
II, we synthesized a variant of CBP(20-44) peptide to contain phosphoserine at the 23 
and 32 positions.5,6 Subsequent FP assays determined that this phosphorylated variant 
bound to CBP KIX with a nearly 2-fold increase in binding affinity (KD of 19 ± 2 µM for the 
doubly phosphorylated variant compared to 35 ± 2 µM), suggesting that phosphorylation 
may play a role in regulating this interaction. Interestingly, this doubly phosphorylated 
Figure A.2. CBP-derived peptides bind to the KIX domain of CBP. The sequence 
of CBP from residues 20-55 is shown; Acidic (red) and hydrophobic (green) residues 
are indicated. CBP(20-44) and CBP(20-55) bind to the CBP KIX domain with 
dissociation constants of 37 ± 2 µM and 49 ± 6 µM, respectively, by fluorescence 
polarization. Data reported are average and standard deviations of triplicates. 
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CBP(20-44) also bound Med25 with an affinity that was 4-fold tighter than the 
non-phosphorylated variant (KD of 0.25 ± 0.01 µM compared to 1.1 ± 0.1 µM). 
 
Following confirmation that CBP(20-44) bound to CBP KIX in FP experiments, 1H-
15N-HSQC experiments were performed to determine the binding location of the peptide 
ligand towards CBP KIX. Acetylated CBP(20-44) peptide was titrated into 15N-labeled 
CBP KIX at 0, 1, and 2 equivalents of peptide relative to protein. This titration 
demonstrated dose-dependent chemical shift perturbations of backbone amide bonds of 
Figure A.3. Chemical shift perturbations within CBP KIX induced by 
complexation with CBP(20-44). The magnitude of chemical shift perturbations, in 
ppm, are shown upon complexation of 15N CBP KIX with two equivalents CBP(20-44). 
Residues that shift 1-2 standard deviation (SD) above the mean (light blue) and >2 SD 
above the mean (dark blue) are considered to be significantly affected by CBP(20-44).  
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selected CBP KIX residues (Figures A.3). These dose-dependent chemical shifts 
demonstrated that CBP(20-44) binds specifically to CBP KIX; additionally, these 
experiments demonstrated that CBP(20-44) does not affect the structural integrity and 
fold of the protein. Furthermore, these data demonstrated that CBP(20-44) binds 
selectively to the MLL site of CBP KIX, evidenced by the significant chemical shift 
perturbation of several residues (I611, F612, E636, K659, K662, E663) known to be 
important for the KIX-MLL interaction(Figure A.4).7 
 
As demonstrated, the minimally defined sequence of CBP that interacts with 
Med25 AcID mimics a canonical TAD (high concentration of acidic and hydrophobic 
amino acids across a predicted α-helix) and makes a specific contact with the MLL site of 
Figure A.4. Chemical shift perturbations induced by CBP(20-44) mapped on CBP 
KIX. Mapped onto the structure of CBP KIX (4I9O) are chemical shift perturbations 
upon binding to 2 eq. CBP(20-44) peptide. Residues that are perturbed by 1-2 
standard deviations (SD) (pink) and >2 SD (red) are considered to be significantly 
affected by CBP(20-44). 
MLL site pKID site 
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CBP KIX. It is possible this interaction between CBP(20-44) and the KIX domain 
represents a novel mechanism through which CBP could be regulated. As described, 
phosphorylation of the CBP(20-44) peptide sequence at Ser23 and Ser32 caused a 2-fold 
increase in its affinity for the KIX domain. Both Ser23 and Ser32 are predicted to be 
phosphorylation sites for casein kinase II, a protein that is activated by Wnt signaling, a 
common dysregulated signaling pathway in cancer.8,9 It is hypothesized that 
phosphorylation of Ser23 and/or Ser32 by casein kinase II would increases the affinity of 
the N-terminus of CBP for the MLL site of the KIX domain (Figure A.5). This intra- or 
inter-molecular PPI and subsequent inhibition of the MLL site of the KIX domain would 
decrease the transcriptional output of MLL and other activators that target this site of the 







Figure A.5. Model for the CBP-CBP interaction. It is proposed that the KIX domain 
of CBP is in a binding equilibrium with the N-terminus of CBP and activators. (A) Under 
normal conditions, the higher relative affinities of KIX-activator interactions cause the 
equilibrium to reside in favor of KIX-activator interactions. (B) Phosphorylation of 
Ser23/Ser32 is proposed to shift the equilibrium towards the KIX-CBP interaction. 
Note that the indicated ratios between KIX-activator and KIX-CBP are arbitrary; Their 
purpose is to demonstrate the relative difference between the two scenarios. 
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B. An identified intramolecular salt bridge within Med25 AcID is likely important for 
Med25 function and stability 
As is the case with many activator-coactivator interactions, electrostatic 
interactions have been demonstrated as a primary binding determinant for Med25 AcID 
and its protein-protein interactions (PPIs).10 It has been demonstrated that ten-fold 
increase the salt concentration of buffers used in fluorescence polarization (FP) 
experiments results in > 30-fold decreases in the binding affinity of VP16 peptides for 
Med25 AcID. Additionally, in Chapter 2, the introduction of negative charge within the H1 
and H2 binding sites of Med25 disrupted the formation of Med25-peptide complexes. 
These data are consistent with Med25 AcID being dependent upon electrostatic 
interactions.  
With this dependence on electrostatic contacts, it is likely that the protein itself 
would contain electrostatic salt bridges to assist with structural stability. Indeed, published 
NMR structures indicated that D529 and R466 are oriented such that they might form a 
salt bridge.11–13 It should be noted that the distance between these two residues is beyond 
that of a traditional salt bridge interaction however, this region of Med25 AcID is dynamic 
and flexible and a crystal structure of Med25 has not been determined. It was 
hypothesized that the addition of a second mutation, D529R to R466D Med25 AcID, could 
partially recover WT Med25 AcID function. This would invert the proposed salt bridge 




Following expression and purification of R466D/D529R Med25 AcID, FP assays 
and CD-observed thermal denaturation experiments were performed (Figure 2.16). 
R466D/D529R bound H2-interacting peptides VP16(467-488), CBP(20-44), and to 
ATF6α(40-66) with binding affinities of 2.3 µM, 4.8 µM, and 3.6 µM, respectively. These 
binding affinities are all >40% tighter than corresponding affinities towards R466D 
(VP16(467-488) - 3.7 µM, CBP(20-44) - 11.3 µM, ATF6α(40-66) - 10.2 µM) and likely 
represent a partial recovery of WT binding function. Completely regained WT function 
would have been unlikely, as the double mutant R466D/D529R does still place a negative 
charge in the middle of the presumed H2 binding site. CD-observed thermal denaturation 
experiments also supported the presence of a 466-529 salt bridge interaction. The single-
Figure A.6. Intramolecular salt bridge within Med25 AcID. (A) D529 and R466 are 
oriented to potentially form a stabilizing salt bridge between α1 and α3. (B) Binding 
affinities of Med25 variants against H2 site-interacting peptides, as measured by FP. 
Two sets of experiments were performed in triplicate. (C) Melting temperatures of 
Med25 variants determined by CD-observed thermal denaturation. 
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point R466D mutation caused a 19% decrease in melting temperature compared to WT 
Med25 AcID (57.0 ± 2.0 °C vs. 70.8 ± 1.3 °C); Restoration of the putative salt bridge with 






C. Garcinolic acid is an effective but non-selective inhibitor of Med25 AcID   
Identification and initial selectivity screening of garcinolic acid 
Garcinolic acid was discovered as a hit molecule in a competition-based FP high-
throughput screening effort against the Med15 KIX-Pdr1 PPI performed using a small 
molecule library maintained by the Center for Chemical Genomics at the University of 
Michigan (Meg Breen, University of Michigan). During selectivity screening of this 
molecule, it was found to be a pan-inhibitor of several disparate coactivator motifs 
including, most notably for this thesis, Med25 AcID (Figure A.7 and Table A.1). 
 
Figure A.7. Garcinolic acid targets several transcriptional coactivation domains. 
Structures of related – cgMed15 KIX (PDB 4D7X), scMed15 KIX (PDB 2K0N), CBP 
KIX (PDB 2AGH) – and unrelated – Med25 AcID (PDB 2XNF) – proteins whose 





Coactivator domain TAD peptide IC50 
scMed15 KIX Pdr1 27 µM 
cgMed15 KIX Pdr1 59 µM 
CBP KIX MLL 3.3 ± 0.9 µM 
CBP KIX c-Myb 4.5 ± 1.0 µM 
p300 KIX MLL 4.6 ± 1.4 µM 
p300 KIX c-Myb 7.2 ± 1.8 µM 
Med25 AcID ATF6α 3.4 ± 0.6 µM 
Med25 AcID VP16 H1 4.9 ± 1.0 µM 
  
 While garcinolic acid was discovered using a HTS of Saccharomyces cerevisae 
(sc) Med15 KIX and Candida galbrata (cg) Med15 KIX, it is more potent against Med25 
AcID and the KIX motifs of CBP and p300. Garcinolic inhibited the Med25 AcID and 
CBP/p300 KIX domains with single-digit micromolar IC50 values in FP assays. While this 
molecule does not offer selectivity between CBP/p300 KIX and Med25 AcID, it did provide 
a non-covalent and potent inhibitor of AcID function in vitro that could be leveraged for 
use in downstream cellular experiments to study AcID function in cellulo and in vivo. 
However, prior to cellular study, we wanted to establish whether garcinolic acid could 
selectively target a single site of either Med25 AcID and CBP/p300 KIX, as potential 
selectivity differences between unique activators of either coactivator domain would be 
beneficial during in cellulo experimental design and interpretation. 
 As described previously, both the CBP/p300 KIX and Med25 AcID motifs contain 
multiple binding sites responsible for interactions with unique transcriptional activators. 
Table A.1. Summary of the inhibitory effects of garcinolic acid. Half maximal 
inhibitory constants of garcinolic acid for tested coactivator-activator PPIs in FP 
assays. (Performed with Meg Breen and Sam DeSalle) 
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Additionally, both the CBP KIX and Med25 AcID domains share at least one common in 
vitro interacting partner, MLL (Data not shown). To provide secondary confirmation of 
these protein-ligand interactions and to determine the binding mode of garcinolic acid for 
each protein, 1H 15N-HSQC and PrOF NMR of the Med25 AcID-garcinolic acid and CBP 
KIX-garcinolic acid interactions were pursued. It was thought that these methodologies 
could test the hypothesis that garcinolic acid functions to potently inhibit two structurally 
distinct coactivator motifs by mimicking a transcriptional activator and whether garcinolic 
acid selectively targets singular sites of both proteins.  
 
Biochemical characterization of the Med25 AcID-garcinolic acid interaction 
1H-15N-HSQC experiments were performed in which garcinolic acid was 
complexed with 15N-labeled Med25 AcID at 0, 1, 2, and 4 equivalents of small molecule 
relative to protein. This set of experiments demonstrated dose-dependent chemical shift 
perturbations and significant broadening of resonances that represented many Med25 
AcID residues (Figures A.8, A.9, A.10). As with previous HSQC experiments with Med25 
AcID, peaks in all of the collected spectra were assigned to specific residues using both 
a previously published NMR assignment11 and a de novo assignment performed by Andy 
Henderson (University of Michigan). Residues that demonstrated a dose-dependent and 
statistically significant (>1 standard deviation above the mean) chemical shift perturbation 
were almost exclusively located within the H2 site of Med25, indicating that garcinolic acid 
likely bound within this region of the protein. Specifically, significantly perturbed residues 
were located across the lengths of β5, β4, β7, and β6, along α1, and near the C-terminal 
end of α2 (L457, G462, L464, R466, M470, F473, H474, M490, G496, M512, L514, K520, 
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F522, M523, N535). In addition to resonances that were significantly perturbed, several 
residues were completely broadened into noise at all tested concentrations of garcinolic 
acid. These residues – 471, 472, 513, 516, 524, and 529 – were within the ‘bottom’ of the 
H2 site (away from α2) except for D529, located on the loop between β7 and α3. 
Collectively, these experiments demonstrated that garcinolic acid is likely making direct 
contact with Med25 AcID at the portion of H2 face away from α2. The large number of 
resonances that are broadened into noise, even at the lowest concentration of garcinolic 
acid, suggested a highly specific and tight affinity interaction. 
 
Figure A.8. 1H-15N-HSQC NMR spectra of Med25 AcID-garcinolic acid complexes. 
Overlay of the HSQC spectra of 15N-labeled Med25 AcID with DMSO (pink), one 
equivalent of garcinolic acid (dark blue), two equivalents (light blue), and four 




Figure A.9. Chemical shift perturbations within Med25 AcID induced by 
saturating garcinolic acid conditions. The magnitude of chemical shift 
perturbations, in Hz, are shown upon saturation of 15N Med25 AcID with four eq 
garcinolic acid. Residues that shift 1-2 standard deviation (SD) above the mean (light 
blue), >2 SD (dark blue), and that broaden into noise (red) are significantly perturbed. 
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Figure A.10. Chemical shift perturbations induced by garcinolic acid mapped on 
Med25 AcID. Mapped onto the structure of Med25 AcID are chemical shift 
perturbations upon binding to four eq. garcinolic acid. Increasing shades of red 
indicate a gradient of increasing chemical shift perturbations. Red balls indicate 
residues that show complete peak broadening.    
H2 site H1 site 
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PrOF NMR spectra of 3FY Med25 AcID in complex with increasing concentrations 
of garcinolic acid (0, 0.1, 0.5, 1 and 2 equivalents of small molecule relative to protein) 
were collected (Figure A.11). As anticipated based on the HSQC results, garcinolic acid 
affected 3FY Med25 similarly to other H2 site ligands (e.g. ATF6α(40-66) peptide) with 
perturbations of all four Tyr residues. However, not all residues shifted in an apparent 
dose-dependent manner. Y528 and Y432 behaved in a typical fashion for Med25 AcID 
ligands with incremental chemical shift perturbations as garcinolic acid was increasing 
added into 3FY Med25 AcID. The Y487/Y515 pair did not appear to share this typical 
behavior. These two resonances were slightly broadened at 0.1 and 0.5 eq. garcinolic 
acid but only Y487 demonstrated relatively minor (for this resonance) chemical shift 
perturbations. Then, starting at 1 eq. garcinolic acid, both the Y487 and Y515 resonances 
demonstrated large upfield perturbations. These results could represent two discrete 
binding modes for garcinolic acid interacting with Med25 AcID, indicating that garcinolic 
acid might adopt multiple orientations with the H2 site or that garcinolic acid might bind 




Together, HSQC and PrOF NMR of the Med25 AcID-garcinolic acid interaction 
suggested that garcinolic acid bound tightly and specifically to the H2 site of Med25 AcID. 
This would indicate that this molecule is capable of orthosteric inhibition of the H2 site. 
The ability of garcinolic acid to inhibit the Med25-VP16 H1 PPI is either a result of 
orthosteric inhibition of VP16 H1 in instances when this peptide is bound at the H2 site or 
allosteric inhibition of the H1 site. However, a lack of HSQC chemical shift perturbations 
in the H1 site makes the latter less likely than the former. Orthosteric inhibition of VP16 
Figure A.11. PrOF NMR of 3FY Med25 AcID in complex with garcinolic acid. 
Spectral analysis of 3FY Med25 AcID in presence of increasing concentrations of 
garcinolic acid demonstrated that garcinolic acid behaves similarly to a H2 site peptide. 
However, differences in the dose-dependence of Y528/Y432 and Y487/Y515 suggest 




H1 at the H2 site would not be surprising considering mutagenesis experiments that 
suggested VP16 H1 bound at both the H1 and H2 sites. 
 
Biochemical characterization of the CBP KIX-garcinolic acid interaction 
 Concurrent with the definition of the Med25-garcinolic acid interaction, similar 
experiments were performed to characterize the CBP KIX-garcinolic acid interaction. 1H-
15N-HSQC experiments were performed in which garcinolic acid was complexed with 15N-
labeled CBP KIX at 0, 0.25, 0.5, and 1.5 equivalents of small molecule relative to protein. 
This data provided dose-dependent chemical shift perturbations in resonances 
corresponding to several CBP KIX residues (Figures A.12, A.13, A.14). Peaks in each 
ofthe collected spectra were assigned to specific residues using a previously published 
NMR assignment16.  
 
Figure A.12. 1H-15N-HSQC NMR spectra of CBP KIX-garcinolic acid complexes. 
Overlay of the HSQC spectra of 15N-labeled Med25 AcID with DMSO (black), 0.25 eq. 
of garcinolic acid (light blue), 0.5 eq. (light blue), and 1.5 eq. (black) is shown. 
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Figure A.13. Chemical shift perturbations within CBP KIX induced by saturating 
garcinolic acid conditions. The magnitude of chemical shift perturbations caused by 
complexation of 15N CBP with 1.5 eq. garcinolic acid. Residues that shift 1-2 (light blue) 
and >2 standard deviations (dark blue) are significantly perturbed. 
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The HSQC NMR titration demonstrated that garcinolic acid induced significant 
chemical shift perturbations within the MLL site of CBP KIX (I611, F612, R624, I660, and 
E663). Critically, while there are minor chemical shift perturbations at the pKID/c-Myb site, 
zero residues within this site of CBP KIX are significantly perturbed. These data are 
consistent with garcinolic acid binding orthosterically at the MLL site. Interestingly, a few 
residues that are 90° from the MLL site at a cleft formed by α1 and α2 – V608, L620, and 
A630 – are also significantly perturbed at the highest tested garcinolic acid condition (1.5 
eq. small molecule). These perturbations could be induced by allosteric or through-
molecule effects induced by garcinolic acid at the MLL site. Alternatively, this region of 
CBP KIX could represent a second binding location. This would suggest either a 1:1 
binding model in which both the MLL site and this binding site share a similar affinity for 
Figure A.14. Chemical shift perturbations induced by garcinolic acid mapped on 
CBP KIX. Mapped onto the structure of CBP KIX (2AGH) are chemical shift 
perturbations upon binding to 1.5 eq. garcinolic acid. Increasing shades of red indicate 
a gradient of increasing chemical shift perturbations. Garcinolic acid significantly 
affects residues within the MLL site and are 90° from the MLL site at a α1/α2 cleft.  
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garcinolic acid or a 2:1 binding model in which a second molecule binds at this site before, 
or after, a binding event at the MLL site.  
 PrOF NMR spectra of 3FY CBP KIX in complex with increasing concentrations of 
garcinolic acid (0, 0.1, 0.5, 1 and 2 equivalents of small molecule relative to protein) were 
collected (Figure A.15). 3FY CBP KIX contains five Tyr residues, all of which can be 
resolved in PrOF NMR spectra. Critically, for this protein-ligand interaction, only one of 
these Tyr residues, Y631, is in the proximity of the MLL site. Y631 is located on α2 of 
CBP KIX and sits near the base of the MLL site. In PrOF experiments, as expected, none 
of the other Tyr residues is affected by the presence of garcinolic acid, consistent with the 
molecule not binding near or within the pKID/c-Myb site. However, interestingly, garcinolic 
acid also did not perturb Y631 at 0.1 or 0.5 eq. relative to Med25 AcID and only provided 
a mild perturbation at 1 eq. molecule. At 2 eq. garcinolic acid, the chemical shift of Y631 
was significantly perturbed. This delayed perturbation of Y631 could indicate that 
garcinolic acid either binds at the ‘top’ of MLL near the loop between α1 and α2 or at the 
‘third’ site 90° from the MLL site at the cleft formed by α1/α2 (Figure A.16). Y631 is next 
to A630, one of the significantly perturbed residues in HSQC NMR experiments that 
residues within this alternative site. Note that the demonstrable loss in signal-to-noise 
observed in the PrOF NMR spectra of 3FY CBP KIX in complex with 2 eq. garcinolic acid 
is thought to have resulted from precipitation of protein during the experiment, which 





Figure A.15. PrOF NMR of 3FY CBP KIX in complex with garcinolic acid. Spectral 
analysis of 3FY CBP in presence of increasing concentrations of garcinolic acid 
demonstrated a significant, dose-responsive chemical shift perturbation of Y631 
(located in proximity of the MLL site). None of the Tyr residues in proximity of the pKID 





The NMR experiments with CBP KIX and garcinolic acid demonstrated that the 
molecule binds to the protein at either the MLL site and that a second binding event could 
occur at the putative ‘third’ site located 90° from the MLL site in a cleft at α1/α2. This result 
suggests that garcinolic acid is an orthosteric inhibitor of the KIX-MLL PPI and an 
allosteric inhibitor of the KIX-cMyb PPI.  
 
Conclusions 
 Garcinolic acid is a potent, single-digit micromolar inhibitor of the AcID domain of 
Med25 AcID and the KIX domain of Med15, CBP, and p300. Because these two domains 
are structurally divergent, the modes of recognition for garcinolic acid interactions were 
desired. Subsequent NMR data suggest that garcinolic acid likely interacts with unique 
sites of both Med25 AcID (H2 site) and CBP KIX (MLL site). However, these data also 
demonstrate that garcinolic acid likely binds both proteins in multiple orientations and/or 
Figure A.16. Garcinolic acid likely binds near the MLL site within CBP KIX. 
NMR methodologies demonstrates that garcinolic acid causes significant chemical 
shift perturbations near the MLL site. Residues perturbed in HSQC NMR 
experiments are shown in red; Y631, the only 3FY residue perturbed in PrOF NMR, 
is depicted as sticks in blue. 
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with >1:1 stoichiometry. These modes of recognition suggest that garcinolic acid, a rigid 
and negatively charged molecule, likely will not allow for selective inhibition of unique 
Med25 AcID functions in cellular experiments due to off-target effects and nonspecific 





D. Follow-up of a Natural Product Extracts screen against Med25-ERM 
Small molecules that target the coactivator Med25 AcID and its protein-protein 
interaction (PPI) are desired to allow for the study of Med25 AcID function in cellular and 
disease contexts. Natural products demonstrate, as evidenced by the examples of 
norstictic acid and the 34913 lipopeptide as described in this dissertation, a large class of 
molecules that exhibit chemical properties (e.g. conformational plasticity, structural 
complexity) that are useful in targeting coactivator-activator complexes that typically 
involve large surface areas and low binding affinity. To discover novel natural product 
inhibitors of this complex, two former graduate students in the Mapp lab, Steve Sturlis 
and Paul Bruno, designed a fluorescence polarization-based competition assay to screen 
the Med25-ERM PPI against a Natural Product Extracts (NPE) library (33,400 total 
Extracts) maintained by the Center for Chemical Genomics (Life Sciences Institute, 
University of Michigan). This highly diverse chemical library of partially fractionated 
extracts has been cultivated from a collection of sediments, cyanobacteria and sponges 
from across the world. Note that a single extract contains a majority of the organic matter 
produced by a single microbe (i.e. one extract ≠ one compound). A primary screen of the 
full NPE library gave a Z’ score of 0.78. Obvious false positives (previously known 
reactive/fluorescent extracts) were eliminated from the initial hits prior to subjecting those 
initial hits to a dose-response assay and a selectivity filter designed to eliminate 
compounds that inhibited unrelated PPIs, other activator-coactivator PPIs, and protein-
DNA interactions. At the conclusion of this screening strategy, 332 natural product 




Secondary confirmation of inhibitory activity of validated hit extracts   
Prior to isolation of the inhibitory molecules-of-interest, validated hit extracts must 
be reproduced for secondary confirmation of their activity. This is necessary to confirm 
that the activity demonstrated in the primary screen was not a result of degradation of the 
sample and that the inhibitory molecule-of-interest can be reproducibly biosynthesized by 
the producing microbial strain.  
 
 Of the 332 inhibitory extracts obtained from the screening strategy, thirty-six were 
selected for initial follow-up (Table A.2). This subset was chosen to maximize potential 
biological diversity as related to location of the collection (i.e. Red Sea, Costa Rica, etc.), 
the culture medium required for the organism to produce secondary metabolites, and the 
Table A.2. Natural Product Extracts selected for initial follow-up after the NPE 
primary screen. (Table prepared by Steve Sturlis)  
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degree of inhibitory activity against the Med25 PPI interface. Additionally, preference was 
given to extracts that had been rarely, if ever, identified previously in other high-
throughput screening efforts against this Extracts library. For each of the thirty-six 
selected extracts, the producing microbial strain were individually re-grown in an identical 
manner (number of days, temperature, media conditions) as the original sample that gave 
a validated hit in the primary screen (Figure A.17). These microbial growths all started 
from frozen spore stocks maintained by Pam Schultz and the Sherman lab. Using the 
spore stocks, microbial strains were streaked onto oatmeal plates for 3-5 days before 
transferring the microbe to 3 mL ISP2 media for 5-7 days. These cultures were then 
transferred to 100 mL of media for growth and secondary metabolite production (8-30 
days at 37 °C. At the end of the growth, microbial strains were centrifuged and XAD-16 
resin was added to the supernatant. After incubation with the supernatant, the XAD-16 
resin, impregnated with all of organic material produced by the microbe, was sequentially 
extracted with two solvent systems – 50:50 methanol:acetone, and dichloromethane. Of 
the thirty-six selected strains, thirty-one were successfully re-grown and their organic 
material extracted; The other five microbial strains did not start to grow after initial 




After successful culturing and extraction of each microbial strain, a FP competition 
assay against Med25-ERM, as performed in the initial HTS, was performed. Additionally, 
a previously validated Med25-dependent luciferase reporter assay, as described in 
Chapter 4, was performed to test the ability of extracts to inhibit Med25 AcID function in 
a cellular context (Figure A.18). Collectively, these data demonstrated that fourteen of the 
originally chosen thirty-six unique extracts exhibit inhibitory activity in vitro and in cellulo. 
(Table A.3). These strains represented excellent starting points for large-scale growths 
and bioassay-guided fractionation to identify active compounds. 





Medium-scale growth and fractionation of selected microbial strains 
 Five of the microbial strains that demonstrated inhibitory activity in vitro and in 
cellulo following re-growth on small-scale were selected for medium-scale growth and 
subsequent bioassay-guided fractionation for isolation of active compounds (Table A.4). 
Figure A.18 Inhibitory activity of selected Natural Product Extract Strains in 
Med25-dependent luciferase assay.  All successfully re-grown strains were tested in 
a Med25-dependent luciferase reporter assay; A selection of the data are shown 
above. The dotted line indicates the negative control; Notably, the NPR strain 91085 
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Table A.3 Analysis of inhibitory activity of re-grown NPE strains. Fourteen of 
thirty-one NPE, highlighted in yellow, demonstrated good inhibition in vitro (FP assays) 




 Near the end of microbial growth, on the penultimate day, XAD-16 resin bags (20 g 
per 1 L culture) were added to growing cultures. After the growth, these resin bags were 
extracted with three organic solvents – acetone, methanol, and dichloromethane – to 
remove the organic material contained within. Extracts were then subjected to 
fractionation using C18 column chromatography. A stepwise gradient of water:acetonitrile 
(100:0, 90:10, 75:25, 60:40, 45:55, 30:70, 15:85, 0:100) was used to collect eight fractions 
that were subsequently subjected to FP inhibition assays (Table A.5).  
 
FP assays of C18 fractions demonstrated that discrete fractions of each NPE 
contained activity against Med25-ERM. In particular, the 90:10 and 45:55 fractions of NPE 
strain 34908 (101% and 42% inhibition, respectively, at 0.75 mg/mL), the 90:10 and 75:25 
fractions of NPE strain 41445 (96% and 60% inhibition, respectively, at 0.75 mg/mL), and 
the 100:0, 90:10, 75:25, 60:40 fractions of NPE strain 91085 (51%, 46%, 57%, and 46% 
Table A.4 NPE strains grown at medium-scale. Growth conditions are provided. 
Note that 91085 was co-cultured with Rhoddococcus after one day of microbial growth; 
10 mL of Rhoddoccus liquid culture (high OD) was added per 1 L of 91085 culture. 
Table A..5 Inhibitory activity of C18 fractionated NPE strains. FP assays were 
performed to test the activity of C18 fractions of each strain grown on medium-scale to 
inhibit the Med25-ERM PPI. Fractions were tested at three concentrations of organic 
material (1.5 mg/mL, 0.75 mg/mL, 0.38 mg/mL) in duplicate. Shown below are the 
average percent inhibition at 0.75 mg/mL organic material. 
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inhibition, respectively, at 0.75 mg/mL) demonstrated sufficiently high inhibitory activity to 
encourage further purification by HPLC. 
 Analytical HPLC runs of each of the aforementioned C18 fractions were performed 
to assess the complexity/total number of potential compounds contained within. These 
analytical runs suggested that the 90:10 and 75:25 fractions of NPE strain 91085 could 
be readily separated to produce purified compounds. HPLC runs of the C18 fractions of 
34908 and 41445 appeared to be complex enough that they were initially passed over to 
focus on purification of 91085. In addition to the relative lack of complexity within the 
HPLC analytical runs, the 91085 strain was prioritized because it was the most potent 
NPE strain in the Med25-dependent luciferase assay performed during the secondary 
validation of hits.  
 
Investigation of NPE strain 91085 
 The medium-scale culture (10.5 L) of 91085 was further fractionated after C18 
chromatography using HPLC. Many different HPLC methods and columns were 
attempted throughout the entirety of this investigation. To simplify the discussion, a small 
fraction of all attempted experiments are described below.  
 The C18 75:25 fraction was purified using a gradient of 10-30% acetonitrile over 
15 min followed by 30-40% acetonitrile over 30 min (7 mL/min) using a C18 preparative 
column on a Beckman HPLC. Collected fractions were tested for inhibition against Med25 
(Figure A.19) to discover that two peaks contained activity and were carried ahead into 
further purifications. As an example, Fraction 22 from that HPLC purification was further 
fractionated using a gradient of 15-17.5% acetonitrile (0.1% formic acid) over 20 min 
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followed by 17.5-35% acetonitrile (0.1% formic acid) over 10 min (4 mL/min) with a C18 
semi-preparative column on a Beckman HPLC. (Figure A.20)  
 
Figure A.19. HPLC purification of 91085 C18-75:25. Representative HPLC 
chromatogram of 91085 C18-75:25. Beckman HPLC; C18 preparative column; 
Gradient - 10-30% acetonitrile over 15 min followed by 30-40% acetonitrile over 30 
min (7 mL/min); Peaks indicated by yellow arrows (Fract. 18-20 and 22-23) were active 




 As indicated in Figure A, the purification of 91085 C18-75:25/HPLC-22 produced 
three active peaks. Each of these was tested for inhibition in the Med25-dependent 
luciferase assay that had been previously utilized successfully against crude NPE 
extracts (Figure A.21). One of these partially purified fractions, termed “91085 C18-
75:25/HPLC-22/HPLC-15.5 min”, demonstrated dose-responsive inhibition of Med25 
function within this assay, suggesting that an active molecule was contained within this 
fraction. Unfortunately, at this stage, after a C18 purification and two sequential HPLC 
purifications, there was a very small amount of this partially purified material, much less 
than a milligram and not enough to collect a full suite of NMR data for structural 
Figure A.20. HPLC purification of 91085 C18-75:25/HPLC-22. Representative 
HPLC chromatogram of 91085 C18-75:25/HPLC-22 (Fraction 22 collected in Figure 
A.). Beckman HPLC; C18 semi-preparative column; 15-17.5% acetonitrile (0.1% 
formic acid) over 20 min followed by 17.5-35% acetonitrile (0.1% formic acid) over 10 
min (4 mL/min); Peaks indicated by yellow arrows (8 min, 9 min, 15.5 min) were active 
against Med25-ERM PPI, as demonstrated in the supplied table. 
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elucidation. In order to follow up this active fraction, it was necessary to grow more of the 
91085 strain and on a much larger scale.  
 
A 40 L growth was performed to generate more 91085 extract to enable isolation 
of active molecules in higher quantities. This growth was performed as before, although 
it is possible that there may have been slight differences in water composition due to 
seasonal variation. After the growth, extraction, and C18 fractionation, the 75:25 fraction 
from C18 was subjected to similar HPLC methods as had been previously used to purify 
91085 C18 75:25. Unfortunately, the composition of the organic compounds within this 
C18 fraction appeared to be rather different than the same fraction from the medium-scale 
growth (Figure A.22). This suggested that the production of 91085 is not particularly 
reproducible and hinted that problems might lie ahead. 
 
Figure A.21 Cellular activity of 91085 C18-75:25/HPLC-22/HPLC-15.5 min. Partially 
purified compounds from 91085 that have undergone C18 fractionation and two HPLC 
purifications were tested in a Med25-dependent luciferase assay. 91085 C18-
75:25/HPLC-22/HPLC-15.5 min (See Figure A) demonstrated dose-dependent 




 Instead of focusing on the C18 75:25 fraction from the large-scale growth, further 
efforts sought to isolate active compounds from the C18 60:40 fraction. Additionally, to 
decrease the added sample complexity that was being demonstrated by the large-scale 
growth, all active C18 fractions were fractionated using size-exclusion chromatography 
(SEC) prior to continued HPLC purifications. Following this SEC purification, the C18 
60:40 fraction from the large-scale was purified by HPLC. After several trials, this fraction 
was purified using an isocratic method (15% acetonitrile) with a C18 semi-preparative 
column on a Shimadzu HPLC. A large quantity of material (~18 mg) was partially purified 
as “28.5 min”. A subsequent HPLC purification of this peak using an isocratic method 
(35% methanol) with a C18 semi-preparative column on a Shimadzu HPLC provided a 
purified molecule, termed “91085 C18-60:40/HPLC-"28.5min"/HPLC-137” (Figure A.23).  
Figure A.22 HPLC purifications of 91085 C18-75:25 are not reproducible from 
one growth of 91085 to the next. 91085 was grown on large-scale (40 L) to acquire 
more material for compound isolation; HPLC analysis of 91085 C18-75:25 after this 
growth is very different than after first medium-scale (10.5 L) growth (See Figure A) 
Beckman HPLC; C18 preparative column; Gradient - 10-30% acetonitrile over 15 min 




The molecule was sufficiently pure and in high enough quantity to allow for a 
complete set of NMR data (13C, 1H, HSQC, HMBC, COSY) to be collected (Figure A. 24). 
Unfortunately, however, this molecule was a poor inhibitor of the Med25-ERM PPI with 
Figure A.23 Sequential HPLC purifications of 91085 C18-60:40. (A) Representative 
HPLC purification of 91085 C18-60:40. Isocratic method (15% acetonitrile) with C18 
semi-prep column on Shimadzu HPLC. Active peaks are indicated by yellow arrows. 
(B) HPLC purifications of 91085 C18-60:40/HPLC-“28.5min” provided a pure molecule. 
Isocratic method (35% methanol) with C18 semi-prep column on Shimadzu HPLC. 
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an IC50 of 818 ± 129 µM. At that point, the NMR data was left to be unanalyzed and 
different avenues were pursed to identify potent molecules from 91085. 
 
 The general story of 91085 C18-60:40/HPLC-"28.5min"/HPLC-137 played out two 
additional times. The exact reasons (e.g. PEG contamination of unknown origin) differed 
but the end result remained the same. The only identified molecules, of which four have 
been sufficiently purified, have proven to be poor inhibitors of Med25 AcID function. It 
should be noted that among those four molecules, complete NMR data sets and high 
resolution mass spectroscopy for three, termed 91085 C18-60:40/HPLC-
"28.5min"/HPLC-137, KG-58, and KG-59, have been collected. Structural elucidation of 
these molecules could be incredibly beneficial in determining whether 91085 should be 
further pursued. It is possible that the discovered molecules are analogues of the actual 
Figure A.24 Characterization of 91085 C18-60:40/HPLC-"28.5min"/HPLC-137. A 
pure molecule was identified; NMR and mass spectroscopy data was collected but not 
fully analyzed. This identified molecule demonstrated weak inhibition with an 
IC50 = 818 ± 129 µM against the Med25-ERM PPI.  
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inhibitor(s) contained within Med25 AcID. To highlight this possibility, consider that 
norstictic acid is potent inhibitor of Med25 AcID (IC50 ~2.5 µM) but that a closely related 










Figure A.25 Comparison of stictic acid and norstictic acid. Methylation of a phenol 
group is the only structural difference between a potent Med25 inhibitor (norstictic acid) 
and an inactive molecule. 
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